Neurology Research and Resources

Neurology

Neurology is the official journal of the American Academy of Neurology.
Current Issue:

  • An error has occurred; the feed is probably down. Try again later.

Recent Issues:
  • An error has occurred; the feed is probably down. Try again later.

Ahead of Print:
  • An error has occurred; the feed is probably down. Try again later.

Most Frequently Read:
  • An error has occurred; the feed is probably down. Try again later.


Weekly podcast of content from Neurology®, the official journal of the American Academy of Neurology.

  • SUDEP in the North American SUDEP Registry: The full spectrum of epilepsies
    In the first segment, Dr. Halley Alexander talks with Dr. Orrin Devinsky about his paper on the full spectrum of epilepsies and the North American SUDEP Registry. In the second part of the podcast, Dr. Ted Burns focuses his discussion with Dr. Gil Wolfe on his Lancet Neurology paper on the long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis. You can read the paper here: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30392-2/fulltext.  
  • Use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease
    In the first segment, Dr. Jeffrey Ratliff talks with Dr. Franziska Hopfner about her paper on the use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Dr. Jerzy Szaflarski on his JAMA Neurology paper on the US Food and Drug Administration’s authorization of the first cannabis-derived pharmaceutical. You can read the paper here: https://jamanetwork.com/journals/jamaneurology/article-abstract/2714720.
  • Current treatment practice of Guillain-Barré syndrome
    In the first segment, Dr. Michelle Mauermann talks with Dr. Bart Jacobs about his paper on current treatment practice of Guillain-Barré syndrome. In the second part of the podcast, Dr. Matthew Harms focuses his discussion with Dr. Guy Rouleau on his Neurology: Genetics paper looking at how somatic expansion of the C9orf72 Hexanucleotide Repeat does not occur in ALS spinal cord tissues.
  • Epilepsy and EEG (Delayed Recall July 2019)
    This month's Delayed Recall highlights interviews on epilepsy and EEG. Dr. Derek Bauer talks with Dr. Paula Emanuela Voinescu about her paper on antiepileptic drug clearances during pregnancy and the relationship between drug serum concentration and seizure frequency from the Sept 25, 2018, podcast.  Next, Dr. Andy Schomer talks with Dr. Chloe Hill on the association between continuous EEG and favorable hospitalization outcomes for critically ill patients from the January 1, 2019, podcast.  For the next segment, we’re back with Derek Bauer, this time talking with Dr. Jacqueline French about the recent practice guideline on the treatment of new-onset epilepsy from the July 10, 2018 episode. And then again from the April 2, 2019, podcast, we hear Derek Bauer talk with Dr. Stephan Schuele about his paper on automated seizure detection accuracy for ambulatory EEG recordings.  Finally, we wrap up with Jeff Ratliff talking to Dr. Anup Patel about the 2017 epilepsy quality measurement set update, which originally aired on the October 30, 2018, podcast.  
  • Interview with Neurology Editor-in-Chief Dr. Bob Gross, pt. 2
    In the second part of a 2-part interview, Dr. Bob Gross discusses changes to the journal and publishing as well as some controversies and challenges as Editor-in-Chief of Neurology.
  • Interview with Neurology Editor-in-Chief Bob Gross, pt. 1
    In the first part of a 2-part interview, Dr. Bob Gross discusses his experiences, opportunities, and challenges as Editor-in-Chief of Neurology.
  • Lumbosacral Radiculoplexus Neuropathy: Incidence and the Association with Diabetes Mellitus
    In the first segment, Dr. Stacey Clardy talks with Dr. P. James B. Dyck about his paper on the incidence of lumbrosacral radiculoplexus neuropathy and association with diabetes mellitus. In the second segment, Dr. David Lapides talks with Dr. Teshamae Monteith about the use of CRGP monoclonal antibodies for migraine prevention. 
  • The Four Score as a predictor of outcome in adults with bacterial meningitis
    In the first segment, Dr. David Lapides talks with Dr. C.N. van Ettekoven about the Four Score as a predictor of outcome in adults with bacterial meningitis, from the May 28th issue. In the second part of the podcast, Dr. Jason Crowell focuses his talk with Dr. Deborah Dowell on her NEJM perspective article looking at opioid prescribing and response to the CDC guidelines. You can read Dr. Dowell’s paper here: https://www.nejm.org/doi/full/10.1056/NEJMp1904190. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
  • Neurology Minute Podcast Highlights (Delayed Recall June 2019)
    This month's Delayed Recall highlights interviews from our new podcast offering, Neurology Minute. In 2019, Neurology launched a new podcast perfect for Alexa and other similar devices. This episode features digestible "minutes" on measles in 2019, gene editing, the SHINE stroke trial, and more. 
  • Out-of-pocket costs are on the rise for commonly prescribed neurologic medications
    In the first segment, Dr. Jason Crowell talks with Dr. Brian Callaghan about rising out-of-pocket costs for commonly prescribed neurologic medications. In the second part of the podcast, Dr. Jeffrey Ratliff focuses his interview with Dr. Stefan Pulst on ataxias.  CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
  • Long-term outcome in neuroZika: When biological diagnosis matters
    In the first segment, Dr. Stacey Clardy talks with Dr. Annie Lannuzel about the importance of biological diagnosis in long-term outcome in neuroZika. In the second part of the podcast, Dr. Will Rondeau focuses his interview with Dr. Stuart Connolly on his NEJM paper on the full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. The paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa1814051. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
  • Developments and Scandals Related to Genetic Testing and Technology in Neurology (Delayed Recall May 2019)
    This month’s Delayed Recall highlights episodes on developments and scandals related to genetic testing and technology in neurology. Dr. Jason Crowell and Dr. Josephine Johnston of the Hastings Center start the show discussing the ethical and philosophical implications of gene editing., which first aired on December 18th, 2018. The next segment, also from December 18th, has Dr. Stacey Clardy and Dr. Stefan Pulst focusing on the scientific and societal impact of the recent first reported gene editing using the CRISPR technology. Following this segment is one from December 3rd and finds Dr. Jeff Waugh talking with Dr. Saadet Andrews about her paper on the genetic landscape of pediatric movement disorders and management implications. This episode continues with an interview on a Neurology: Genetics on the long journey to diagnosis for patients with mitochondrial disease between Dr. Jason Crowell and Drs. John L.P. Thompson and Michio Hirano from April 3rd, 2018. The episode wraps up with a talk between Dr. Jeffrey Ratliff and Dr. Thomas Bird from March 20th, 2018, on Dr. Bird’s Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias.
  • Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus
    In the first segment, Dr. Lindsay Higdon talks with Dr. Ivan Sanchez Fernandez about his paper on the meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus. In the second part of the podcast, Dr. Stacey Clardy talks with Dr. Anthony Fauci about the measles outbreak of 2019. You can read the paper in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMp1905099. 
  • Practice guideline recommendations summary: The treatment of tics in people with Tourette syndrome and chronic tic disorders
    In the first segment, Dr. Jeffrey Ratliff talks with Dr. Tamara Milka Pringsheim about her practice guideline recommendations summary paper on the treatment of tics in people with Tourette syndrome and chronic tic disorders. In the What's Trending segment, you'll hear the second part of an interview between Dr. Jason Crowell and New York Times staff writer Pam Belluck on CRISPR and gene editing.
  • Mouse model of anti-NMDA receptor post–herpes simplex encephalitis
    In the first segment, Dr. Stacey Clardy talks with Dr. Jenny Linnoila about her March 2019 Neurology: Neuroimmunology & Neuroinflammation paper on a mouse model of anti-NMDA receptor post–herpes simplex encephalitis. In the second segment, Jason Crowell talks with Pam Belluck of the New York Times about He Jiankui, gene editing, and CRISPR. 
  • Montreal Cognitive Assessment as a screening tool: Influence of performance and symptom validity
    In the first segment, Dr. Gregory Day talks with Dr. Brigid Waldron-Perrine about her Neurology: Clinical Practice paper addressing the Montreal Cognitive Assessment as a screening tool. In the second part of the podcast, Dr. Jeffrey Burns focuses his interview with Dr. Mathias Jucker on how serum neurofilament dynamics predict neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. The article can be found in Nature: https://www.nature.com/articles/s41591-018-0304-3.
  • Comparative effectiveness of teriflunomide and dimethyl fumarate. A nationwide cohort study
    In the first segment, Dr. Stacey Clardy talks with Dr. Mathias Buron about his paper addressing the comparative effectiveness of teriflunomide and dimethyl fumarate. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Joanna Hellmuth on the rise of pseudomedicine for dementia and brain health.
  • How much do periventricular lesions assist in distinguishing migraine with aura from CIS?
    In the first segment, Dr. Stacey Clardy talks with Dr. Caterina Lapucci about her paper addressing how much periventricular lesions assist in distinguishing migraine with aura from CIS. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Sarah Karlin-Smith and Sarah Owermohle from Politico on drug pricing.
  • Automated seizure detection accuracy for ambulatory EEG recordings
    In the first segment, Dr. Derek Bauer talks with Dr. Stephan Schuele about his paper on automated seizure detection accuracy for ambulatory EEG recordings. In the second part of the podcast, Dr. Nicole Chiota-McCollum focuses her interview with Dr. Kevin Barrett on the SHINE stroke trial.
  • Practice Current: Autoimmune Encephalitis & the Role of Antibody Testing
    Dr. Luca Bartolini discusses autoimmune encephalitis and the role of antibody testing based on a Practice Current survey run between November 2017 and May 2018.
  • Effect of prolonged antibiotic treatment on cognitive performance in patients with Lyme borreliosis
    Dr. Jeffrey Ratliff talks with Dr. Anneleen Berende about her paper on the effect of prolonged antibiotic treatment on cognitive performance in patients with Lyme borreliosis. Dr. Andrew Southerland focuses his interview with Dr. Stephen Klasko on hospitals of the future, following a panel at the World Economic Forum in Davos, Switzerland. The article can be found here: https://www.statnews.com/2019/01/26/dispatch-from-davos-future-hospitals/.
  • Autoimmune Neurology (Delayed Recall March 2019)
    This month’s Delayed Recall highlights episodes on autoimmune neurology. Dr. David Lapides and Dr. Maarten Titulaer start the show discussing the long-term neuropsychological outcome following pediatric anti-nmdar encephalitis, which first aired on May 29th, 2018. The next segment, from January 15th, has Dr. Lapides and Dr. Balu focusing on a score that predicts one year functional status in anti-NMDA receptor encephalitis patients. Following this segment is one from October 23rd and finds Dr. Stacey Clardy talking to Dr. Andrew McKeon about his paper on paraneoplastic neuronal intermediate filament autoimmunity. This episode concludes with an interview on a Neurology: Neuroimmunology & Neuroinflammation paper on IgLON5 autoimmunity between Dr. Stacey Clardy and Dr. Andrew McKeon from March 27th, 2018.
  • Predictors of dementia misclassification when using brief cognitive assessments
    In the first segment, Dr. James Grogan talks with Dr. David Llewellyn about his Neurology: Clinical Practice paper on predictors of dementia misclassification when using brief cognitive assessments. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Rob M.A. de Bie on a randomized delayed-start trial of Levodopa in Parkinson’s Disease, published in the New England Journal of Medicine. The article can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa1809983.
  • A multicentre comparison of MOG-IgG cell based assays
    1. A multicentre comparison of MOG-IgG cell based assays. 2. [What’s Trending]: the DEFUSE 3 study. In the first segment, Dr. Stacey Clardy talks with Dr. Paddy Waters about his paper on a multicentre comparison of MOG-IgG cell based assays. In the second part of the podcast, Dr. Andrew Southerland focuses his interview with Dr. Adam de Havenon on the DEFUSE 3 study.  CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
  • The prevalence of MS in the United States: A population-based estimate using health claims data
    1. The prevalence of MS in the United States: A population-based estimate using health claims data. 2. [What’s Trending]: Neurology on the Hill and advocacy issue. In the first segment, Dr. Stacey Clardy talks with Dr. Mitch Wallin about his paper examining a population-based estimate on the prevalence of MS in the United States. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Nick Johnson on Neurology on the Hill and advocacy issues. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
  • Quality Improvement in Neurology: Universal Neurology Quality Measurement Set Executive Summary
    1. Quality Improvement in Neurology: Universal Neurology Quality Measurement Set Executive Summary2. [What’s Trending]: The 2018 report of the Lancet Countdown on health and climate change: shaping the health of nations for centuries to come. In the first segment, Dr. Stacey Clardy talks with Dr. Wayne Anderson and Dr. Justin Martello about their paper on quality improvement in neurology. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Nick Watts on health and climate change shaping the health of nations for centuries to come. DISCLOSURES: Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Wayne Anderson reports no disclosures. Dr. Justin Martello has received travel funding or speaker honoraria from 1) Teva, cash, (2) Abbvie, cash, (3) Lundbeck, cash and is a member of the AAN’s Quality and Safety Subcommittee. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
  • Physical activity, common brain pathologies, and cognition in community-dwelling older adults
    1.Physical activity, common brain pathologies, and cognition in community-dwelling older adults 2. [What’s Trending]: Deep space medicine. In the first segment, Dr. Jeff Burns talks with Dr. Aron Buchman about his paper on physical activity, common brain pathologies, and cognition in community-dwelling older adults. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Alejandro Rabinstein on the medicine of deep space. Dr. Jeff Burns has served on the DSMB for three NIH-funded trials; has received honorarium and travel for speaking at an Astra-Zeneca symposium; has served on the editorial board of Journal of Alzheimer's Disease; has served as a consultant for protocol development for Stage 2 Innovations; has received commercial research support from Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, vTv Therapeutics, Janssen, and Roche and for investigator-initiated studies from Eli Lilly and Astra-Zeneca; has received governmental research support from the National Institutes of Health; and has provided expert witness testimony in legal cases. Dr. Aron Buchman has received government research support from the National Institutes of Health. Dr. Jason Crowell reports no disclosures. Dr. Alejandro Rabinstein has served as a member of the external committee for adverse event adjudication for PREVAIL trial/CAP2 registry; has served on the editorial boards of Neurology, Neurocritical Care, Stroke, CONTINUUM , and UpToDate; and has received publishing royalties from Elsevier and Oxford.
  • February 12 2019 Issue
    1.Quality of Life Outcomes in Patients Presenting for Evaluation of Central Nervous System Tumors 2. [What’s Trending]: 'Landmark study’ shows brain cells revamp their DNA, perhaps sparking Alzheimer’s disease. In the first segment, Dr. Ted Burns talks with Dr. Irene Katzan about her paper on quality of life outcomes in patients presenting for evaluation of central nervous system tumors. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Jerold Chun on a 'Landmark study’ showing brain cells revamp their DNA, perhaps sparking Alzheimer’s disease.Dr. Ted Burns has served on scientific advisory boards for Argenx, Momenta, received travel funding or speaker honoraria from Argenx, Alexion and received support for consulting activities from UCB Pharma, CSL Behring, Momenta, Argenx. Dr. Irene Katzan has served on editorial boards for Stroke (American Stroke Association), 2014-present Editorial Board - Circulation: Cardiovascular Quality & Outcomes (American Heart Association) 2013 – present. Dr. Irene Katzan has received research from one commercial entity including Novartis Pharmaceuticals and received research support from the following government entity: Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Jerold Chun reports no disclosures.
  • February 5 2019 Issue
    1. Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program 2. [What’s Trending]: Mapping Symptoms to Brain Networks with the Human Connectome. In the first segment, Dr. Teshamae Monteith talks with Dr. Roy Hamilton about his paper on reducing neurodisparity. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Michael D. Fox on mapping symptoms to brain networks with the human connectome.DISCLOSURES Dr. Teshamae Monteith has served on Scientific Advisory Boards for Lilly, Supernus, Teva, Electrocore, Promius and is an editorial advisory board member for Neurology. Dr. Roy Hamilton has served without compensation on the scientific advisory board for an NIH-funded R21 project titled ""Combining tDCS and neurorehabilitation to treat age-related deficits of mobility and cognition (UPfront Walking Study) as the data safety monitor. Dr. Hamilton has served on editorial boards for (1)Cognitive and Behavioral Neurology, editorial board member, and (2)Restorative Neurology and Neuroscience, editorial board member, 2011 to present. Dr. Hamilton is employed by Neuronix LTD as a Medical consultant, 2014 to present. Dr. Hamilton has done consultancies for Geurbet Ltd. on the development of an FDA-mandated clinical trial and received approximately $6000 for work in the last 2 years (2017-18). Dr. Hamilton received research support from 1) NIH/NIA 5P30-AG-010124-27 Co-Investigator 7/15/97-6/30/19 2) NIH/NIDCD 1 R01 DC012780-01A1 Principal Investigator 7/01/2013 - 6/30/2019 3) NIH/NIDCD 2-R01-DC-009209-11 Co-Investigator 6/01/2014 - 5/31/2019 4) NIH/NIDCR DP5OD021352 Co-Investigator 9/19/2015 - 08/31/2020 5) NIH/NIDCD 1R01DC015359-01A1 Co-Investigator 4/01/2016 - 3/31/2021 6) University of Pennsylvania/Translational Neuroscience Initiative (TNI) Co-Investigator 7/01/2016 - 6/30/2019 . 7) NIH/NEI R01EY022350 Co-Investigator 9/01/2016 - 8/31/2021 8) NIH/NINDS 5P30NS045839-12 Co-Investigator 2/1/2014-1/31/2018 9) Templeton Foundation/Imagination Institute Principal Investigator 7/01/2015 – 6/30/2017 10) Association for Frontotemporal Dementia Principal Investigator 1/01/2016 – 12/31/2016 11) Dana Foundation Principal Investigator 12/13/2012 - 4/24/2018. Dr. Hamilton’s legal proceedings include Kline & Specter Attorneys at Law, Consultant, 2014, 2015. Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Michael D. Fox has patents issues or submitted using brain imaging to guide brain stimulation. Dr. Fox has done consultancies for Mint Labs and has received research support from one government entity (1) NIH, K23NS083741 and research support from two foundations and societies (1) Dystonia Medical Research Foundation (2) National Parkinson's Foundation.
  • January 29 2019 Issue
    1. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement. 2. [What’s Trending]: On tau protein and Alzheimer dementia symptoms. In the first segment, Dr. Jason Crowell talks with Dr. James Russell about his paper on brain death, the determination of brain death, and member guidance for brain death accommodation requests. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Matthew Brier on tau protein and Alzheimer dementia symptoms.DISCLOSURES: Dr. Jason Crowell reports no disclosures. Dr. James Russell has served on Scientific Advisory Boards for Cytokinetics - Data Monitoring Board PROTOCOL CY 5022 A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE- RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). Dr. James Russell received travel funding from 1) Non-profit - Mexican Academy of Neurology - Funded travel and lodging to speak at Annual Meeting Nov 2018 - no honorarium (2) Non-profit - ALS Association - funded travel and lodging to do site visit for ALSA certification of UVA ALS Clinic. Dr. James Russell has publishing royalties from (1) Neuromuscular Disorders, McGraw-Hill, 2nd edition published 2015, with subsequent royalities 2) Honorarium for published article in Continuum: Approach to peripheral neuropathy. Continuum: Peripheral Nervous System Disorders. Fall 2017. Dr. James Russell has done consultancies with compensation for market research interviews regarding ALS therapeutics and is currently being compensated for expert opinion in two medical legal cases, one in support of the defendant and one in support of the plaintiff. Dr. Matthew Brier has received funding for Biogen, travel and accommodation and received research support for Medical Scientist Training Program Grant to WUSTL (5T32GM007200-37.
  • January 22 2019 Issue
    1. Aspirin Reduces Long Term Stroke Risk in Women with Prior Hypertensive Disorders of Pregnancy 2. [What’s Trending]: Top-selling drug price hikes and patients bearing the cost. In the first segment, Dr. Andrew Southerland talks with Dr. Eliza Miller about her paper on aspirin reducing the long term stroke risk in women with prior hypertensive disorders of pregnancy. In the second part of the podcast, Dr. Ted Burns focuses his talk with Casey Ross on makers of top-selling drugs hiking prices and patients bearing the costs.DISCLOSURES: Dr. Eliza Miller has served on Editorial Boards for Stroke, Assistant Editor, InterSECT, 2017-2018. Dr. Eliza Miller Research Support, Government Entities including (1) NIH NINDS 5U10NS086728-05, Fellow, 2017-2018 (2) NIH NINDS U01 NS095869, Subsite PI, 2018 (3) NIH NCATS 5KL2TR001874-02, KL2 Scholar, 2018-2020 and she has received research support from Foundations and Societies including American Medical Association Foundation and Louis V. Gerstner Foundation. Casey Ross reports no disclosures.
  • January 15 2019 Issue
    1. A score that predicts one year functional status in anti-NMDA receptor encephalitis patients. 2. [What's Trending]: Part 2: Drug pricing and the Institute for Clinical and Economic Review framework. In the first segment, Dr. David Lapides talks with Dr. Ramani Balu about his paper on a score that predicts one year functional status in anti-NMDA receptor encephalitis patients. In the second part of the podcast, you'll hear the the second part of Dr. Gordon Smith's interview with Dr. Steve Pearson on the Institute for Clinical and Economic Review and drug pricing. DISCLOSURES: Dr. David Lapides has served as a consultant for Board Vitals; and has received foundation/society research support from the National Multiple Sclerosis Society Clinical Fellowship. Dr. Ramani Balu has received governmental research support from the National Institutes of Health and the Department of Defense. Dr. A. Gordon Smith has served on the scientific advisory board of the Regenesis Data Monitoring Committee; has served on the editorial boards for Continuum and Annals of Clinical and Translational Neurology; has served as a consultant for Regenesis; has served on the speakers' bureau for Alexion; has received commercial research support from Impeto Medical SAS; and has received governmental research support from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Neurological Disorders and Stroke. Dr. Steve Pearson's Institute for Clinical and Economic Review has received membership dues from Aetna, Alnylam, America’s Health Insurance Plans (AHIP), Anthem, AstraZeneca, Blue Shield of CA, Cambia Health Solution, CVS, Caremark, Editas, Express Scripts, Genentech, GlaxoSmithKline, Harvard Pilgrim Health Care, Health Care Service Corporation (HCSC), HealthPartners, Johnson & Johnson, Kaiser Permanente, Mallinckrodt Pharmaceuticals, Merck & Co., National Pharmaceutical Council (NPC), Novartis, Premera Blue Cross, Prime Therapeutics, Regeneron, Sanofi, and United Healthcare; and has received foundation/society research support from the Laura and John Arnold Foundation, the California Health Care Foundation, Blue Shield of California Foundation, Kaiser, East Bay Community Foundation, and the Commonwealth Fund.
  • January 8 2019 Issue
    1. Development and validation of a score to detect paroxysmal atrial fibrillation after stroke. 2. [What's Trending]: Drug pricing and the Institute for Clinical and Economic Review framework. In the first segment, Dr. Andy Southerland talks with Dr. Timo Uphaus about his paper on the development and validation of a score to detect paroxysmal atrial fibrillation after stroke. In the second part of the podcast, Dr. Gordon Smith focuses his interview with Dr. Steve Pearson on the Institute for Clinical and Economic Review and drug pricing. DISCLOSURES: Dr. Southerland has severed on editorial boards for the Journal Neurology and is Section Editor for the Neurology Podcast. Dr. Timo Uphaus reports no disclosures. Dr. A. Gordon Smith has served on the scientific advisory board of the Regenesis Data Monitoring Committee; has served on the editorial boards for Continuum and Annals of Clinical and Translational Neurology; has served as a consultant for Regenesis; has served on the speakers' bureau for Alexion; has received commercial research support from Impeto Medical SAS; and has received governmental research support from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Neurological Disorders and Stroke. Dr. Steve Pearson's Institute for Clinical and Economic Review has received membership dues from Aetna, Alnylam, America’s Health Insurance Plans (AHIP), Anthem, AstraZeneca, Blue Shield of CA, Cambia Health Solution, CVS, Caremark, Editas, Express Scripts, Genentech, GlaxoSmithKline, Harvard Pilgrim Health Care, Health Care Service Corporation (HCSC), HealthPartners, Johnson & Johnson, Kaiser Permanente, Mallinckrodt Pharmaceuticals, Merck & Co., National Pharmaceutical Council (NPC), Novartis, Premera Blue Cross, Prime Therapeutics, Regeneron, Sanofi, and United Healthcare; and has received foundation/society research support from the Laura and John Arnold Foundation, the California Health Care Foundation, Blue Shield of California Foundation, Kaiser, East Bay Community Foundation, and the Commonwealth Fund.
  • January 1 2019 Issue
    1. Continuous EEG is Associated with Favorable Hospitalization Outcomes for Critically Ill Patients. 2. [What's Trending]: Investigation of "generic" cartel. In the first segment, Dr. Andy Schomer talks with Dr. Chloe Hill on the association between continuous EEG and favorable hospitalization outcomes for critically ill patients. In the second part of the podcast, Dr. Ted Burns focuses his interview with Christopher Rowland of the Washington Post on the investigation into a generic drug "cartel." Dr. Chloe Hill has served as an epileptologist for clinical procedures or imaging studies; and has received governmental research support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke. Dr. Ted Burns has served on the scientific advisory boards for Argenx and Momenta; has received funding for travel or speaker honoraria from Argenx and Alexion; has served on editorial boards as the Section Editor for Neurology Podcast and as Section Deputy Editor, Neurology Podcast; and has received support for consulting activities from UCB Pharma, CSL Behring, Momenta, and Argenx. Christopher Rowland is employed as a full-time reporter for the Washington Post.
  • December 18 2018 Issue
    1. The ethical and philosophical implications of gene editing. 2. [What’s Trending]: Scientific and societal impact gene editing , Dr. Jason Crowell talks with Dr. Josephine Johnston of the Hastings Center on the ethical and philosophical implications of gene editing. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Stefan Pulst on the scientific and societal impact of the recent first reported gene editing using the CRISPR technology. Dr. Jason Crowell reports no disclosures. Dr. Josephine M. Johnston has received honoraria for speaking or travel from The Hastings Center, the University of Toronto, Danbury Hospital, World Science festival, the Yale School of Medicine, the University of Pennsylvania Law School, the Royal Society of New Zealand, McGill University, Dalhousie University, and Queensland University of Technology; and has received foundation/society research support from the John Templeton Foundation. Dr. Clardy serves as the Podcast Section Editor for Neurology and has received research support from Western Institute for Biomedical Research (WIBR). Dr. Stefan Pulst has served on the editorial boards of Journal of Cerebellum, NeuroMolecular Medicine, Experimental Neurology, Neurogenetics, Nature Clinical Practice, Neurology, and as the Editor-in-Chief of Neurology: Genetics; holds numerous patents (for the following: Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Shwannomin-binding-proteins; Compositions and methods for spinocerebellar ataxia); has received publishing royalties from The Ataxias (Churchill Livingston, 2007), Genetics in Neurology (ANN Press, 2005), Genetics of Movement Disorders (Academic Press, 2003), Neurogenetics (Oxford University Press, 2000), Molecular Genetic Testing in Neurology, 2nd - 5th (AAN Press, 1996); has served as a consultant for Ataxion Therapeutics; has served on the speakers' bureau for Athena Diagnostics, Inc.; has received governmental research support from National Institutes of Health and the Clinical Research Consortium for Spincerebellar Ataxias; has received foundation/society research support for serving as a fellowship award mentor from National Ataxia Foundation; and has received license fee payments for technology or inventions from the Cedars-Sinai Medical Center.
  • December 11 2018 Issue
    1. Body mass index, but not vitamin D status, is associated with brain volume change in MS. 2. [What’s Trending]: preventing firearm injury. In the first segment, Dr. Stacey Clardy talks with Dr. Ellen Mowry about her paper on the associations between body mass index and brain volume change in MS. In the second part of the podcast, Dr. Ted Burns focuses his interview with Dr. Christine Laine on preventing firearm injury. Dr. Clardy serves as the Podcast Section Editor for Neurology and has received research support from Western Institute for Biomedical Research (WIBR). Dr. Ellen Mowry has served on a liothyronine study Data and Safety Monitoring Board; serves on the editorial board of Frontiers in Neuroepidemiomology; has received royalties as an UptoDate chapter editor; has received commercial research support from Teva Neuroscience, Biogen Idec, Genzyme, and Sun Pharma; has received governmental research support from the Department of Defense; and has received foundation/society research support from the National Multiple Sclerosis Society and the Patient-Centered Outcomes Research Institute. Dr. Christine Laine serves on the editorial board of Annals of Internal Medicine; has served as the Senior Vice President of American College of Physicians; and has received foundation/society research support from the Robert Wood Johnson Foundation.
  • December 4 2018 Issue
    1. Patient-reported outcomes across cerebrovascular event types - more similar than different 2. [What’s Trending]: Genetic landscape of pediatric movement disorders and management implications.In the first segment, Dr. Andrew Southerland talks with Dr. Irene Katzan about her paper on patient-reported outcomes across cerebrovascular event types. In the second part of the podcast, Dr. Jeff Waugh focuses his interview with Dr. Saadet Andrews on the genetic landscape of pediatric movement disorders and management implications. DISCLOSURES: Dr. Southerland has severed on editorial boards for the Journal Neurology and is Section Editor for the Neurology Podcast. Dr. Katzan served on editorial boards for Stroke (American Stroke Association) and Circulation: Cardiovascular Quality & Outcomes (American Heart Association). Dr. Katzan has received funding for research support from Novartis Pharmaceuticals and research support from the Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Waugh was employed by Children's Hospital Boston, Resident in Pediatric Neurology, 2009-2015. Dr.Saadet Andrews served on a scientific advisory board for non-profit data safety board member for a research study at The Hospital for Sick Children (2015-2017), a Commercial: Epileptic encephalopathy scientific board meeting attended in December 2017, organized by BioMarin, and a Commercial: Advisor cost effectiveness of ERT (March 2018) Commercial: Advisory board and speaker for homocysteine and betaine treatment (December 2017). Dr. Andrews received funding for travel from BioMarin (Epileptic encephalopathy scientific board meeting attended as invited speaker in December 2017) and was paid honorarium and travel-expenses. Dr. Andrews served on editorial boards for Non-profit: Journal of Pediatric Genetics Editorial Board Member (2015-present) and received research support from industry funding (2015-2016) for prevalence of mucopolysaccharidosis if rheumatology and NCV patients.
  • November 27 2018 Issue
    1. Early predictors of mortality in parkinsonism and Parkinson’s disease: a population-based study 2. [What’s Trending]: Data from the Largest Natural History Study of Stiff Person Syndrome. In the first segment, Dr. Jeffery Ratliff talks with Dr. David Bäckström about his paper on Early predictors of mortality in parkinsonism and Parkinson’s disease. In the second part of the podcast, Dr. Jeffery Ratliff focuses his interview with Marinos Dalakas on Stiff Person Syndrome. DISCLOSURES:Dr. Jeff Ratliff has received speaker honoraria from Teva and US WorldMeds LLC; is the deputy editor for the Neurology Podcast; has been a consultant for UCB Pharmaceuticals, US WorldMeds LLC, Medscape, and Retrophin Inc; and has served on speakers' bureaus for Teva and US WorldMeds LLC. Dr. David C Bäckström holds patents for chemical compounds that may be developed as treatments for premenstrual dysphoric disorder, but has not received any personal compensation for the patents. Dr. David C Bäckström has received Research Support from Swedish Medical Research Council, grant number (K2013- 62X-15224-10-4) and unrestricted grant for Parkinson's disease research and has received foundation and societies research support from Erling Persson Foundation, Umeå University, Västerbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Kempe Foundation, and Swedish Parkinson’s Disease Association. Dr. Marinos Dalakas serves the CIDP steering committee for Novartis and on DSMB for Baxalta and Octapharma, has received funding or served as a travel speaker honoraria for Merck/Serono, OCTAPHARMA, PFIZER AG. Dr. Marinos Dalakas has served on editorial board including Neurology, editorial board (5 years, not compensated), BMC Neurology (Section Editor, 5 years not compensated), Acta Myologica, editorial board (5 years, not compensated), Acta Neurologica Scandinavica editorial board (5 years, not compensated), and Therapeutic Advances in Neurology (Associate Editor; 4 years, compensated). Dr. Marinos Dalakas consultancies include work with Therapath, Baxter, Octapharma, CSL, Dysimmune Diseases Foundation and he has received research and institutional support from Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Genzyme, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, CSL, Biogen and Newfactor.
  • November 20 2018 Issue
    1. Devastating neurological injuries in the Syrian War 2. [What’s Trending]: Standards for Neurologic Critical Care Units: A Statement for Healthcare Professionals from The Neurocritical Care Society. In the first segment, Dr. Jason Crowell talks with Dr. Maher Saqqur and Yasmeen El Hajj Abdallah about neurological injuries in the Syrian War. In the second part of the podcast, Dr. Andrew Schomer focuses his interview with Dr. Asma Moheet on Standards for Neurologic Critical Care Units. DISCLOSURES: Drs. Jason Crowell, Maher Saqqur, Asma Moheet, and Andrew Schomer report no disclosures. Yasmeen El Hajj Abdallah reports employment with Shoppers Drugmart Pharmacy as pharmacy student for less than one year.
  • November 13 2018 Issue
    1. Gray matter differences in patients with functional movement disorders 2. [What’s Trending]: Recovery of Over-Ground Walking after Chronic Motor Complete Spinal Cord Injury. In the first segment, Dr. David Lapides talks with Dr. Carine Maurer about her paper on gray matter differences in patients with functional movement disorders. In the second part of the podcast, Dr. Alex Menze focuses his interview with Claudia Angeli on recovery of over-ground walking after chronic motor complete spinal cord injury. Dr. David Lapides reports no disclosures. Dr. Carine Maurer received research support from NIH, Intramural Research Program and academic research support from Stony Brook University School of Medicine. Dr. Maurer has done consultancy work for Gerson Lehrman Group. Dr. Alex Menze reports no disclosures. Dr. Claudia Angeli reports no disclosures.
  • November 6 2018 Issue
    1. Featured Article Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US 2. [What’s Trending]: Acute flaccid myelitis In the first segment, Dr. Nick Brenton talks with Dr. Kristen Krysko about her paper on therapies for pediatric multiple sclerosis. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Kenneth Tyler on acute flaccid myelitis. DISCLOSURES: Dr. Nick Brenton does not report any disclosures.Dr. Kristen Krysko received fellowship support from he National Multiple Sclerosis Society.Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for DNAtrix (DSMB, active), LPath (DSMB)(completed), and PML Consortium (Scientific Advisory Board, completed); is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from Taiga Biotechnologies and the NIH/NIAID, 1R01 NS101208, PI, 2018-2022, Dept. of Veterans Affairs Merit Grant (BX000963, Role: PI, 2017-21), NIH/NINDS, (5R21NS103186, PI, 2017-2019); and serves as Officer (Treasurer) and Member Board of Directors American Neurological Association (ANA)- Uncompensated.
  • Stroke risk, prevention and treatment (Delayed Recall - November 2018)
    This month’s Delayed Recall highlights episodes on stroke risk, prevention and treatment. Dr. Jim Siegler and Dr. Christian Gerloff begin the show discussing the results of the WAKE-UP stroke trial. This episode first aired on October 2, 2018. The next segment, from September 11, 2018 focuses on acute ischemic stroke, where Dr. Dan Ackerman talks with Dr. Andrei Alexandrov about his paper on dual antiplatelet therapy pretreatment. This interview is followed by a segment that first appeared in the August 21, 2018 show on silent infarct and the risk of infarct recurrence in adults with sickle cell anemia with Dr. Justin Sattin and Dr. Lori Jordan. The episode concludes with another interview on acute ischemic stroke from August 14, 2018 investigating a POINT study on Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA with Dr. Will Rondeau interviewing Dr. Clay Johnston.
  • October 30 2018 Issue
    1. Featured Article: Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 Update2. What’s Trending: Using artificial intelligence in neurological diagnosisDr. Jeff Ratliff talks with Dr. Anup Patel about his paper on the 2017 epilepsy quality measurement set update. In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Eric Oermann on the use of artificial intelligence in diagnosing neurological conditions. DISCLOSURES: Dr. Anup D Patel has been a consultant for Greenwich Biosciences, UCB Pharma, LivaNova, and Supernus. Dr. Patel’s other activities include Greenwich Biosciences, UCB Pharma, LivaNova, and Supernus. Dr. Patel’s has received research support for commercial entities from Greenwich Biosciences Brain Sentinel Upsher Smith Pharmaceuticals LivaNova, and research support from foundations and societies from Pediatric Epilepsy Research Foundation (PERF) American Academy of Neurology (AAN). Dr. Patel’s non-financial disclosures include serving on a voluntary basis as the vice chair for the AAN Quality Safety Subcommittee and as the chair for the Epilepsy Quality Measure work group.Dr. Andy Southerland has served on editorial boards for Journal Neurology, Section Editor Neurology Podcast Patents Intellectual property unrelated to current work: U.S. Patent Application No. 14/910,890 (iTREAT study) U.S. Provisional Patent Application No. 62/620,096 (BANDIT study). Dr. Southerland's consultancies include National Stroke Association - helped develop website for resources regarding telestroke and teleneurology, Research Support, Commercial Entities. Dr. Southerland's Edwards Lifesciences include perform neurological assessments for the PARTNER clinical trials of transcatheter aortic valve replacement. Dr. Southerland's Research Support, Government Entities include Stroke Hyperglycemia Insulin Network Effort (SHINE) NINDS/NIH U-01 NS 069498, Health Resources Services Administration - Evidence based tele-emergency network grant (RURAL EQUIT-E Project) HRSA G01RH27869, and NHLBI/NINDS - Cardiothoracic Surgical Trials Network (CTSN) - performed neurological assessments in conjunction with the neuroprotection trial of aortic valve replacement. Dr. Southerland's Research Support, Foundations and Societies include American Heart Association-American Stroke Association National Clinical Research Program, Cervical Artery Dissection Expression (CADEX) AHA 3CRP141400001, American Academy of Neurology - Education Research Grant, American Board of Psychiatry and Neurology - Faculty Fellowship Award. Dr. Southerland's legal proceedings include Legal Expert Review - perform expert review, on behalf of the UVA University Physician's Group, pertaining to stroke and vascular neurology questions for both plaintiff and defense cases.Dr. Eric Karl Oermann has received research support for foundations and societies from Doris Duke Charitable Research Foundation.
  • October 23 2018 Issue
    1. Featured Article: “‘Is there a neurologist on this flight?’ An update”2. What’s Trending: paraneoplastic neuronal intermediate filament autoimmunityDr. Jason Crowell talks with Dr. Joseph Sirven about his NCP paper entitled “‘Is there a neurologist on this flight?’ An update.” In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Andrew McKeon on paraneoplastic neuronal intermediate filament autoimmunity.DISCLOSURES:Dr. McKeon has patent applications pending: Septin 5 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; his Consultancies include Grifols Medimmune Euroimmun with no personal compensation received for these activities; he has received research support from Medimmune, Inc Euroimmun Grifols. Dr. Sirven has served on scientific advisory boards Commercial- Advisory role for Eisai, Upsher - Smith Non- profit- Epilepsy Foundation, AAN, FAA; has has funding for travel or speaker honoraria for Epilepsy Foundation- travel; has served on Editorial Boards for Epilepsy.com; has published royalties for Up to Date 2010 Clinical Neurology of the Older Adult, LWW, 2008; has completed projects for Medscape; is on the Board of Directors of the American Brain Foundation; has supported research for Government Entities, NINDS sub Investigator and supported research for Foundations and Societies, Epilepsy Foundation. Dr. McKeon has patent applications pending: Septin 5 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; his Consultancies include Grifols Medimmune Euroimmun with no personal compensation received for these activities; he has received research support from Medimmune, Inc Euroimmun Grifols.
  • October 16 2018 Issue
    1. Featured Article: Primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome: A comparative study2. What’s Trending: Cannabis and chronic neuropathic painDr. Andy Southerland talks with Dr. Anne Ducros about her paper on primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome. In the second part of the podcast, Dr. Heather Harle focuses her interview with Dr. Haggai Sharon on the use of cannabis analgesia in chronic neuropathic pain. DISCLOSURES:Dr. Ducros has served on scientific Advisory Boards for Novartis, Eli Lilly, and TEVA;has served on editorial boards for Cephalalgia: Associate Editor, Headache: editorial advisory board member, Journal of Headache and Pain: editorial advisory board member. Dr. Sharon reports no disclosures Dr. Southerland has served on editorial boards for Journal Neurology, Section Editor Neurology PodcastPatents Intellectual property unrelated to current work: U.S. Patent Application No. 14/910,890 (iTREAT study) U.S. Provisional Patent Application No. 62/620,096 (BANDIT study). Dr. Southerland's consultancies include National Stroke Association - helped develop website for resources regarding telestroke and teleneurology, Research Support, Commercial Entities. Dr. Southerland's Edwards Lifesciences include perform neurological assessments for the PARTNER clinical trials of transcatheter aortic valve replacement. Dr. Southerland's Research Support, Government Entities include Stroke Hyperglycemia Insulin Network Effort (SHINE) NINDS/NIH U-01 NS 069498, Health Resources Services Administration - Evidence based tele-emergency network grant (RURAL EQUIT-E Project) HRSA G01RH27869, and NHLBI/NINDS - Cardiothoracic Surgical Trials Network (CTSN) - performed neurological assessments in conjunction with the neuroprotection trial of aortic valve replacement. Dr. Southerland's Research Support, Foundations and Societies include American Heart Association-American Stroke Association National Clinical Research Program, Cervical Artery Dissection Expression (CADEX) AHA 3CRP141400001, American Academy of Neurology - Education Research Grant, American Board of Psychiatry and Neurology - Faculty Fellowship Award. Dr. Southerland's legal proceedings include Legal Expert Review - perform expert review, on behalf of the UVA University Physician's Group, pertaining to stroke and vascular neurology questions for both plaintiff and defense cases.
  • October 9 2018 Issue
    1. Featured Article: Neurology: Clinical Practice: Presentation and management of community onset vs. hospital onset first seizures2. What’s Trending: Acute viral encephalitisIn the first segment, Dr. Katherine Zarroli talks with Dr. Emma Foster about her paper comparing the presentation and management of patients with community- and hospital-onset first seizures attending the same hospital. In the second part of the podcast, Dr. Stacey Clardy and Dr. Kenneth Tyler review the diagnosis and treatment of acute viral encephalitis.DISCLOSURES: Dr. Zarroli reports no disclosures. Dr. Foster has received research support from National Health and Medical Research Council (NHMRC) Medical / Dental Research Postgraduate Scholarship, APP1150482, CIA, funding 2018-2020 and Royal Australasian College of Physicians (RACP) Research entry scholarship, 2018. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for DNAtrix (DSMB, active), LPath (DSMB)(completed), and PML Consortium (Scientific Advisory Board, completed); is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from Taiga Biotechnologies and the NIH/NIAID, 1R01 NS101208, PI, 2018-2022, Dept. of Veterans Affairs Merit Grant (BX000963, Role: PI, 2017-21), NIH/NINDS, (5R21NS103186, PI, 2017-2019); and serves as Officer (Treasurer) and Member Board of Directors American Neurological Association (ANA)- Uncompensated.
  • Drug Pricing (Delayed Recall - October 2018)
    This month’s Delayed Recall episode includes interviews on drug pricing. The episode starts with Dr. Jason Crowell’s interview with Dr. Gordon Smith from September 26, 2017 on orphan drug pricing. Following this clip, we have the full-length interview from the December 5, 2017 episode where Dr. Ted Burns speaks with Dr. John Mytinger on the drug Achtar for infantile ataxia. Next, in an interview from the July 4, 2017 podcast, Dr. Stacey Clardy focuses her interview with Dr. Dennis Bourdette on new immunotherapies. In the fourth and final interview, Dr. Ted Burns and reporter Ike Swetlitz discuss drug pricing practices and the different players in determining drug prices, which first aired in the May 1, 2018 episode of the podcast.
  • October 2 2018 Issue
    1. Featured Article: Nusinersen in spinal muscular atrophy type 1 patients older than 7 months: a cohort study2. What’s Trending: MRI-guided thrombolysis for stroke with unkown time of onset (WAKE-UP study)In the first segment, Dr. Ted Burns talks with Dr. Laurent Servais about his paper on safety and efficacy of nusinersen treatment in patients with SMA type 1 older than 7 months. In the second part of the podcast, we are featuring a discussion with Dr. Jim Siegler and Dr. Christian Gerloff on the results of the WAKE-UP stroke trial.DISCLOSURES: Dr. Servais has served as scientific consultant in the S.A.B of Roche, Biomarin, aTyr Pharma, Dynacure, Biogen, Bamboo, Sarepta, and Avexis; has received speaker honoraria gave lecture sponsored by Biomarin, Biogen, and Sarepta; holds patents as co-inventor of the Moviplate device, and of Actimyo; has consulted for Bamboo therapeutics, Pfizzer, Anagenesis, Avexis, and Dynacure; has received research support from NHS, Valerion, Dynacure, Avexis, Biogen, Roche, FP7 programs Skip and Scope, Université de Liège, and Association Française contre les Myopathies.
  • September 25 2018 Issue
    1. Antiepileptic Drug Clearances during Pregnancy and Clinical Implications for Women with Epilepsy2. AAN Position Statement: Lawful physician-hastened deathIn the first segment, Dr. Derek Bauer talks with Dr. Paula Emanuela Voinescu about her paper on antiepileptic drug (AED) clearances during pregnancy and the relationship between AED serum concentration and seizure frequency. In the second part of the podcast, we are featuring a discussion with Dr. Jason Crowell and Dr. James Russell on the recent AAN position statement regarding lawful physician-hastened death.DISCLOSURES: Dr. Voinescu has received speaker honoraria from SUNOVION, and has received research support from American Academy of Neurology, Susan Spencer Clinical Training Fellowship. Dr. Russell has received funding for travel from the Mexican Academy of Neurology; receives publishing royalties from Neuromuscular Disorders (McGraw-Hill, 2nd ed, 2015) and honorarium for a published article in Continuum Peripheral Neuropathy 2017; has received compensation for market research interviews regarding ALS therapeutics; and has received reimbursement for record review of medical legal proceedings without testimony or document authorship. All other participants report no disclosures.
  • September 18 2018 Issue
    1. Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial2. What’s Trending: Emerging therapies for spinal muscular atrophy and Duchenne muscular dystrophyDr. Jeff Ratliff talks with Dr. Alberto Benussi about his paper on cerebellar anodal and spinal cathodal transcranial direct current stimulation as a therapeutic approach for reducing symptoms in patients with neurodegenerative ataxia. In the second part of the podcast, we are featuring a discussion with Dr. Ted Burns and Stat reporter Adam Feuerstein on two emerging therapies for spinal muscular atrophy and Duchenne muscular dystrophy.DISCLOSURES: Dr. Ratliff has received speaker honoraria from Teva and US WorldMeds LLC; is the deputy editor for the Neurology Podcast; has been a consultant for UCB Pharmaceuticals, US WorldMeds LLC, Medscape, and Retrophin Inc; and has served on speakers' bureaus for Teva and US WorldMeds LLC. Dr. Burns has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Benussi and Mr. Feuerstein report no disclosures.
  • September 11 2018 Issue
    1. Featured Article: Dual antiplatelet therapy pretreatment in intravenous thrombolysis for acute ischemic stroke2. What’s Trending: Recurrent glioblastoma treated with recombinant poliovirusDr. Dan Ackerman talks with Dr. Andrei Alexandrov about his paper on dual antiplatelet therapy pretreatment. In the second part of the podcast, Dr. Kait Nevel focuses her interview with Dr. Darrell Bigner on treatment for recurrent glioblastoma. DISCLOSURES: Dr. Alexandrov has served on a scientific advisory board and consulted for Cerevast Therapeutics, Inc.; has served on editorial boards for Cerebrovascular Diseases and Interventional Neurology; holds a patent, and receives associated license fee and royalty payments, for "Therapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue” (US patent 6,733,450 - May 11, 2004); receives publishing royalties for Cerebrovascular Ultrasound in Stroke Prevention and Treatment (Futura / Blackwell Publishing. 2003.), Cerebrovascular Ultrasound in Stroke Prevention and Treatment (Oxford: Blackwell Publishing (in Chinese) 2007), Cerebrovascular Ultrasound in Stroke Prevention and Treatment (2nd Edition) (Oxford: Wiley-Blackwell Publishers. 2011); has served on speakers' bureau for Genentech, Inc.; has received research support from Cerevast Therapeutics, Inc. and NINR (R01 pending); holds stock or stock options in Cerevast Therapeutics, Inc.; receives Board of Reagents compensation from Cerevast Therapeutics, Inc.; and serves as President-Elect for the American Society of Neuroimaging. All other participants report no disclosures.
  • September 4 2018 Issue
    1. Practice guideline recommendations summary: Disorders of consciousness2. Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human HerpesvirusIn the first segment, Dr. Jeff Burns talks with Dr. Joseph Giacino about the AAN Guideline update on disorders of consciousness. In the second part of the podcast, we are featuring a discussion with Dr. Jason Crowell and Dr. Joel Dudley discuss the detection of human herpesvirus genes in in a large cohort patients with Alzheimer disease.DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001). Dr. Giacino has served on the scientific advisory board for the Traumatic Brain Injury Model Systems National Data and Statistical Center (federal agency); serves on the editorial board for Journal of Head Trauma Rehabilitation; serves as Director of the Spaulding Rehabilitation Network Disorders of Consciousness Program; has received research support from the U.S. Department of Defense, (Co-Investigator, W81XWH-11- 2-0210; Co-Investigator, W81XWH- 08-2-0159; Co-PI, W81XWH-14-2-0176), National Institute on Disability and Rehabilitation Research, (PI, H133A120085; site PI, 90DP0060; PI 4, 90DPTB0011), National Institutes of Health (Co-PI, 1U01NS086090-01; Co-PI, UH3NS095554), James S. McDonnell Foundation, and the The Barbara Epstein Foundation, Inc; and served as expert witness in legal proceedings for DeCorato Cohen Sheehan & Federico. Dr. Crowell and Dr. Dudley report no disclosures.
  • 2018 AAN Annual Meeting plenary interviews (Delayed Recall September 2018)
    For the September 2018 Delayed Recall episode, we are featuring recordings of in-person interviews that took place at the April 2018 AAN Annual Meeting. All interviewees were plenary speakers who gave talks throughout Annual Meeting week. These recordings originally appeared as “What’s Trending” segments in July 2018 (July 17, 24, and 31, respectively). In the first interview, we will hear Dr. Alberto Espay speak with Dr. Jeff Lichtman about connectomics. Next, Dr. Stacey Clardy interviews Dr. Michael Wilson about his talk on next-generation sequencing and diagnosing meningitis and encephalitis. Last, Dr. Alberto Espay discusses the matter of who should be the primary caregivers for functional disorder patients with Dr. Andrea Leigh Haller and Dr. David Perez.
  • August 28 2018 Issue
    1. How Early Can We Diagnose Alzheimer’s Disease (And Is It Sufficient)? 2. What's Trending: Updates to the International Classification of Headache Disorders (ICHD-3)Dr. Stacey Clardy talks with Dr. Ronald Petersen about his paper on Alzheimer disease diagnosis. In the second part of the podcast, Dr. Tesha Monteith focuses her interview with Dr. Jes Olesen on what's new in the 3rd edition of the International Classification of Headache Disorders (ICHD-3). The full ICHD-3 can be found at https://www.ichd-3.org/wp-content/uploads/2018/01/The-International-Classification-of-Headache-Disorders-3rd-Edition-2018.pdfDISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Petersen receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); has consulted for Roche Incorporated, Merck, Genentech, Biogen, and GE Healthcare (presentation); and has received research support from the National Institute on Aging (U01-AG006786, P50-AG016574, U01-AG024904, U01 AG016976). Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Olesen has consulted for Jannsen Pharmaceutical Products and served on speakers' bureaus for Allergan.
  • August 21 2018 Issue
    1. Featured Article: Silent infarct is a risk factor for infarct recurrence in adults with sickle cell anemia2. What’s Trending: Neuropalliative Care: Priorities to move the field forwardDr. Justin Sattin talks with Dr. Lori Jordan about her paper on silent infarct and the risk of infarct recurrence in adults with sickle cell anemia. In the second part of the podcast, Dr. Maisha Robinson focuses her interview with Dr. Claire Creutzfeldt on neuropalliative care.DISCLOSURES: Dr. Jordan serves on the editorial boards of the Journal of Child Neurology, Pediatric Neurology and Stroke; and has received research support from Dr. Creutzfeldt has received research support from NINDS (K23 NS099421-01A1) and Cambia Health Foundation's Sojourn Scholars Program. Dr. Sattin and Dr. Robinson reports no disclosures.
  • August 14 2018 Issue
    1. Neurology® Clinical Practice: Safety and efficacy of plasma exchange in pediatric transverse myelitis2. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA (POINT study)Dr. Stacey Clardy talks with Dr. Benjamin Greenberg about his paper on therapeutic plasma exchange in a cohort of pediatric transverse myelitis patients. Next, Will Rondeau interviews Dr. Clay Johnston about findings from the POINT study on clopidogrel and aspirin in acute ischemic stroke.DISCLOSURES:Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Greenberg has received travel funding from the Transverse Myelitis Association; has filed has filed patents on the use of antibody biology in multiple sclerosis; has consulted for Novartis, Alexion, and EMD Serono; and has received research support from Medimmune, Chugai, Medday, Genentech, NIH (RO1 NS071463), Unviersity of Texas Southwestern, Guthy Jackson Foundation, PCORI, Transverse Myelitis Association, and the National MS Society.Dr. Johnston has received travel reimbursements from the National Academies of Sciences, US News, Austin Chamber of Commerce, Johns Hopkins, UT Health Science Center, University of Utah Medical School, Medtronic, Astrazeneca, University of Rochester NY, and Duke University; has received research support from AstraZeneca, NIH/NCATS (UL1 RR024131), UCSF Clinical-Translational Science Institute, and NIH/NINDS (U01 NS062835-01A1, U01 NS062835).Mr. Rondeau reports no disclosures.
  • August 7 2018 Issue
    1. Diagnosing Cerebral Ischemia with Door-to-Thrombolysis Times Below 20 Minutes2. What’s Trending: Tenecteplase versus Alteplase before Thrombectomy for Ischemic StrokeDr. Jimmy Berthaud speaks with Dr. Perttu Lindsberg about his paper on the accuracy and consequences of rapid stroke diagnostics in a neurological emergency department. In the second segment of the podcast, Dr. Kevin Barrett interviews Dr. Bruce Campbell about the EXTEND-IA TNK trial of tenecteplase for patients with ischemic stroke.DISCLOSURES: Dr. Berthaud reports no disclosures. Dr. Lindsberg serves as Assistant Editor for the medical journal DUODECIM; serves as chairman of the ad hoc committee on Current Therapy Guidelines in Stroke for the Finnish Medical Society; and has recieved research support for Helsinki University Hospital District, the Sigrid Jusélius Foundation, the Jane and Aatos Erkko Foundation, and the Signe and Ane Gyllenberg Foundation. Dr. Barrett has received research support from Axovant Sciences, Inc., the Virginia Center of Alzheimer's and Related Diseases, and the Department of Defense. Dr. Campbell serves on the editorial board for Stroke Stroke; served as PI of the EXTEND-IA trial, partially funded by unrestricted grant from Medtronic; and has received research support from the National Health and Medical Research Council of Australia (GNT1111972 2016-2019) and the Heart Foundation, Australia.
  • Lessons of the Week on Functional Disorders (Delayed Recall August 2018)
    This month’s Delayed Recall features the Lesson of the Week series on functional disorders with Dr. David Lapides interviewing Dr. Jon Stone. The first interview provides an overview of functional disorders; next is a discussion of diagnostic approaches. The third segment highlights how to deliver a functional disorder diagnosis to a patient, and the final interview discusses treatment management. All these interviews were originally published in June and July 2018.
  • July 31 2018 Issue
    1. Organic solvents and MS susceptibility: Interaction with MS risk HLA genes 2. AAN 2018 Controversies in Neurology plenary: Andrea Leigh Haller and David Perez discuss primary caregivers for functional disorder patientsDr. Stacey Clardy talks with Dr. Anna Hedström about her paper on exposure to organic solvents and the associated risk of developing multiple sclerosis, followed by a discussion with Dr. Alberto Espay, Dr. Andrea Leigh Haller, and Dr. David Perez on who should be the primary caregivers for functional disorder patients. The second interview was originally recorded at the AAN Annual Meeting in Los Angeles.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Drs. Hedström, Leigh Haller, and Perez report no disclosures. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; and receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation, and the NIH.
  • July 24 2018 Issue
    1. Non-invasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study2. AAN 2018 Hot Topics plenary: Michael Wilson discusses metagenomics for diagnosing CNS infectionsDr. Teshamae Monteith talks with Dr. Cristina Tassorelli about her paper on vagus nerve stimulation for treating migraine, followed by a discussion with Dr. Stacey Clardy and Dr. Michael Wilson on next-generation sequencing and diagnosing meningitis and encephalitis. The second interview was originally recorded at the AAN Annual Meeting in Los Angeles.DISCLOSURES: Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Tassorelli has served on scientific advisory boards for Allergan Inc., ElectroCore LLC, Eli-Lilly and Company, Novartis, Teva Pharmaceutical Industries Ltd; has received funding for travel or speaker honoraria from Novartis, Allergan Inc, and Teva Pharmaceutical Industries Ltd; serves on editorial boards for Journal of Headache and Pain and Frontiers in Neurology; has consulted for Allergan Inc. and Eli Lilly and Company; has received research support from Eli Lilly and Company, Novartis, Teva Pharmaceuticals, ElectroCore, and the Italian Ministry of Health; and serves as Chairman of the Committee for the Guidelines of Clinical Trials of the International Headache Society. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Wilson has received research support from NIH/National Center of Advancing Translational Science (NCATS), Clinical and Translational Science Institute (CTSI), and the American Brain Foundation Clinical Research Training Fellowship.
  • Lessons of the Week on Migraine (Delayed Recall July 2018)
    This month’s Delayed Recall episode consists of the Migraine Lesson of the Week series posted each week in January 2018. The episode starts with Dr. Teshamae Monteith’s interview with Dr. Stephen Silberstein (January 9, 2018) about updates in chronic migraine risk factors and management, followed by her interview with Dr. Jelena Pavlovic (January 16, 2018) on the interplay between migraine and hormones. Next, Dr. Monteith focuses her interview with Dr. Stuart Tepper on neuromodulation (January 23, 2018). In the fourth and final interview, Dr. Monteith and Dr. Benjamin Friedman discuss emergency management of migraine (January 30, 2018).
  • July 17 2018 Issue
    1. Featured Article: Longitudinal analysis of impulse control disorders in Parkinson disease2. What's Trending: Frontiers in Neuroscience plenary interview from 2018 Annual MeetingThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 17, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. Alexis Elbaz about his paper on impulse control disorders in Parkinson disease. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. Jeff Lichtman on connectomics. The interview was recorded at the 2018 AAN Annual Meeting in Los Angeles.DISCLOSURES: Drs. Crowell and Lichtman reports no disclosures. Dr. Elbaz has received research support from Agence nationale de la recherche (ANR), Agence nationale de sécurité du médicament et des produits de santé, JPND (Joint Programme - Neurodegenerative Disease Research), Institut de santé publique (IRESP), French ministry of agriculture, and Anses (government agency for food and environment safety). Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.
  • July 10 2018 Issue
    1. Featured Article: Practice guideline update summary: Efficacy and tolerability of new antiepileptic drugs I: Treatment of new-onset epilepsy2. Lesson of the Week: Functional Disorders This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 10, 2018 issue of Neurology. In the first segment, Dr. Derek Bauer talks with Dr. Jacqueline French about her paper, a summary of a recent practice guideline on the treatment of new-onset epilepsy. In the second part of the podcast, Dr. David Lapides continues the Lesson of the Week discussion on functional disorders with Dr. Jon Stone. DISCLOSURES: Dr. French has served on scientific advisory boards and consulted for the Epilepsy Foundation, Acadia, Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cavion, Cerecor, Cerebral Therapeutics, Concert Pharmaceuticals, Covance, CuroNZ, Eisai, Empatica, Engage, Georgia Regents University, Glaxo Smith-Kline, GW Pharma, J&J Pharmaceuticals, Marinus, MonosolRx, Monteris, Nestle-Health Science, Neurelis, Novartis, Otsuka, Ovid, Pfizer, Pfizer-Neusentis, Sage Therapeutics, Shire, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Ultragenyx, Xenon Pharmaceuticals, Xeris, Zogenix and Zynerba; has received research support from Alexza, Acorda, LCGH, Eisai Medical Research, LCGH, Lundbeck, Neurelis, Pfizer, SK life sciences, Sunovion, Takeda, UCB, Upsher-Smith, Biogen, NINDS (2U01NS038455-11A1), Epilepsy Foundation, and Epilepsy Study Consortium; has received paid travel to present findings at scientific meetings, present at investigators' meetings, attend advisory boards, or give lectures from Epilepsy Study Consortium, Epilepsy Foundation, International League Against Epilepsy, American Academy of Neurology, American Epilepsy Foundation, Adamas, Biogen, Eisai, Engage, GW Pharma, GSK, Novartis, Otsuka, Ovid, Pfizer, Sage, Sunovion, Takeda, UCB, Ultragenyx, Upsher-Smith, Zynerba, Blackfynn Pfizer, Pfizer-Neusentis, Sage, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith,Zogenix, and Zynerba; serves on editorial boards for Lancet Neurology, Neurology Today, and Epilepsy Currents; and serves as President, Epilepsy Study Consortium Chief Scientific Officer, Epilepsy Foundation. Drs. Bauer and Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders http://www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.
  • July 3 2018 Issue
    1. Featured Article: Conscious sedation or local anesthesia during endovascular treatment for acute ischemic stroke2. Lesson of the Week: Functional disordersThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 3, 2018, print issue of Neurology. In the first segment, Dr. Brian Eckerle talks with Dr. Rob van de Graaf about his paper on conscious sedation vs local anesthesia during endovascular treatment for ischemic stroke. For the Lesson of the Week segment, Dr. David Lapides and Dr. Jon Stone continue their discussion of functional disorders. DISCLOSURES: Drs. Eckerle, van de Graaf, and Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders http://www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.
  • June 12 2018 Issue
    1. Featured Neurology® Clinical Practice Article: Reflections on Translation: Views of Participants in a Multi-Site Canadian CCSVI Clinical Trial2. Lesson of the Week: Functional disorders This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 12, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Shelly Benjaminy about her paper on patients’ perspectives from the chronic cerebrospinal venous insufficiency clinical trial in Canada. In the second segment, Dr. David Lapides continues his discussion with Dr. Jon Stone about how to approach functional disorders.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Benjaminy has received research support from Canadian Institutes of Health Research [INV-126709], University of British Columbia [Public Scholars Award, Li Tze Fong Memorial Fellowship, Millie and Ralph Drabinsky Graduate Scholarship in Medicine, and Faculty of Medicine Graduate Scholarship], and Stem Cell Network Canada. Dr. Lapides reports no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders http://www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.
  • June 5 2018 Issue
    1. Featured Article: Validation of a simple disease-specific quality of life measure for diabetic polyneuropathy; the CAPPRI2. Lesson of the Week: Functional disorders This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 5, 2018, print issue of Neurology. In the first segment, Dr. Alex Menze interviews Dr. Kelly Gwathmey about her paper on a new quality of life measure for diabetic polyneuropathy. For the second segment, Dr. David Lapides speaks with Dr. Jon Stone about updates in approaching functional disorders in the clinic.DISCLOSURES: Dr. Menze, Dr. Gwathmey, and Dr. Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders http://www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.
  • Multiple Sclerosis (Delayed Recall June 2018 )
    The Delayed Recall episode for June takes a look at recent guidelines and developments in the field of multiple sclerosis treatment. In the first interview, Dr. Stacey Clardy and Dr. Alexander Rae-Grant discuss recent practice guidelines for multiple sclerosis, and talk about Dr. Rae-Grant’s paper regarding these guidelines. This interview first aired on April 24, 2018. The second interview, from the May 15, 2018 episode, features Dr. Clardy speaking with Dr. Riley Bove about her recent paper on rituximab treatment during pregnancy. Next, hear Dr. Clardy speak with Dr. Raed Alroughani about relapse occurrence of MS during pregnancy, in an interview that appeared in the March 6, 2018 episode. In the conclusion to this month’s episode, Dr. Mark Keegan and Dr. Gavin Giovannoni discuss the topic of alemtuzumab treatment for multiple sclerosis patients. This interview first appeared on April 18, 2017.
  • May 29 2018 Issue
    1. Featured Article: Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis2.What's Trending: Amateur fundus photographyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 29, 2018 issue of Neurology. In the first segment, Dr. David Lapides talks with Dr. Maarten Titulaer about his paper on long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis. Next, Dr. Roy Strowd talks with Dr. Saman Zafar about her paper on amateur fundus photography for our “What’s Trending” feature of the week. DISCLOSURES: Dr. Titulaer serves on the editorial board of Neurology: Neuroimmunology & Neuroinflammation; filed a patent for "methods for typing neurological disorders and cancer, and devices for use therein" specifically about diagnostics for anti-GABAB receptor antibodies and KCTD antibodies; and has received research support from Medimmune LLC, Guidepoint Global LLC, Novartis, Euroimmun AG, the Netherlands Organisation for Scientific Research, an ErasmusMC fellowship, and the Dutch Epilepsy Foundations. Dr. Strowd serves on the editorial board for Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology. Dr. Lapides and Dr. Zafar report no disclosures.
  • May 22 2018 Issue
    1. Featured Article: ABBY: A Phase 2 randomized trial of crenezumab in mild-to-moderate Alzheimer's Disease2. What’s Trending: Epilepsy Birth Control Registry This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 22, 2018, print issue of Neurology. In the first segment, Dr. Jeff Burns talks with Dr. Jeffrey Cummings about results from the ABBY clinical trial on crenezumab as a potential treatment for mild to moderate Alzheimer Disease. For the “What’s Trending” segment, Dr. Katherine Zarroli interviews Dr. Andrew Herzog about the Epilepsy Birth Control Registry (http://www.epilepsybirthcontrolregistry.org).
  • May 15 2018 Issue
    1. Featured Neurology® Clinical Practice Article: Ask a Neurologist: What Primary Care Providers ask, and reducing referrals through eConsults2. What’s Trending: Update on arboviruses This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 15, 2018, print issue of Neurology. In the first segment, Dr. Heather Harle interviews Drs. Ana Bradi and Erin Keely about their paper on implementing an eConsult service between primary care providers and neurologists at the Ottawa Hospital. For the “What’s Trending” segment, Dr. Amanda Piquet and Dr. Daniel Pastula discuss what every neurologist should know about mosquito- and tick-borne disease. DISCLOSURES: Dr. Harle and Dr. Bradi report no disclosures. Dr. Keely served as Associate Editor for Obstetric Medicine (2010 - 2017); and has received research support from CIHR (Partnerships for Health System Improvement, 367535 and 358003), Stemmler Medical Education Research Fund, and National Board of Medical Examiners, and Physicians' Services Incorporated Foundation. Dr. Piquet and Dr. Pastula report no disclosures.
  • May 8 2018 Issue
    1. Featured Article: Factors associated with treatment delays in pediatric refractory convulsive status epilepticus2. What’s Trending: Focused ultrasound for treating tremorThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 8, 2018 issue of Neurology. In the first segment, Dr. Erika Axeen talks with Dr. Iván Fernández about his paper on factors that influence treatment delays in pediatric refractory convulsive status epilepticus. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Jeff Elias on two recent articles published in the New England Journal of Medicine regarding focused ultrasound treatment for tremor. DISCLOSURES: Drs. Axeen and Crowell report no disclosures. Dr. Fernández has received research support from Epilepsy Research Fund, Fundación Alfonso Martín Escudero (Grant for the study of Epileptic Encephalopathies), and HHV6 Foundation. Dr. Elias reports grant support from InSightec, the BIRD Foundation, and the Focused Ultrasound Foundation.
  • Best Advances in neurology in 2017 (Delayed Recall May 2018)
    This month’s Delayed Recall episode includes interviews on topics that were highlighted in the Neurology Today "Best Advances of 2017" editorial. The episode starts with Dr. Andy Southerland's interview with Dr. Joseph Safdieh (April 10, 2018) that features a few editor's pick from the Best Advances in neurology in 2017. Following this clip, we have the full-length interview from the February 28, 2017 episode where Dr. Ted Burns speaks with Dr. Richard Finkel about nusinersen and spinal muscular atrophy. Next, in an interview from the February 13, 2018 podcast, Dr. Tesha Monteith focuses her interview with Dr. Peter Goadsby on CGRP treatments and migraine. In the third and final interview, Dr. Nicole Chiota-McCollum and Dr. Greg Albers regarding the DEFUSE trial results, which first aired in the April 17, 2018 episode of the podcast.
  • May 1 2018 Issue
    1. Featured Article: Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease2. What’s Trending: Drug pricing This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 1, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Matthew Barrett about his paper on predictors of psychosis in Parkinson disease. For the “What’s Trending” segment, Dr. Ted Burns discusses drug pricing with journalist Ike Swetlitz.DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Barrett has received research support from Axovant Sciences, Inc. (clinical trial site PI), Azevan Pharmaceuticals (clinical trial site PI), Merck Sharp & Dohme Corp. (Clinical trial site PI), Biogen (clinical trial site PI), Virginia Center of Alzheimer´s and Related Diseases Research Award Fund (PI), U.S. Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Career Progress Award (PI), and NIH (clinical trial site PI).Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Mr. Swetlitz is a reporter for StatNews.
  • April 24 2018 Issue
    1. Featured Article: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis2. What’s Trending: Global, regional, and national burden of neurological disorders during 1990–2015 (from Lancet Neurology)This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 24, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Alexander Rae-Grant about the AAN Practice Guideline on disease-modifying therapies for adults with multiple sclerosis. For the “What’s Trending” segment, Dr. Jason Crowell interviews Dr. Theo Vos about findings from the Global Burden of Diseases, Injuries, and Risk Factors Study and the growing need for clinicians with neurologic expertise.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Rae-Grant has served on the Neurology Evidence Review Team, 2011-2018; receives publishing royalties from Handbook of Multiple Sclerosis (Springer Healthcare, 2010), Comprehensive review of clinical neurology, (Wolters Kluwer, 2012), 5 minute consult in neurology (Wolters Klower, 2012), Comprehensive review of clinical neurology second edition ( LWW, 2016), Ultimate review of neurology (DEMOS 2016), and Multiple Sclerosis and Related disorders (DEMOS, 2014); edits neurology chapters for Dynamic Medical, an online text book of medicine which is funded via library subscriptions; was involved in a clinical trial of biotin for multiple sclerosis with MedDay (no personal remuneration); and receives research support from NIH (grant #A6022304). Dr. Crowell reports no disclosures.
  • April 17 2018 Issue
    1. Featured Article: Clinical Reasoning: A young woman with symmetric weakness and behavioral disturbance2. What’s Trending: DEFUSE 3 trial results on thrombectomy vs. standard therapy alone for ischemic stroke This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 17, 2018, print issue of Neurology. In the first segment, Dr. Dan Ackerman talks with Dr. Jon Rosenberg about the differential diagnosis of a young patient with symmetric weakness, behavioral changes, and bilateral infarcts. For the “What’s Trending” segment, Dr. Nicole Chiota-McCollum speaks with Dr. Gregory Albers about findings from the DEFUSE 3 clinical trial.DISCLOSURES: Dr. Ackerman, Dr. Rosenberg, and Dr. Chiota-McCollum report no disclosures. Dr. Albers has served on a steering committee for Lundbeck and Covidien; serves on the editorial board for Stroke; holds a patent for RAPID software for MRI and CTP analysis of diffusion and perfusion data; has consulted for Astra Zeneca, Biogen, and iSchemaView; holds stock in iSchemaView; and has received research support from NINDS.
  • April 10 2018 Issue
    1. Featured Article: Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD2. Neurology Today: Top research advances in 2017This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 10, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy interviews Dr. Riley Bove about her paper on rituximab treatment before and during pregnancy in patients with multiple sclerosis and NMOSD. For the second segment, Dr. Andy Southerland speaks with Dr. Joseph Safdieh on the Neurology Today editorial selections for the top research advances in 2017.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Safdieh has served on scientific advisory board for Upsher Smith; receives publishing royalties from Rubin MP, Safdieh JE. Netters Concise Neuroanatomy (Elsevier 2007); and serves as Editor-in-Chief of Neurology Today.
  • April 3 2018 Issue
    1. Featured Article: The Mitochondrial Disease Patients’ Diagnostic Odyssey: Results of A Survey2. What’s Trending: Teen concussion and early tauopathyThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 3, 2018, print issue of Neurology. In the first segment, Dr. Jason Crowell talks with Drs. John L.P. Thompson and Michio Hirano about their Neurology: Genetics paper on the long journey to diagnosis for patients with mitochondrial disease. For the “What’s Trending” segment, Dr. Jeff Ratliff speaks with Dr. Lee Goldstein about teen concussion and early tauopathy.DISCLOSURES: Dr. Crowell reports no disclosures. Dr. Thompson has recieved research support from Novartis, NIH/NINDS (1U54 NS078059-06), NIEHS (P30 ES009089-15), and the FDA (UFDSP00011270). Dr. Hirano has received honoraria for serving on advisory boards of Stealth Biotherapeutics, Sarepeta, and Biogen; received received travel funds from the American College of Medical Genetics; has served as Nerve and Muscle editor of Current Neurology and Neuroscience Reports (2002-present); holds Rare Pediatric Disease (RPD) and Orphan Drug Designations (ODD) for deoxynucleoside therapy for mitochondrial DNA depletion syndrome including TK2 deficiency; received honoraria as a member of the Speakers' Bureau of Athena Diagnostics; and received research support from Santhera Pharmaceutical, Edison Pharmaceutical, National Institutes of Health (U54NS078059, R01HD056103 RC1NS070232 P01HD032062), Muscular Dystrophy Association (MDA) USA and Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF). Dr. Goldstein is a consultant for Rebiscan, Inc. Dr. Ratliff has received a speaker honorarium from Haverford College.
  • Practice Current: Managing Epilepsy during Pregnancy (April 2018)
    This special Delayed Recall episode is the third installment of our new Practice Current segment. In this episode, Dr. Luca Bartolini speaks with epilepsy experts Dr. Cynthia Harden and Dr. Torbjörn Tomson. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding epilepsy treatment and management during pregnancy, and share their thoughts regarding best practices. This is the first appearance of this interview in the podcast.
  • March 27 2018 Issue
    1. Featured Article: IgLON5 antibody: Neurological Accompaniments & Outcomes in 20 patients2. What’s Trending: Health policy update - Coding, Reimbursement & Quality Payment ProgramThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 27, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Andrew McKeon about his Neurology: Neuroimmunology & Neuroinflammation paper describing IgLON5 autoimmunity. For the “What’s Trending” segment, Dr. Jason Crowell speaks with Luana Ciccarelli and Amanda Napoles on regulatory updates in coding and reimbursement, MACRA, and tips for private practitioners on participating in the Quality Payment Program.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. McKeon has patent applications pending for GFAP and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; has consulted for Grifols, Medimmune, Inc., and Euroimmun (but did not receive personal compensation for these activities); and has received research support from Medimmune, Inc. and Euroimmun. Dr. Crowell reports no disclosures. Luana Ciccarelli and Amanda Napoles are employed by the American Academy of Neurology.
  • March 20 2018 Issue
    1. Featured Article: Molecular Genetic Testing for Hereditary Ataxia – What Every Neurologist Should Know2. What’s Trending: Recent changes to Maintenance of Certification Requirements This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 20, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Thomas Bird about his Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias. For the “What’s Trending” segment, Dr. Stacey Clardy with Dr. Laurie Gutmann about recent updates to the Maintenance of Certification requirements and tips to ease the process for neurologists.DISCLOSURES: Dr. Bird serves on the editorial board for GeneReviews.org; holds patents for genetic testing technology for CMT1C and SCA14; and has received research support from the Department of Veterans' Affairs (Merit Research Grant, PI, 2009-2017). Dr. Gutmann serves on the editorial board for Up-to-Date Online (Hypokalemic and Hyperkalemic Periodic Paralysis); and has recieved research support from Alexion Pharmaceuticals, Inc. and the NIH (U01 NS069498-01 A1, 3P50NS044283-07S1, U01 NS026835-01A1, U01 NS058728-01, and U01 NS077179-01). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).
  • March 13 2018 Issue
    1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence2. What’s Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnosesThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the “What’s Trending” segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy diagnoses.DISCLOSURES: Dr. Sposato has received travel or speaker honoraria from Boehringer Ingelheim and Pfizer; serves on the Editorial Board for Neurology; and has received research support from Kathleen & Dr Henry Barnett Research Chair in Stroke Research, Boehringer Ingelheim (salary support for a fellow), Edward and Alma Saraydar Neurosciences Fund, Opportunities Fund of the Academic Health Sciences Centre Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario, and Boehringer Ingelheim. Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press, 2016); has consulted for Novartis, Bristol Meyers Squibb, and Bionest; and has received research support from Biogen (ARISE study). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. McAllister and Dr. Zalewski report no disclosures.
  • Delayed Recall - Cognitive Impairment (March 2018)
    This month’s Delayed Recall episode includes three recent interviews on the topic of cognitive impairment. In the first interview, from the January 16, 2018 episode, Dr. Jeff Burns speaks with Dr. Ronald Petersen about the recent AAN practice guideline paper on mild cognitive impairment. Next, in and interview from the January 2, 2018 podcast, Dr. Ted Burns and Dr. Damian Garde discuss recent Alzheimer disease trials; and in the third and final interview, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper “Multimodal MRI markers and dementia risk in cerebral small vessel disease.” This interview first aired in the October 31, 2017 episode of the podcast.
  • March 6 2018 Issue
    1. Featured Article: Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era2. What’s Trending: Sleep architecture and risk of dementiaThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 6, 2018, issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Raed Alroughani about his article on relapse recurrence during pregnancy in women with multiple sclerosis. In the second part of the podcast, you’ll hear Dr. Jeff Burns interviews Dr. Sudha Seshadri about sleep and dementia risk.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Alroughani served in scientific advisory boards of Novartis, Bayer, Merck-Sorono, Roche, Biogen, Sanofi-Geznyme; has received speaker and travel honoraria from Novartis, Bayer, Merck-Sorono, Biogen, Roche, Sanofi-Genzyme and GSK; and has received research grants from Biogen, Novartis and Sanofi-Genzyme.Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Seshadri serves on editorial boards for Journal of Alzheimer's Disease, Stroke, and Neurology; and has received research support from NIA (AG008122, AG033040, AG049505, AG033193, AG049607, AG054076).
  • February 27 2018 Issue
    1. Featured Article: Interdisciplinary Response to Contemporary Concerns about Brain Death Determination2. What’s Trending: Gene Drive, part 2This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 27, 2018 issue of Neurology. In the first segment, Dr. Andy Schomer talks with Dr. Ariane Lewis about her paper on the determination of brain death. In the second part of the podcast, Dr. Ted Burns speaks with Dr. Kevin Esvelt for part two of the discussion on gene drives (the first of these segments aired in the Feb. 20 episode).
  • February 20 2018 Issue
    1. Featured Article: Intravenous thrombolysis and platelet count2. What’s Trending: Gene Drives, part IThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 6, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Henrik Gensicke about his article on the effect of platelet count on bleeding risk and mortality in stroke patients treated with IV thrombolysis. In the second part of the podcast, you’ll hear the first part of Dr. Ted Burns’ interview with Dr. Kevin Esvelt about gene drives.DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and Neurohospitalist; has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials; and receives publishing royalties from Wiley Blackwell. Dr. Gensicke receives research support from Swiss National Science Foundation (33CM30-124119 and P300PB_161071). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Esvelt reports no disclosures.
  • February 13 2018 Issue
    1. Featured Article: Medical Retirement from Sport after Concussions: a practical guide for a difficult discussion2. What’s Trending: CGRP drugs and treatment of migraineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 13, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. James Noble about his Neurology® Clinical Practice paper on athletes who retire from sport following concussion. In the second part of the podcast, Dr. Tesha Monteith focuses her interview with Dr. Peter Goadsby on CGRP and migraine. DISCLOSURES: Dr. Crowell reports no disclosures. Dr. Noble received travel honoraria for the Big 10/Ivy League concussion summit; has a pending patent for a real-time concussion diagnostic tool; has consulted with Prophase, LLC; has received research support from NIH (U54 NS081765, R01 NS067443, R01AG054536, T35 AG044303); and holds stock options in BATS-TOI. Dr. Goadsby has consulted for Akita, Allergan, Amgen, Autonomic Technologies Inc, Avanir, Cipla, Dr Reddy's Laboratories, Eli-Lilly, Electrocore, eNeura, Pfizer, Scion, Teva, and Trigemina; serves on editorial boards for NEJM Journal Watch, and Neurology Up-to-Date; receives publishing royalties for Mechanism and Management of Headache (Elsevier 2005); holds stock options in Trigemina Inc.; and receives research support from Amgen, and Eli-Lilly. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.
  • February 6 2018 Issue
    Featured Article: Burnout, Wellness, and the Future of Our ProfessionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 6, 2018, issue of Neurology. This week, Dr. Ted Burns talks with Dr. Terry Cascino about his special address on burnout and the future of neurology. DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Cascino is the immediate past president of the American Academy of Neurology.
  • Delayed Recall - February 2018
    This month's Delayed Recall episode comprises an update regarding recent developments in the field of stroke, and includes four interviews from 2017 that focused on this topic. The first interview aired in the September 12 episode, and features a discussion between Dr. Kevin Barrett and Dr. Tudor Jovin regarding the recent DAWN trial. Next, Dr. David Ackerman and Dr. Gene Latorre take a look at the stroke rehabilitation quality measurement set update that was published in Neurology® in October of 2017. This interview appeared as part of the Oct. 10 podcast episode. The third interview of this month's Delayed Recall was featured in the October 24 episode; in it, Dr. Justin Sattin talks about the use of Tenecteplase for acute ischemic stroke with Dr. Nicola Logallo. The final interview, by Dr. Nichole Chiota with Dr. Steven Messe, covers the recent PFO Update. This segment was featured in the November 7 episode.
  • January 30 2018 Issue
    1. Featured Article: Racial disparities in refusal of stroke thrombolysis in Chicago2. Lesson of the Week: Emergency management of migraineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 30, 2018, issue of Neurology. In the first segment, Dr. Jennifer Majersik talks with Dr. Scott Mendelson about his paper on differences in tPA refusal in black vs non-black patients with acute ischemic stroke. In the second part of the podcast, Dr. Teshamae Monteith focuses her Lesson of the Week interview with Dr. Benjamin Friedman on IV prochlorperazine plus diphenhydramine vs IV hydromorphone for emergency migraine treatment.DISCLOSURES: Dr. Majersik serves on the editorial board for Neurology; receives research support from National Institutes of Health (grant U10 NS086606); and served as an expert witness for FAVROS, LCC. Dr. Mendelson has received travel honoraria from Medtronic; has received research support from University of Chicago and Institute of Medicine of Chicago. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Friedman reports no disclosures.
  • Jan 23 2018 Issue
    1) Featured Article: Collateral response modulates the time–penumbra relationship in proximal arterial occlusions2) Lesson of the Week: Migraine and neuromodulationThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 23, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Smriti Agarwal about her paper on collateral circulation in proximal arterial occlusions and extending the scope of thrombolytic therapy. In the second part of the podcast, Dr. Teshamae Monteith focuses her Lesson of the Week interview with Dr. Stewart Tepper on acute and preventative neuromodulation treatment for migraine. DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and Neurohospitalist; has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials; and receives publishing royalties from Wiley Blackwell.Dr. Agarwal reports no disclosures.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Tepper is a member of the board for the American Headache Society and has been a consultant for or participated on a paid advisory board for Acorda Therapeutics, Inc; Alder BioPharmaceuticals, Inc; Allergan plc; Amgen, Inc; Avanir Pharmaceuticals, Inc; BioVision, Inc; Charleston Laboratories, Inc; Dr. Reddy’s Laboratories, Ltd; electroCore, LLC; eNeura, Inc; Eli Lilly and Company; GLG Pharma, LLC; Guidepoint Inc, LLC, Ltd; Kimberly-Clark Corporation; Pernix Therapeutics Holdings, Inc; Pfizer, Inc; Scion NeuroStim, LLC; Teva Pharmaceutical Industries, Ltd; and Zosano Pharma, Corp.
  • January 16 2018 Issue
    1. Featured Article: Practice guideline update summary: Mild cognitive impairment2. Lesson of the Week: Migraine and hormonesThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 16, 2018, print issue of Neurology. In the first segment, Dr. Jeff Burns talks with Dr. Ronald Petersen about the updated 2001 AAN guideline on prevalence, prognosis, and treatment of MCI. For the Lesson of the Week, Dr. Teshamae Monteith speaks with Dr. Jelena Pavlovic about the association between hormones and migraine. DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Petersen receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); has consulted for Roche Incorporated, Merck, Genentech, and Biogen; and receives research support from National Institute on Aging (U01-AG006786, P50-AG016574, U01-AG024904, and U01-AG016976). Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Pavlovic has received consulting honoraria and travel support from Allergan, Inc. and travel/conference registration support from The American Headache Society.
  • January 9 2018 Issue
    1) Featured Article: Quality improvement in neurology: Child neurology quality measure set2) Lesson of the Week: Update on chronic migraine risk factors, management, and treatmentThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 9, 2018, issue of Neurology. In the first segment, Dr. Adam Numis talks with Dr. Jeffrey Buchhalter and Dr. Anup Patel about their quality measure set executive summary article regarding child neurology. For the “Lesson of the Week” segment, Dr. Tesha Monteith speaks with Dr. Stephen Silberstein about chronic migraine.DISCLOSURES:Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section; has received speaker honorarium from LivaNova; and has received research support from American Academy of Neurology, Clinical Research Training Fellowship in Epilepsy, 2017-2019, and American Epilepsy Society, Research and Training Fellowships for Clinicians, 2017-2018.Dr. Bucchalter has served on advisory and safety monitoring boards for NIH, NINDS, Observational Safety Monitoring Board for NIH, and the Charlie Foundation; has received travel and speaker honoraria from AAN, Eisai Co. Ltd., Child Neurology Society, Lundbeck, and Upsher-Smith Labs; serves on the editorial board for Pediatric Neurology; has consulted in the past with Lundbeck Inc., Eisai Co. Ltd., UCB, and Upsher-Smith; and has received research support from Alberta Health Services.Dr. Patel has served on scientific advisory board for UCB Pharma; has served as book and associate editor for Journal of Child Neurology; has consulted for Greenwich Biosciences, LivaNova, and Supernus; and has received research support from Greenwich Biosciences, Brain Sentinel, Upsher Smith Pharmaceuticals, LivaNova, Pediatric Epilepsy Research Foundation (PERF), and American Academy of Neurology (AAN).Dr. Silberstein has served on scientific advisory boards for Alder, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Mitsubishi Tanabe, Neuralieve, NINDS, Pfizer, Supernus, Teva, Curelator, Depomed, Dr. Reddy's Laboratories, Lilly, and Trigemina; has served on editorial boards for Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management, and Neurology; has consulted for Allergan, Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Neuralieve, Pfizer, Supernus, and Teva; served on speaker's bureaus in the past for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck; and has received research support from GlaxoSmithKline, Allergan, Merck, Novartis, NIH, Neurolieve, MAP, Endo, Amgen, ElectroCore, Avanir, NIH, AHS, and IHS.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.
  • January 2 2018 Issue
    1) Featured Article: Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy 2) What’s Trending: Clinical Trials in Alzheimer Disease This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Carlos Pardo about his paper on clinical biomarkers and differential diagnosis of myelitis. For the “What’s Trending” segment, Dr. Ted Burns speaks with journalist Damian Garde about the recent Clinical Trials in Alzheimer Disease conference. DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Pardo has served on scientific advisory board for the Transverse Myelitis Association; has received research support from Accorda Pharmaceuticals, Chugai Pharmaceutical Co. LTD, Medimmune, NIH/NINDS (R21NS076381, R01NS055628, R21TW0009741, P30MH075673, 1R01HL130649-01), and the Bart McLean Neuroimmunology Fund from the Transverse Myelitis Association. Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Mr. Garde reports no disclosures.
  • Delayed Recall - Patient Perspectives, Part II (January 2018)
    Patient Perspectives, Part II (January 2018)This month’s Delayed Recall episode is the second part of our feature including interviews that focus on the patient perspective. The first part of this feature aired as the Delayed Recall episode for December 2017. We feature four interviews in this second installment; the first is Dr. Alberto Espay’s interview with Dr. Ted Burns in the Sept. 3, 2013 episode, in which they discuss Dr. Burns’ cancer diagnosis and his subsequent experience as a patient. In the second interview, with Dr. Lara Marcuse, Dr. Marcuse responds to Dr. Espay’s Sept. 2013 interview with Dr. Burns, and remarks briefly on her own time as a patient. This interview was part of the October 29, 2013 episode. The third interview features Dr. Espay and Dr. Burns once more; they discuss Dr. Burns’ cancer recurrence, as well as Dr. Burns’ view about the kind of care that he believes is important for healthcare providers to focus on. This interview first appeared in the August 1, 2017 episode. Last, we feature an interview from the June 3, 2008 episode, between Dr. Ted Burns and Dr. Bob Joynt, in which Dr. Joynt offers his advice regarding patient treatment.
  • December 12 2017 Issue
    1) Neurology: Neuroimmunology & Neuroinflammation: Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy 2) What’s Trending: R&F section update with Dr. Roy StrowdThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 12, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Takahiro Iizuka about his paper on diagnosis and treatment of new-onset refractory status epilepticus (NORSE). In the second part of the podcast, Dr. Jeff Ratliff focuses his interview with Dr. Roy Strowd on a highlighted Clinical Reasoning case from the new “Resident & Fellow Rounds” feature debuting in 2018.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society. Dr. Iizuka serves on editorial boards for Current Treatment Options in Neurology and Rinsho Shinkeigaku (Clinical Neurology), and has received research support from Mitsubishi Tanabe Pharma Corporation (MTPS20160504012) and the Japan Epilepsy Research Foundation (JERFTENKAN 17002).Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Strowd serves on the editorial board of Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology.
  • December 5 2017 Issue
    Show description/summary:1) Long-term benefit of enzyme-replacement therapy in Pompe disease: A 5-year prospective study2) What’s Trending: ACTH or prednisolone for infantile ataxiaThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 5, 2017 issue of Neurology. In the first segment, Dr. Kelly Gwathmey talks with Dr. Nadine van der Beek about her paper on enzyme-replacement therapy in Pompe disease. In the second part of the podcast, Dr. Ted Burns focuses his interview with Dr. John Mytinger on the topic of ACTH or prednisolone for infantile ataxia. DISCLOSURES: Dr. Gwathmey reports no disclosures.Dr. van der Beek has received speaker honoraria from Sanofi-Genzyme (paid to to Erasmus MC for further research purposes); and has received research support from Sanofi-Genzyme, Colciencias, ZonMW - the Netherlands Organization for Health Research and Development, the Prinses Beatrix Spierfonds, SSWO – Sophia Children’s Hospital Foundation, and TKI-Health Holland.Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring.Dr. Mytinger reports no disclosures.
  • Delayed Recall - Patient Perspectives, Part I (December 2017)
    This month’s Delayed Recall episode is the first in a duo of episodes featuring interviews that focus on the patient perspective. The second part of this feature will appear as the Delayed Recall episode for January 2018. As the first of the three interviews included in December’s episode, we feature an interview by Dr. Ted Burns with Dr. Oliver Sacks regarding Dr. Sacks’ experience with ocular melanoma. This interview originally aired in January 2011, and appeared again as part of a Delayed Recall episode in 2015, which was aired as a tribute to Dr. Sacks following his passing. In the second interview of this episode, from February 19, 2013, Dr. Burns speaks with Dr. Bob Holloway on communicating prognosis for patients with serious neurological diseases. In the third and final interview in this episode, Dr. Burns speaks with Dr. Richard Morton about his essay regarding his experience as a patient. This interview was part of the July 25, 2017 podcast episode.
  • November 28 2017 Issue
    1) Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study2) What’s Trending: Neurology paper on breast feeding, ovulatory years, and risk of multiple sclerosisThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 28, 2017 issue of Neurology In the first segment, Dr. Jeff Burns talks with Dr. Keenan Walker about his paper on the association between systemic inflammation and brain volume over time. For our What’s Trending segment, Dr. Stacey Clardy focuses her interview with Dr. Annette Langer-Gould about her recent Neurology article on breast feeding, ovulatory years, and risk of multiple sclerosis.DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001)Dr. Walker has received research support from the National Institute of Aging (AG027668, postdoc fellow, 2016-17).Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society.
  • November 21 2017 Issue
    Show description/summary:1) Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players 2) Neurology Today® paper on the increase in gabapentinoid prescriptionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Kathryn Manning and Dr. Ravi Menon about their paper regarding the effects of concussion on adolescent hockey players. In the second part of the podcast, Dr. Burns focuses his interview with Dr. Christopher Goodman about a recent Neurology Today article discussing the increase in gabapentinoid prescriptions. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring.Dr. Manning reports no disclosures.Dr. Menon has served on the scientific advisory board of International Initiative for Traumatic Brain Injury Research (NIH/EU/CIHR); has served on the editorial boards of NeuroImage, Journal of Neurophysiology, Scientific Reports, and Tomography; has received research support from Siemens Healthineers, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Canada First Research Excellence Fund, and Brain Canada Foundation; and has received royalty payments from Siemens Healthcare for US Patent 8,193,812.Dr. Goodman reports no disclosures.
  • November 14 2017 Issue
    Show description/summary:1) Infliximab for the treatment of central nervous system sarcoidosis: A multi-institutional series2) What’s Trending: Sonic traumatic brain injuryThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 14, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Siddharama Pawate and Dr. Jeff Gelfand about their paper on infliximab for treatment of central nervous system sarcoidosis. In the second part of the podcast, Dr. Alex Menze focuses his interview with Dr. Jeffrey Kim on the recent speculation around sonic traumatic brain injury.DISCLOSURES: Dr. Gelfand has served on scientific advisory boards for Genentech; has received compensation for consulting with Genentech; has received research support from Quest Diagnostics, Genentech, MedDay, and NIH National Center for Advancing Translational Sciences (KL2TR000143); and has received compensation for serving as expert witness in medical-legal consulting. Dr. Pawate has served on scientific advisory board for Biogen, and has received research support from Biogen.Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).All other participants report no disclosures.
  • November 7 2017 Issue
    Show description/summary:1) This variant alters protein function, but is it pathogenic? (Neurology® Genetics)2) What’s Trending: PFO UpdatesThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 7, 2017 issue of Neurology. In the first segment, Dr. Michelle Mauermann talks with Dr. Massimo Pandolfo about his recent Neurology® Genetics editorial, entitled “This variant alters protein function, but is it pathogenic?”. In the second part of the podcast, Dr. Nicole Chiota focuses her interview with Dr. Steven Messe on recent PFO/stroke updates. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives publishing royalties from Oxford, and has received research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals.Dr. Pandolfo has served on the scientific advisory boards of Apopharma and Voyager Therapeutics; has served on the editorial boards of Acta Neurologica Belgica, Orphanet Journal of Rare Diseases, and Neurology Genetics; is co-holder of a patent for Direct molecular diagnosis of Friedreich’s ataxia; has been a consultant for Biomarin and UCB; has received research support from Biomarin, Fonds National de la Recherche Scientifique (Belgium), Offrez-moi-la-lune, Friedreich's Ataxia Research Alliance, and Association Belge contre les Maladies neuro-Musculaires, and receives royalty payments from Athena Diagnositcs for a Friedreich's ataxia diagnostic test.Dr. Chiota reports no disclosures.Dr. Messe has served on the scientific advisory board of the Yale University Cardiovascular Research Group; has received travel funding from the American Academy of Neurology; has received publishing royalties from Up To Date; has been a consultant for Claret Medical; and has received research support from WL Gore, Glaxo Smith Kline, Bayer, Mallinkrodt, and NIH.
  • Delayed Recall - Immunotherapy (November 2017)
    This month’s Delayed Recall episode features Dr. Stacey Clardy’s Lesson of the Week interviews on the topic of immunotherapy, which originally aired in July 2017. In the first interview, Dr. Clardy speaks with Dr. Dennis Bourdette about new immunotherapies in neurology. This interview first appeared in the July 4 episode. In the interview from July 11, Dr. Clardy continues the discussion about new immunotherapies with Dr. Jeffrey Cohen. The third interview, from the July 18 episode, features Dr. Clardy speaking with Dr. Emmanuelle Waubant about immunotherapy as it applies to multiple sclerosis patients. To conclude this episode, we offer Dr. Clardy’s interview with Dr. Anne Cross, in which they talk about immunosuppressants in Neurology; this interview was part of the July 25 episode.
  • October 31 2017 Issue
    Show description/summary:1) Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease2) What’s Trending: dabigatran reversal in patients with uncontrolled bleeding This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 31, 2017, issue of Neurology. In the first segment, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper multimodal MRI markers and dementia risk in cerebral small vessel disease. In the second part of the podcast, Dr. Bryan Eckerle focuses his interview with Dr. Charles Pollack on dabigatran reversal in patients with uncontrolled bleeding or receiving surgery. DISCLOSURES: Dr. Markus serves as section editor of International Journal of Stroke; serves on the editorial board for Clinical Neurology and Neurosurgery, and BMC Medicine; serves as Associate Editor for Fronteirs in Neurology; receives publishing royalties from Stroke Medicine (OUP 2016); has consulted and led a teaching session for Astra Zeneca; and has received research support from MRC, NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK. Dr. Eckerle and Dr. Elliot report no disclosures.Dr. Pollack has received research support from Boehringer Ingelheim, Daiichi Sankyo, CSL Behring, Janssen Pharma, AstraZeneca, and Portola; and has served as scientific consultant for Boehringer Ingelheim, BMS/Pfizer, Janssen Pharma, AstraZeneca, and Portola.
  • October 24 2017 Issue
    Show description/summary:1) Persistent focal enhancement of the cisternal segment of oculomotor nerve in ophthalmoplegic migraine (Neurology® Clinical Practice)2) What’s Trending: Tenecteplase for acute ischemic strokeThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 24, 2017 issue of Neurology. In the first segment, Dr. Heather Harle talks with Dr. Ihtesham Qureshi about his Neurology® Clinical Practice paper on ophthalmoplegic migraine. In the second part of the podcast, Dr. Justin Sattin focuses his interview with Dr. Nicola Logalio on using tenecteplase for acute ischemic stroke. Disclosures can be found at Neurology.org.DISCLOSURES: All participants report no disclosures.
  • October 17 2017 Issue
    Show description/summary:1) Qualitative study of burnout, career satisfaction, and well-being among US neurologists in 20162) What’s Trending: gene editing in human embryosThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 17, 2017, issue of Neurology. In the first segment, Dr. Pearce Korb talks with Dr. Janis Miyasaki about her paper on burnout, career satisfaction and well-being among US neurologists. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Shoukhrat Mitalipov on gene editing in human embryos for correction of a pathogenic mutation.DISCLOSURES: Dr. Miyasaki has received honoraria from Davis Phinny Foundation, Sunovion, and NINDS; receives publishing royalties from “Up to Date: Psychogenic Movement Disorders;” has consulted for Cynapsus and GE; has served on a scientific advisory board for Parkinson Society Canada; and has received research support from Allergan, PCORI, and Parkinson Alberta.Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer” (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq.Dr. Korb and Dr. Crowell report no disclosures.
  • October 10 2017 Issue
    Show description/summary:1) Quality improvement in neurology: Stroke and stroke rehabilitation quality measurement set update2) Neurology Today® paper on Parkinson disease and autoimmunityIn the first segment, Dr. Dan Ackerman talks with Dr. Gene Latorre about his paper on the updated quality measurement set for stroke and stroke rehabilitation. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. David Sulzer on Parkinson disease and autoimmunity. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.All other participants report no disclosures.
  • October 3 2017 Issue
    Show description/summary:1) Functional impairments for outcomes in a randomized trial of of unruptured brain AVMs2) What’s Trending: Hurricane Harvey and patient care in TexasThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 3, 2017, issue of Neurology. In the first segment, Dr. Andrew Southerland talks with Dr. JP Mohr about his paper on functional impairment outcome measurements in a randomized trial of unruptured brain arteriovenous malformations. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Aziz Shaibani on Hurricane Harvey and its effect on patient care in Texas. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Mohr serves as Associate Editor for History of Stroke and Cerebrovascular Disease; has consulted for Schering-Plough; has given expert testimony on unruptured brain AVMs; and has received research support from NINDS associated with the ARUBA trial. Dr. Crowell reports no disclosures.Dr. Shaibani is President-Elect for the Texas Neurology Society.
  • Delayed Recall - Practice Current: Treatment of neuromyelitis optica (October 2017)
    This special Delayed Recall episode is the second installment of our new Practice Current segment. In this episode, Dr. Luca Bartolini speaks with neuromyelitis optica (NMO) experts Dr. Tarso Adoni and Dr. Michael Levy. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding NMO treatment, and share their thoughts on best practices. This is the first appearance of this interview in the podcast.
  • September 26 2017 Issue
    Show description/summary:1) Neurology® Genetics: ExACtly zero or once: A clinically helpful guide to assessing genetic variants in mild epilepsies 2) What’s Trending: Orphan drug pricingThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 26, 2017 issue of Neurology. In the first segment, Dr. Jim Kiely talks with Dr. Samuel Berkovic about his Neurology® Genetics paper on assessing genetic variants in mild epilepsies. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Gordon Smith on orphan drug pricing. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Kiely is employed at InTouch Health Physician Services as a teleneurologist, and holds stock with InTouch Health. Dr. Berkovic serves on scientific advisory board for UCB Pharma and Eisai Australia; has served on editorial boards for Brain, Epileptic Disorders, and Lancet Neurology; is an investor listed on a Bionomics Inc patent on diagnostic testing using SCN1A gene (WO2006/133508), and is an investor on a pending patent for a therapeutic compound related to a genetic cause of familial epilepsy with mental retardation in females (WO61/010176); receives research support from UCB, SciGen, and Eisai Australia, the National Health and Medical Research Council of Australia (Program Grant #1091593; 2016-2020), and NINDS (U01 NS077367-01; 2011-2014).Dr. Smith serves on the Celegene data monitoring committee; serves as editor for NeuroLearn; has consulted for Regenesis, Allergan, and Viromed; and receives research support from Impeto Medical, and NIDDK (DK064814), NINDS (U10NS077305 and U10NS086606).Dr. Crowell reports no disclosures.
  • September 19 2017 Issue
    Show description/summary:1) Medication-overuse headache: An entrenched idea in need of scrutiny 2) What’s Trending: DAWN TrialThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 19th, 2017 issue of Neurology. In the first segment, Dr. Alex Menze talks with Dr. Elizabeth Loder about her paper on medication overuse headache. In the second part of the podcast, Dr. Kevin Barrett focuses his interview with Dr. Tudor Jovin on the DAWN trial on Trevo thrombectomy for acute ischemic stroke. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Menze reports no disclosures.Dr. Loder has received travel funding from the American Headache Society and American Migraine Foundation and The British Medical Journal; has served on the editorial boards of The British Medical Journal, Cephalalgia, and Headache; receives publishing royalties from Cambridge University Press; and has received research support from Harvard Medical School.Dr. Barrett serves on the editorial boards of Neurology and Neurohospitalist; receives publishing royalties from Wiley-Blackwell; and has received research support from NINDS.Dr. Jovin has served on the Codman Neurovascular Data Safety Monitoring Board; has received travel funding from Stryker Neurovascular and Fundacio Ictus; and holds stock/stock options in Silk Road Medical, Anaconda, and Blockade Medical.
  • September 12 2017 Issue
    Show description/summary:1) National randomized controlled trial of virtual house calls for Parkinson disease2) Neurology Today: Interview with Joseph Safdieh, the new Editor-in-Chief of Neurology Today®This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 12, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Ray Dorsey about his paper on virtual house calls for Parkinson disease. In the second part of the podcast, Dr. Andy Southerland interviews Dr. Joseph Safdieh about Dr. Safdieh’s new position as Editor in Chief of Neurology Today. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College.Dr. Dorsey has served on the scientific advisory boards of Shire Pharmaceuticals and Huntington's Disease Society of America; has received travel funding and/or honoraria from the American Academy of Neurology and the American Neurological Association; has served on the editorial boards of the Journal of Huntington's Disease, HD Insights, and Digital Biomarkers; has been a consultant for 23andMe, Abbott Nutrition, Abbvie, Amgen, Biogen, Clintrex, GlaxoSmithKline, Grand Rounds, Lundbeck MC10, MedAvante, Medico Legal services, NIH/NINDS Optio, Shire, Sunovion Pharma, Teva, UCB, Voyager Therapeutics, State of Georgia, Mednick Associates, and Putnam Associates; has performed clinical practice, including telemedicine, as a movement disorder neurologist; has received research support from Abbvie, AMC Health, Avid Radiopharmaceuticals, BioMarin, GlaxoSmithKline, Great Lakes Neurotechnologies, Lundbeck, Medtronic, Prana Biotechnology, Raptor Pharmaceuticals, Roche, Teva Pharmaceuticals, National Institute of Neurological Disorders and Stroke, Patient-Centered Outcomes Research Institute, University of California Irvine, Duke University, Burroughs Wellcome Fund, Davis Phinney Foundation, Michael J. Fox Foundation, Safra Foundation, Greater Rochester Health Foundation, Huntington Study Group, and National Science Foundation; holds Grand Rounds and BlackFlynn stock options; and has received compensation for expert testimony.Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Safdieh has served on the scientific advisory board for Upsher Smith; is the Editor-in-Chief of Neurology Today, has received publishing royalties from Elsevier, and has performed consultant work regarding legal proceedings.
  • September 5 2017 Issue
    Show description/summary:1) Longitudinal diffusion changes following postoperative delirium in older people without dementia2) What’s Trending: Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adultsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 5, 2017 issue of Neurology. In the first segment, Dr. Pearce Korb talks with Dr. Michele Cavallari and Dr. David Alsop about their paper on longitudinal diffusion changes following postoperative delirium in people without dementia. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Barbara Bendlin on poor sleep and biomarkers of amyloid pathology in cognitively normal adults. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Alsop serves as associate editor for Magnetic Resonance in Medicine; has received research support from GE Healthcare Technologies, NIH (P01 AG031720, R01 MH080729, R01 NS047029, R21 EB014471, R01 CA169470, P20 DK108276, R44 DK111260); and receives royalty payments for Patent 7,545,142 (arterial spin labeling with pulsed radio frequency sequences) and from GE Healthcare, Philips Healthcare, Siemens Medical, Hitachi Medical, and Animage Technology.Dr. Cavallari has received research support from NIA (P01AG03172).Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001). Dr. Bendlin serves as associate editor for Journal of Alzheimer's Disease; and has received research support from NIH/NIA (Alzheimer's Disease Connectome Project, U01AG051216, P50 AG033514, R01AG037639, R56AG052698, R21AG053738, P50 AG033514, 1U54AI117924).Dr. Korb reports no disclosures.
  • Delayed Recall - Concussion and Chronic Traumatic Encephalopathy (September 2017)
    The first interview in this month’s Delayed Recall episode is from March 17, 2015; in this interview, Dr. Howard Goodkin and Dr. Robert Stern discuss the effect that age of first exposure to football has on later-life cognitive impairment in former NFL players. The second interview, from August 29, 2017, is a discussion between Dr. Jason Crowell and Dr. Jesse Mez about a July 2017 JAMA paper on occurrence of CTE in American football players. In the third interview, Dr. Christopher Giza speaks with Dr. John Hart about Dr. Hart’s paper regarding depressive symptoms and white matter dysfunction in retired NFL players with concussion history. This interview originally appeared in the July 1, 2013 episode. The fourth and final interview is a discussion between Dr. Ted Burns and former NFL player Ben Utecht, regarding Mr. Utecht’s Sept 23, 2014 editorial, “Concussed.”
  • August 29 2017 Issue
    Show description/summary:1) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome2) What’s Trending: CTE and American football playersThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 29, 2017 issue of Neurology. In the first segment, Dr. Nicholas Brenton talks with Dr. Kevin Rostásy about his paper on the prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Jesse Mez on chronic traumatic encephalopathy and American football players. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Rostásy serves on a scientific advisory board for Novartis regarding a fingolimod project, and has received speaker honoraria for Merck-Serono.Dr. Smith serves on the Celegene data monitoring committee; serves as editor for NeuroLearn; has consulted for Regenesis, Allergan, and Viromed; and receives research support from Impeto Medical, and NIDDK (DK064814), NINDS (U10NS077305 and U10NS086606).All other participants report no disclosures.
  • August 22 2017 Issue
    Show description/summary:1) Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome2) Neurology Today: FDA Approves Edaravone for ALS: Phase 3 Trial Finds It Slows ProgressionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 22, 2017 issue of Neurology. In the first segment, Dr. Halley Alexander talks with Mr. Mohit Sodhi about his paper on oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome. In the second part of the podcast, Dr. Kelly Gwathmey focuses her interview with Dr. Terry Heiman-Patterson on a Neurology Today® story about the FDA-approval of edaravone for the treatment of ALS. Disclosures can be found at Neurology.org.DISCLOSURES: All participants report no disclosures.
  • August 15 2017 Issue
    Show description/summary:1) Quality improvement in neurology: Inpatient and emergency care quality measure set executive summary 2) Neurology Today: Incidental findings and normal variants on MRI of the brain in adults for primary headachesIn the first segment, Dr. Jason Crowell talks with Dr. Paul Vespa about his paper on quality improvement in inpatient and emergency neurologic care. In the second part of the podcast, Dr. Teshamae Monteith focuses her interview with Dr. Randolph Evans on a Neurology Today® story about incidental findings and normal variants on brain MRI for primary headache in adults. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Vespa serves on scientific advisory boards for Intouch Health, Edge Pharmaceuticals, and Sage Pharmaceuticals; serves on editorial boards for Critical Care Medicine, Neurocritical Care, and Surgical Neurology International; has consulted for General Electric and Neuren; receives research support from NINDS; holds stock in Intouch Health and stock options in Pfizer; and gave expert testimony about brain trauma.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Crowell and Dr. Evans report no disclosures.
  • August 8 2017 Issue
    Show description/summary:1) Neurology® Clinical Practice: Barriers and Facilitators to ER Physician Use of the Test and Treatment for BPPV2) What’s Trending: New crowd-funding research initiative from ABFIn the first segment, Dr. Jim Siegler talks with Dr. Kevin Kerber and Dr. William Meurer about their Neurology® Clinical Practice article on ER physician use of the test and treatment for benign paroxysmal positional vertigo. In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Robert Griggs and Jane Ransom on the new crowd-funding research initiative from the American Brain Foundation. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Siegler serves on the Resident and Fellow Section Team for Neurology, and has received research support from NIH (U10 StrokeNet grant, 2017-2018).Jane Ransom is Executive Director of the American Brain Foundation.Dr. Kerber received funding for travel from Elsevier Inc. and the American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; is a consultant for the American Academy of Neurology, University of California San Francisco (including work on a project funded by AstraZeneca), and Best Doctors, Inc.; receives research support from the NIH; received speaker honoraria from American Academy of Neurology and University of California San Francisco and loan repayment award from the NIH; reviewed legal records of Phil Pearsons, MD, JD and National Medical Consultants.Dr. Meurer serves as Decision Editor for the Annals of Emergency Medicine; serves as Methodology Statistics Reviewer for Academic Emergency Medicine; and has received research support from the Massey Foundation for TBI research. Dr. Griggs has served on scientific advisory boards for National Hospital Queen Square, Marathon Pharmaceuticals, Taro Pharmaceuticals, and Sarepta Pharmaceuticals; has served on the data monitoring and safety board for PTC Therapeutics, Inc.; serves on the editorial board for NeuroTherapeutics and Current Treatment Opinions in Neurology; serves as Correspondence Editor for Neurology; receives publishing royalties from Andreoli and Carpenter’s Cecil Essentials of Medicine (Eighth Edition, Elsevier), Cecil Textbook of Medicine (multiple editions, Elsevier), and Evaluation and Treatment of Myopathies (2014, Oxford); has consulted for Marathon, PTC Therapeutics, Sarepta, Taro Pharmaceuticals, Idera Pharmaceuticals, and Strongbridge Pharmaceuticals; receives data royalties and research support from Taro Pharmaceuticals and Marathon Pharmaceuticals; has received research support from NINDS (T32 NS07338, 5U01NS061799, 1R13NS084687), the FDA (R01 FD003923), Parent Project Muscular Dystrophy, Inc., and the Muscular Dystrophy Association; and is the recent past Chair of Executive Committee of the Muscle Study Group.
  • August 1 2017 Issue
    Show description/summary:1) On being sick: Musings about kindness, side effects, and slowing down2) Resident & Fellow Section Update: Annual Writing AwardIn the first segment, Dr. Alberto Espay talks with Dr. Ted Burns about his Special Editorial, “On being sick: Musings about kindness, side effects, and slowing down.” In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. John Millichap on the annual Resident & Fellow writing award. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.
  • July 25 2017 Issue
    Show description/summary:1) Neurology and the Humanities: Discovering the patient within2) Topic of the Month: immunosuppressants in neurologyIn the first segment, Dr. Ted Burns talks with Dr. Richard Morton about his Neurology and the Humanities paper, “Discovering the Patient Within.” In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Anne Cross on immunosuppressants in neurology. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Burns serves as a section editor for the Neurology® podcast; serves on advisory boards for Argenx, UCB, and CSL Behring; receives travel or speaker honoraria from Argenx and Alexion; and received support for consulting from UCB Pharma and CSL Behring.Dr. Morton reports no disclosures. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Cross has served on advisory boards for Roche and Genentech; has served on editorial boards for Brain Pathology, Journal of Neuroimmunology, and Annals of Clinical Translational Neurology; receives research support from Roche, Teva Neuroscience, OBOE, NIH, Barnes-Jewish Hospital Foundation, and Conrad N Hilton Foundation; consults with Biogen, Sanofi-Aventis/Genzyme, Novartis, Teva Neuroscience, Gerson Lehrman Group, Guidepoint Global, LLC, AbbVie, EMD Serono, Genentech, and Bayer; and receives honoraria from Projects in Knowledge, Prime Education, Inc., Race to Erase MS, Conrad N. Hilton Foundation, and WebMD.
  • July 18 2017 Issue
    Show description/summary:1) Diagnosis of DWI-negative acute ischemic stroke: a meta-analysis 2) Topic of the Month: Multiple sclerosis therapeutics and pediatric multiple sclerosis patientsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 18, 2017 issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Brian L. Edlow about his paper on the diagnosis of DWI-negative acute ischemic stroke: a meta-analysis. In the second part of the podcast Dr. Stacey Clardy focuses her interview with Dr. Emmanuelle Waubant on MS therapeutics and pediatric MS patients. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Barrett has served on the editorial boards of both Neurology® and The Neurohospitalist; receives publishing royalities from the book Stroke; and receives research support from NINDS.Dr. Edlow receives research support from Guger Technologies, NIH, American Academy of Neurology/American Brain Foundation, and the James S. McDonnell Foundation.Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR).Dr. Waubant volunteers on a Novartis advisory board; serves on the editorial board of Annals of Clinical and Translational Neurology; serves as editor of MSARD; receives royalties from the publication of the book Demyelinating disorders of the central nervous system in childhood; and receives research support from Roche, Novartis, NIH, National MS Society, and Race to Erase MS.
  • July 11 2017 Issue
    Show description/summary:1) Neurology® Neuroimmunology & Neuroinflammation: Antiepileptic drug therapy in patients with Autoimmune Epilepsy3) Topic of the Month: immunotherapy in neurologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 11, 2017 issue of Neurology. In the first segment, Dr. Lara Marcuse talks with Dr. Anteneh Feyissa about his Neurology: Neuroimmunology & Neuroinflammation paper on antiepileptic drug therapy in patients with autoimmune epilepsy. In the second part of the podcast Dr. Stacey Clardy focuses her interview with Dr. Jeffrey A. Cohen on new immunotherapies in neurology. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR). Dr. Cohen has served on scientific advisory boards for Adamas, Celgene, Genentech, Genzyme/Sanofi, Merck, and Novartis; serves as co-editor for Multiple Sclerosis Journal; receives publishing royalties from Multiple Sclerosis Therapeutics (Cambridge University Press, 4th ed., 2011); and has received research support form the Department of Defense, NIH, National MS Society, and Consortium of MS Centers. All other participants report no disclosures.
  • July 4 2017 Issue
    Show description/summary:1) Intake of dairy foods and risk of Parkinson disease 2) Topic of the Month: Immunotherapies in neurology This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 4, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Katherine C. Hughes about her paper on intake of dairy foods and risk of Parkinson disease. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Dennis Bourdette on new immunotherapies in neurology. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Fullard has received training support from NIH. Dr. Hughes received research support from the U.S. Department of Defense. Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR). Dr. Bourdette serves as an editorial board member on Neurology®, receives funding for travel from the National Multiple Sclerosis Society, the Consortium of MS Centers, and the Paralyzed Veterans of America; consults with Magellan Health and is a patient consultant for Best Doctors, Inc.; has a patent and a second patent pending for drug treatments of multiple sclerosis; and serves as a PI for the National MS Society.
  • Delayed Recall - Neuro-oncology Lessons of the Week (July 2017)
    In this month's Delayed Recall episode, we are featuring four interviews by Dr. Kait Nevel on the topic of neuro-oncology. In the first interview, Dr. Nevel speaks with Dr. Jennie Taylor about neuro-oncology and seizures. In the second, she discusses intracranial pressure with Dr. Mariza Daras. These interviews originally appeared in the March 7 and March 14 episodes, respectively. Next, Dr. Nevel and Dr. Lisa DeAngelis talk about metastatic diseases in neurology, in a segment that appeared in the March 21 episode. Last, Dr. Nevel discusses gliomas with Dr. David Schiff in an interview from March 28.
  • June 13 2017 Issue
    Show description/summary:1) Evaluating the safety of beta-interferons in multiple sclerosis 2) Neurology® Today: New Classifications of Seizures and Epilepsies Include New Seizure Types, Simpler TermsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 13, 2017 issue of Neurology. In the first segment, Dr. Michael Levy talks with Dr. Helen Tremlett and Dr. Hilda De Jong about their paper on evaluating the safety of beta-interferons in multiple sclerosis. In the next part of the podcast Dr. Nathan Fountain focuses his interview with Dr. Robert Fisher on the new classifications of seizures and epilepsies presented by the International League Against Epilepsy. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Levy serves on advisory boards for Asterias, Chugai, and Alexion; serves as Editorial Board member of Multiple Sclerosis and Related Disorders; holds patents for an aquaporin-4 sequence that elicits pathogenic T cell response in animal model of neuromyelitis optica, and for use of a peptide for diagnostic and therapeutic developments; has consulted for Guidepoint Global, Gerson Lehrman Group, and Cowen Group; and has received research support from Viropharma/Shire, Acorda, ApoPharma and Sanofi, Genzyme, Alnylam, Alexion, Terumo BCT, National Institute of Neurological Diseases and Stroke, and Guthy-Jackson Charitable Foundation.Dr. Tremlett has served on scientific advisory boards for US National MS Society and the Centers for Disease Control and Prevention; is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis; has received research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, Canada Foundation for Innovation, the Multiple Sclerosis Society of Canada, US National Multiple Sclerosis Society, Multiple Sclerosis Scientific Research Foundation, Michael Smith Foundation for Health Research, and the UK MS Trust; has received speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres, the National MS Society, ECTRIMS, the Chesapeake Health Education Program, US Veterans Affairs, Novartis Canada, Biogen Idec, American Academy of Neurology.Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort).All other participants report no disclosures.
  • Practice Current: Antiepileptic Drug Discontinuation
    Delayed Recall - June 2017In this special Delayed Recall episode, Dr. Luca Bartolini speaks with epilepsy experts Dr. Greg Cascino, Dr. Ali Asadi-Pooya, and Dr. Ley Sander. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding antiepileptic drug discontinuation, and share their thoughts on best practices with regard to the case studies presented to the survey respondents. This is the first appearance of this interview in the podcast.
  • Responsible Opioid Prescribing—Special Podcast #4
    We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 3 and 4, Dr. Andy Southerland interviews Dr. Gary Franklin. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.
  • June 6 2017 Issue
    Show description/summary:1) Post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage2) Neurology Today® paper on migraine and young adults' risk of cervical artery dissectionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 6, 2017 issue of Neurology. In the first segment, Dr. Rahul Guha talks with Dr. Anna-Maija Lahti about her paper on post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage. In the next part of the podcast Dr. Andrew Southerland talks with Dr. Valeria De Giuli about a Neurology Today® story on migraine and young adults' risk of cervical artery dissection. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.All other participants report no disclosures.
  • May 30 2017 Issue
    Show description/summary:1) Evidence-based guideline summary: Reducing brain injury following cardiopulmonary resuscitation2) Neurology Today® paper: “Prolonged Holter-ECG monitoring found to improve detection of atrial fibrillation after acute stroke”This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 30, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer talks with Dr. Romergryko Geocadin about the AAN practice guideline on reducing brain injury following cardiopulmonary resuscitation. In the next part of the podcast Dr. Matthew Ehrlich focuses his interview with Dr. Rolf Wachter on the Neurology Today feature, “Prolonged Holter-ECG monitoring found to improve detection of atrial fibrillation after acute stroke.” Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Geocadin serves on the DSMB for the PEARL Study: “A Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography for Post-Cardiac Arrest Patients with No ST Segment Elevation on the ECG” funded by the State of Arizona Biomedical Research Commission; serves on editorial boards for Neurocritical Care and Resuscitation; receives research support from NIH (grant R01 HL071568); and is co-author of "Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care."All other participants report no disclosures.
  • May 23 2017 Issue
    Show description/summary:1) A randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study2) What's Trending: Survival and dementia in GBA-associated Parkinson disease This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 23, 2017 issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Hubert Fernandez about his paper on deutetrabenazine for tardive dyskinesia. For our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Roberto Cilia about his Annals of Neurology paper on survival and dementia in GBA-associated Parkinson disease. Disclosures can be found at Neurology.org. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Barrett receives research support from Axovant Sciences, Inc., Azevan Pharmaceuticals, Merck Sharp & Dohme Corp, Virginia Center of Alzheimer´s and Related Diseases, Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program, and NIH.Dr. Fernandez serves on scientific advisory boards for Solvay Duodopa Global Study, EMD Serono Safinamide Global Study, and the Xeomin Registry (all uncompensated); has received travel or speaker honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape, Biogen GE Healthcare, Lundbeck, and Pfizer; served as Medical Editor for the Movement Disorders Society; co-owns the patent for COMPRESS; receives royalty payments from book publications with Demos Publishing, Manson Publishing, and Springer Publishing; has received research support from AbbVie, Acadia, Teva Pharmaceuticals, Biotie Therapeutics, Civitas, Kyowa Kirin International, Rhythm Pharmaceuticals, Synosia Therapeutics, Abbott, Merz Pharmaceuticals, Xeomin Registry Study, Ipsen Pharmaceuticals, Michael J. Fox Foundation, Movement Disorders Society, Huntington Study Group, Parkinson Study Group, National Parkinson Foundation, Society of Progressive Supranuclear Palsy, and NIH/NINDS.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Cilia receives research support from Fondazione Grigioni per il Morbo di Parkinson.
  • Responsible Opioid Prescribing—Special Podcast #3
    We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 3 and 4, Dr. Andy Southerland interviews Dr. Gary Franklin from the University of Washington. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.
  • May 16 2017 Issue
    Show description/summary:1) Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE2) Neurology Today® paper on a new guideline for preventing, diagnosing, and treating diabetic neuropathyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 16, 2017 issue of Neurology. In the first segment, Dr. Justin Sattin talks with Dr. Yilong Wang about his paper on risks and benefits of clopidogrel-aspirin in minor stroke. In the next part of the podcast Dr. Michelle Mauermann focuses her interview with Dr. Rodica Pop-Busui on diabetic neuropathy. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Wang receives research support from the Ministry of Science and Technology of the People's Republic of China (No. 2011BAI08B02) and the National Natural Science Foundation of China (No. 81322019).Dr. Mauermann serves on the editorial board for Mayo Clinic Proceedings; receives publishing royalties from Autonomic Neurology (Oxford 2015); and receives research support from Ionis Pharmaceuticals, Inc., and Alnylam Pharmaceauticals.All other participants report no disclosures.
  • May 9 2017 Issue
    Show description/summary:1) Serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports2) What's Trending: Biomarker validation and precision medicine in Parkinson disease.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 9, 2017 issue of Neurology. In the first segment, Dr. Kristen Heinan talks with Dr. Pashtun Shahim about his paper on serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports. In the next part of the podcast Dr. Alberto Espay focuses his discussion with Dr. David Standaert on biomarker validation and precision medicine in Parkinson disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Standaert serves on scientific advisory boards for the American Parkinson Disease Association; serves on the DSMB for Shire/Biropharma; received honoraria from the Movement Disorder Society and Georgia Regents University; is Associate Editor for Movement Disorders; receives publishing royalties for Movement Disorders (McGraw-Hill Publishers, 3rd ed.); consulted for Serina Therapeutics, Kirchner Group, Teva Neuroscience, Abbvie, and the U.S. Attorney's Office; receives research support from Abbvie, Acerta Pharmaceuticals, Ceregene, Quintiles, NIH, Alabama Department of Commerce, American Parkinson Disease Association, Michael J. Fox Foundation for Parkinson Research, Bachmann-Strauss Dystonia & Parkinson Foundation, and the Dystonia Medical Research Foundation.All other participants report no disclosures.
  • Responsible Opioid Prescribing—Special Podcast #2
    We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 1 and 2, Dr. Ted Burns interviews Dr. Charles Argoff from Albany Medical College in New York. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.
  • Responsible Opioid Prescribing—Special Podcast #1
    We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 1 and 2, Dr. Ted Burns interviews Dr. Charles Argoff from Albany Medical College in New York. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.
  • May 2 2017 Issue
    Show description/summary:1) Outcome of intracerebral hemorrhage associated with different oral anticoagulants2) Neurology Resident & Fellow section yearly recruitmentThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 2, 2017 issue of Neurology®. In the first segment, Dr. Andrew Southerland talks with Dr. David Werring about his paper on outcome of intracerebral hemorrhage with oral anticoagulants. Then, for our “What's Trending” feature of the week, Dr. Southerland focuses his interview with Dr. John Millichap on recent updates regarding the Neurology Resident & Fellow section. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Werring has served on scientific advisory boards for Allergan, Bayer, IXICO, and Amgen; has received speaker honoraria from Bayer; has served on the editorial board of the European Stroke Journal; has received publishing royalties from Cambridge University Press; has been a consultant for Ixico Ltd.; and has received research support from Pfizer, the Department of Health/Higher Education Funding Council For England, the Stroke Association/British Heart Foundation, and the Rosetrees Trust.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.
  • April 18 2017 Issue
    Show description/summary:1) Epidemiology and Prognosis of Mild Traumatic Brain Injury in Returning Soldiers: A Cohort Study2) What's Trending: Alemtuzumab treatment and multiple sclerosisThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 18, 2017 issue of Neurology. In the first segment, Dr. Michael Jaffee talks with Dr. Karen Schwab about her paper on mild traumatic brain injury in returning soldiers. For our “What's Trending” feature of the week, Dr. Mark Keegan talks with Dr. Gavin Giovannoni about his paper on alemtuzumab treatment and multiple sclerosis. For more information on traumatic brain injury services for active duty military and veterans, please visit the Defense and Veterans Brain Injury Center website at http://dvbic.dcoe.mil. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Jaffee serves on the scientific advisory board for Neurohabitation, Inc., and has received research support from the Florida State Department of Elderly Affairs.Dr. Schwab receives research support from Congressionally Directed Medical Research Programs (Grant #W81XWH-08-2-0105).Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; served as eMedicine Chief Editor from 2009 to 2015; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press 2016); consults for Novartis, Bristol Meyers Squibb, and Bionest; and received research support from Biogen for the ARISE study.Dr. Giovannoni consulted and served on scientific advisory boards for Biogen-Idec, Fiveprime, Genzyme, GW Pharma, Ironwood, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Synthon BV, Teva, Vertex Pharmaceuticals, Abbvie, and Canbex; receives speaker honoraria from Biogen-Idec, Genzyme, GW Pharma, Merck-Serono, Novartis, Roche, and Teva Pharmaceuticals; serves as an editor for Multiple Sclerosis and Related Disorders; served on speaker's bureaus for Novartis and Teva; and received research support from Genzyme and Merck.
  • April 25 2017 Issue
    Show description/summary:1) Practice guideline summary: Sudden unexpected death in epilepsy 2) What's Trending: 21st Century Cures ActThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 25, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer interviews Dr. Cynthia Harden about the AAN practice summary guideline on sudden unexpected death in epilepsy (SUDEP). Then, for our “What's Trending” feature of the week, Dr. Jason Crowell talks with Dr. Nicholas Johnson about the 21st Century Cures Act. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Johnson serves as Associate Editor for Neurology: Genetics; receives research support from Ionis Pharmaceuticals, Biogen Idec, Balerion Therapeutics, Cytokinetics, Acceleron, NINDS (grant 1K23NS091511-01), Muscular Dystrophy Association, and Myotonic Dystrophy Foundation; and consults for AMO Pharma and AveXis. Dr. Schomer, Harden, and Crowell report no disclosures.
  • April 11 2017 Issue
    Show description/summary:1) Intracerebral hemorrhage location and outcome among clinical trial participants 2) What's Trending: childhood amnesiaThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 11, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer talks with Dr. Craig Anderson about his paper on intracerebral hemorrhage location and outcome among clinical trial participants. Then, for our “What's Trending” feature of the week, Dr. Ted Burns talks with Dr. Cristina Alberini about her paper on childhood amnesia. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Anderson served on scientific advisory boards for Astra Zeneca and Medtronic; receives honoraria and travel funding from Takeda China and Boehringer Ingelheim; serves on editorial boards for Stroke, Cerebrovascular Diseases, and International Journal of Stroke; and receives research support from the National Medical Research Council of Australia (grants 1052555, 1020462, and 1081356).Dr. Alberini serves on editorial boards for Neural Plasticity, Journal of Cell Science, Frontiers in Neuroscience, Neurobiology of Learning and Memory, Behavioral Neuroscience, Learning and Memory, European Brain Research Institute (EBRI) International Scientific Council (ISC), and Cellular and Molecular Neuroscience of Hippocampus. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.
  • Delayed Recall - Motor neuron disorders (April 2017)
    The first interview is with Dr. Ted Burns and Dr. Merit Cudkowicz on the topic of ALS. This interview was part of the January 31, 2017 episode. The second interview, from October 25, 2016, is with Dr. Nath on HERV-K and ALS. In the third and final interview, originally released on February 28, 2017, Dr. Burns speaks with Dr. Richard Finkel about nusinersen and spinal muscular atrophy.
  • April 4 2017 Issue
    Show description/summary:1) Reduction in Time to Treatment in Pre-hospital Telemedicine Evaluation and Thrombolysis2) What's Trending: gut microbiota regulate motor deficits and neuroinflammation in Parkinson diseaseOur podcast has changed to a two-segment format! Enjoy two in-depth interviews each week, starting with one featured article from the Neurology® family of journals followed by an interview on a trending topic or on a notable article from Neurology Today.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 4, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland interviews Dr. Shazam Hussain about his paper on time-to-treatment in pre-hospital telemedicine evaluation and thrombolysis. Then, for our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Sarkis Mazmanian about his paper on how gut microbiota regulate motor deficits and neuroinflammation in Parkinson Disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Hussain served on scientific advisory boards for pulsar neurovascular, penumbra, Inc., and Prolong Medical.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.For full disclosures, please contact Dr. Mazmanian directly at sarkis [at] caltech.edu.
  • March 28 2017 Issue
    1) Early Decompressive Craniectomy for Malignant Cerebral Infarction: Meta-analysis and Clinical Decision Algorithm2) What's Trending: Update on the Resident and Fellows section 3) Topic of the Month: Brain tumors - gliomasThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 28, 2017 issue of Neurology. In the first segment, Dr. Bryan Eckerle talks with Dr. Bradley Molyneaux and Dr. Christopher Streib about their Neurology® Clinical Practice paper on early decompressive craniectomy for malignant cerebral infarction. Dr. Ted Burns talks with Dr. Roy Strowd about recent updates regarding the Neurology® Resident & Fellows section for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Kait Nevel focuses her interview with Dr. David Schiff on gliomas. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Molyneaux has received research support from Remedy Pharmaceuticals, Inc.Dr. Streib has served on the Institute for Clinical Systems Improvement (ICSI) Stroke Guidelines Committee (no reimbursement).Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Strowd serves on the editorial board of Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology.Dr. Schiff has served on the scientific advisory boards of Genetech, Celldex, Orbus, and Vascular Biogenics Oxigene; has received travel funding/speaker honoraria from Merck; serves on the editorial boards of Neurology, Neurosurgery, Neuro-Oncology, and Lancet Neurology; receives publishing royalties from UpToDate, and has been a consultant for Cavion.All other participants report no disclosures.
  • March 21 2017 Issue
    1) Pure autonomic failure: Predictors of conversion to clinical CNS involvement2) What's Trending: ocrelizumab in multiple sclerosis 3) Topic of the Month: neuro-oncologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 21, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff interviews Dr. Wolfgang Singer about his paper on pure autonomic failure. For our “What's Trending” feature of the week, Dr. Mark Keegan talks with Dr. Stephen Hauser about his paper on ocrelizumab in multiple sclerosis. In the next part of the podcast Dr. Kait Nevel focuses her interview with Dr. Lisa DeAngelis on metastatic disease. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Singer serves as Associate Editor for Clinical Autonomic Research; serves on the Autonomic Neuroscience: Basic and Clinical editorial board; holds a patent for use of 3,4 diaminopyridine in the treatment of orthostatic hypotension and postural tachycardia syndrome; received research support from NH, FDA, Cure MSA Foundation, Dysautonomia International, and American Dysautonomia Institute. Dr. Keegan serves on editorial boards for eMedicine (Chief Editor 2009-2015) and Multiple Sclerosis and Related Disorders; receives publishing royalties from Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning Cambridge University Press 2016; consulted for Novartis, Bristol Meyers Squibb, and Bionest Partners; and received research support from Terumo Corporation and BCT International Ltd.Dr. Hauser serves on scientific advisory boards for Bionure, Annexon, Symbiotix, Neurona, and Molecular Telescope; receives publishing royalties from Harrison's Principles of Intervnal Medicine (McGraw Hill 1994); holds stock options in Bionure, Annexon, Symbtiotix, all of which were transferred to University of California – San Francisco; and received funding from NIH, National Multiple Sclerosis Society, and the Conrad Hilton Foundation.Dr. DeAngelis serves on scientific advisory board for Celgene and CarThera; serves on editorial boards for Neurology, Neuro-Oncology, Journal of Neuro-oncology, and Neuro-Oncology Practice; receives publishing royalties from The Neurologic Complications of Cancer (Oxford University Press 2008); and receives research support from NIH.All other participants report no disclosures.
  • March 14 2017 Issue
    1) Moderators and Predictors of Response to Behavior Therapy for Tics in Children and Adults with Tourette's Disorder2) What's Trending: Exercise and VCI 3) Topic of the Month: Neuro-oncology and ICPThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 14, 2017 issue of Neurology®. In the first segment, Dr. John Mytinger talks with Dr. Denis Sukhodolsky and Dr. Lawrence Scahill about their paper on therapy for tics in children and adults with Tourette's Disorder. For our “What's Trending” feature of the week, Dr. Ted Burns talks with Dr. Teresa Liu-Ambrose about her paper on exercise and vascular cognitive impairment. In the next part of the podcast, Dr. Kait Nevel focuses her interview with Dr. Mariza Daras on neuro-oncology and intracranial pressure. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Sukhodolsky has received travel funding/speaker honoraria from the Tourette Association of America; has served on the editorial board of the Journal of Autism and Developmental Disabilities; receives publishing royalties from Guilford Press; notes that 5% of his effort is dedicated to providing clinical care at the Yale TS clinic (including the form of behavior therapy for tics (CBIT) that was tested in the study reported in the previously noted paper); and has received research support from NMH.Dr. Scahill has served on the scientific advisory boards of Roche, Neuren, and Supernus; has received gifts from Bracket; has served on the editorial boards of the Journal of Child & Adolescent Psychopharmacology and the International Journal of Developmental Disabilities; receives publishing royalties from Oxford and Guilford; and has received research support from the Department of Defense and NIMH.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Liu-Ambrose has received travel funding and speaker honoraria from the Resistance Training Conference and the Traumatic Brain Injury Conference; serves on the editorial boards of the British Journal of Sports Medicine, the Physical Therapy Journal, and the Journal of Cognitive Enhancement; has been a consultant for a project entitled The Average Human (funded by Wellcome Trust); has been involved with operations for Synaptitude Inc.; and has received research support from the Canadian Stroke Network.All other participants report no disclosures.
  • March 7 2017 Issue
    1) Neurology® Genetics: Clinical and Genetic Study of Hereditary Spastic Paraplegia in Canada2) What's Trending: Subarachnoid hemorrhage and smoking rates 3) Topic of the Month: Neuro-oncologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 7, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Nicolas Chrestian about his Neurology® Genetics paper on hereditary spastic paraplegia in Canada. For our “What's Trending” feature of the week, Dr. Ted Burns talks with Dr. Miikka Korja about his paper on subarachnoid hemorrhage and smoking rates. In the next part of the podcast Dr. Kathryn Nevel focuses her interview with Dr. Jennie Taylor on seizure management in neuro-oncology patients. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.
  • Delayed Recall - Movement Disorders (March 2017)
    The first interview is with Dr. Michelle Fullard and Dr. John Winkleman on the topic of RLS and RLS treatment. The second is with Dr. Jeff Ratliff and Dr. Anhar Hassan on orthostatic tremor. These interviews originally appeared on December 13, 2016 and February 2, 2016, respectively. In the third week's interview, originally released on June 7, 2016, Dr. Fullard talks with Dr. Mark LeDoux on the topic of cervical dystonia. In the fourth and final interview, from September 27, 2016, Dr. Ted Burns speaks with Mrs. Susan Schneider Williams about her late husband Robin Williams's Lewy Body Disease.
  • February 28 2017 Issue
    1) Symptoms from Repeated Intentional and Unintentional Head Impact in Soccer Players2) What's Trending: Nusinersen for treatment of spinal muscular atrophy3) Topic of the Month: Neurology Today® paper on pulmonary embolismThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 28, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Michael Lipton about his paper on repeated head impact in soccer players. Dr. Ted Burns talks with Dr. Richard Finkel about his recent study on nusinersen as a promising treatment for spinal muscular atrophy for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Sofia Barbar on a Neurology Today story about her article on pulmonary embolism. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Lipton has served on the scientific advisory boards of Guerbet and Bracco; has served on the editorial boards of the American Journal of Neuroimaging and Brain Imaging and Behavior; holds a patent on EZ-MAP image processing software; receives publishing royalties from Springer; has been a consultant for Bracco; and has received research support from Philips Medical Systems, NIH/NINDS, NIH/NIA, NIH/NICHD, the Dana Foundation, and the Resurrecting Lives Foundation.Dr. Finkel has served on the scientific advisory boards of Families of SMA, Nationwide Children's Hospital, SMA Europe, Pediatric Neuromuscular Clinical Research Network, and SMA REACH (UK); has received travel funding from Families of SMA, SMA Foundation, and the Muscular Dystrophy Association; has received travel funding and speaker honoraria from Ionis Pharmaceuticals; serves on the editorial boards of Neuromuscular Disorders and the Journal of Neuromuscular Diseases (additionally, spouse serves on editorial board of Arthritis Research and Therapy); his spouse holds patents for Mouse Anti-TCR Zeta Antibody to Southern Biotechnology Associate, Anti-Human TCR Zeta mAb to Upstate Pharmaceuticals, and Anti-Human TCR Zeta mAb to Santa Cruz Biotechnology; he receives publishing royalties from Elsevier; has been a consultant for Ionis Pharmaceuticals, Biogen, Roche, Novartis, Motobridge, Capricor, Lilly, and Summit; spends approximately 30% of his time working with spinal muscular atrophy patients; has received research support from Isis Pharmaceuticals, Biogen, Eli Lilly Pharmaceuticals, Cytokinetics, RevereGen, BMS, Summit, Sarepta, NIH, the Spinal Muscular Atrophy Foundation, Families of Spinal Muscular Atrophy, the Muscular Dystrophy Association, and the Charcot-Marie-Tooth Association; and his spouse receives licensing fee payments for aforementioned patents.All other participants have no disclosures.
  • February 21 2017 Issue
    1) Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes2) What's Trending: video gaming in children 3) Topic of the Month: Neurology Today® paper on mitochondrial replacementThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Hugh Willison about his Neurology® Neuroimmunology & Neuroinflammation paper on microarray screening of autoantibodies to glycolipid complexes in Guillain-Barre syndrome. Dr. Ted Burns talks with Dr. Gerard Martínez Vilavella about video gaming in children for our “What's Trending” feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Shoukhrat Mitalipov on mitochondrial replacement for genetic diseases. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Willison serves on the scientific advisory board for Wellcome Trust; serves on editorial boards for Nature Clinical Practice Neurology; Journal of Neuroimmunology, Muscle and Nerve, J Peripheral Nervous System, BMC Neurology (Associate Editor), Clinical and Experimental Neuroimmunology, and Experimental Neurology; holds a patent for combinatorial glycoarray technology; and receives research support from Ipsen, Annexon Biosciences, Alexion Pharmaceuticals, Inc., Medical Research Council, and Wellcome Trust. Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer” (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq.All other participants report no disclosures.
  • February 14 2017
    1) Prognosis of carotid dissecting aneurysms: results from CADISS and a systematic review2) What's Trending: CRISPR gene editing in neuromuscular diseases3) Neurology Today® paper – spotlight on Dr. John NoseworthyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 14, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Hugh Markus about his paper on the prognosis of carotid dissecting aneurysms. For our "What's Trending" feature of the week, Dr. Ted Burns interviews Dr. Eric Olson regarding CRISPR at the 2016 AANEM meeting. In the next part of the podcast, Dr. Ted Burns speaks with Mayo Clinic CEO Dr. John Noseworthy about his meeting with President Trump and his experience as Editor-in-Chief of Neurology. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Markus has served on the editorial boards of the International Journal of Stroke, Clinical Neurology and Neurosurgery, BMC Medicine, and Frontiers in Neurology; receives publishing royalties from Oxford University Press; has received reimbursement from Astra Zeneca for teaching a session to employees; and has received research support from NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing.Dr. Noseworthy receives publishing royalties for the following publications: Fifty Neurologic Cases, Oxford, 2004, Multiple Sclerosis 2, Blue Books; Butterworth, 2003, Neurologic Therapeutics, Edition 1, Martin Dunitz, 2003, Neurologic Therapeutices, Edtion 2, Informa, 2006, McAlpine's Multiple Sclerosis, 4th Edition, 2006.All other participants have no disclosures.
  • February 7 2017 Issue
    1) Dystonia treatment: patterns of medication use in an international cohort2) What's Trending: Without Borders global neurology site 3) Topic of the Month: Neurology Today® paper on the expansion of teleneurologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 7, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Sarah Pirio Richardson about her paper on patterns of medication use in dystonia treatment. Dr. Ted Burns talks with Dr. Gretchen Birbeck about the Without Borders global neurology site for our “What's Trending” feature of the week. In the next part of the podcast Dr. Andy Southerland focuses his interview with Dr. Larry Wechsler on a Neurology Today® story about the expansion of teleneurology. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Willison serves on a scientific advisory board and receives research support from Wellcome Trust; possesses a patent for combinatorial glycoarray technology; and has received research support from Ipsen, Annexon Biosciences, Alexion Pharmaceuticals, Inc., and the Medical Research Council.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Pirio Richardson receives research support from the NIH.Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Birbeck serves on scientific advisory board for Lift the Burden Global Campaign against Headache Board; curates the Neurology®: Without Borders site; and receives research support from the NIH.Dr. Wechsler serves on scientific advisory boards for Remedy Pharmaceuticals, Inc., Forest Devices, and Silk Road Medical, Inc.; receives research support from NIH/NINDS and Athersys, Inc., and SanBio Co. Ltd.; provides telestroke services through UPMC Telemedicine network; and holds stock options in Silk Road Medical, Inc. Remedy Pharmaceuticals, Inc., and Forest Devices. Dr. Ratliff reports no disclosures.
  • Delayed Recall - CDC guidelines on prescribing opioids (February 2017)
    Interviews regarding the CDC guidelines on prescribing opioids
  • January 31 2017 Issue
    Show description/summary:1) Progressive rural-urban disparity in acute stroke care2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topicsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 31, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Allison Willis about her paper on disparities in stroke care between rural and urban areas. Dr. Ted Burns talks with Dr. Eric Olsen regarding CRISPR at the 2016 AANEM meeting for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Merit Cudkowicz on amyotrophic lateral sclerosis (ALS). Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Allison Willis has served on the editorial board of Pharmacoepidemiology and Drug Safety; and has received research support from NIH/NINDS.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing.Dr. Merit Cudkowicz has served on the editorial board of DSMB AstraZenica (through Clintrex); has served on the editorial boards of Neurotherapeutics and JAMA Neurology; holds a patent for Metabolomics in ALS; receives publishing royalties from UpToDate; has been a consultant for Cytokinetics, Biogen-Idec, Voyager, Biohaven, Astrazenica, Genentech, Karyopharm, and Neuraltis; has received research support from NINDS, the Muscular Dystrophy Association, the ALS Association, and the ALS Finding a Cure Association; and has provided expert witness for defense (TEVA).All other participants have no disclosures.
  • January 24 2017 Issue
    1) Relationship between Risk Factor Control and Vascular Events in the SAMMPRIS Trial 2) What's Trending: 2017 AAN Annual Meeting3) Topic of the Month: neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 24, 2017 issue of Neurology. In the first segment, Dr. Joseph Carrera talks with Dr. Tanya Turan about her paper on risk factor control and vascular events in the SAMMPRIS trial. Dr. Ted Burns talks with Christy Phelps about the 2017 AAN Annual Meeting for our “What's Trending” feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Anthony Amato on myositis. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Turan serves on a scientific advisory board for Boehringer Ingelheim; serves on blinded Neurological Events Adjudication Committees for Boehringer Ingelheim and W.L. Gore and Associates; is Review Editor for Frontiers in Endovascular and Interventional Neurology and specialty editor of Frontiers in Neurology; serves on editorial boards for World Journal of Neurology, Brain and Behavior, and Annals of Translational Medicine; and received research support from NIH/NINDS K23 award for activities in the SAMMPRIS trial.Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Amato serves on medical advisory boards for MedImmune, Amgen, Novartis, DART, Biogen, Acceleron, and DSMB for NIH; is Associate Editor for Neurology and Muscle & Nerve; possesses publishing royalties for Neuromuscular Disease (McGraw-Hill 2016); serves as medical consultant for MedImmune, Amgen, Biogen, Novartis, Acceleron, Analgesic Solutions, Up-to-Date, and Best Doctors; and receives research support from Novartis, Alexion, and Amgen.Christy Phelps serves as Deputy Executive Director for the AAN.Dr. Carrera reports no disclosures.
  • January 17 207 Issue
    1) Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topicsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 17, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Aneesh Singhal about his paper on glucocorticoid-associated worsening of reversible cerebral vasoconstriction syndrome. Dr. Ted Burns talks with Dr. Roy Strowd about upcoming changes regarding the Neurology Resident & Fellow section for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Volker Straub on limb-girdle dystrophy. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Aneesh Singhal has served on the scientific advisory boards of Biogen and DSMB; has served on the editorial board of Medical Gas Research; has received publishing royalties for the book Reversible Cerebral Vasoconstriction Syndromes; has been a consultant to Biogen; has acted as an event adjudicator for the Thrombolysis in Myocardial Infarction (TIMI) Trial Group; has received research support from Boehringer Ingelheim, NIH-NINDS, the American Academy of Neurology, UpToDate, and Medlink; and has served as a medicolegal expert witness for individual cases concerning stroke. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Straub has served on the scientific advisory boards for Pfizer, Italfarmaco, Audentes Therapeutics, Bristol-Myer Squibb, Summit Therapeutics, Tivorsan, and the Nationwide Children's Hospital; has received travel funding and speaker honoraria from Sanofi Genzyme; has served on the editorial boards of Neuromuscular Disorders, the Journal of Neuromuscular Diseases, and PLoS Currents Muscular Dystrophy; has been a consultant for Sanofi Genzyme; and has received research support from Sanofi Genzyme, BioMarin, Ionis Pharmaceuticals, Sarepta Therapeutics, Ultragenyx, the European Commission, the UK Medical Research Council, Newcastle University, the Parent Project Muscular Dystrophy, the Association Fracaise Contre les Myopathies, the LGMD2I Research Fund, the Wellcome Trust, the Sylvia Aitken Charitable Trust, Muscular Dystrophy UK, and Action Medical Research.All other participants have no disclosures.
  • January 10 2017 Issue
    1) A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington's Disease 2) What's Trending: Risk assessment in Duchenne dystrophy3) Topic of the Month: Neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 10, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Andrew McGarry about his paper on a randomized trial of coenzyme Q10 in Huntington Disease. Dr. Ted Burns talks with Dr. Sindhu Ramchandren about her Neurology: Genetics paper on Duchenne dystrophy for our “What's Trending” feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Gil Wolfe on myasthenia gravis. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. McGarry serves on an advisory board for Teva Pharmaceutical Industries, Ltd.; receives speaker honoraria for Teva Pharmaceutical Industries, Ltd. and ACADIA Pharmaceuticals, Inc.; and has received research support from Teva Pharmaceutical Industries, Ltd. and NINDS. Dr. Ramchandren received research support from the NIH.Dr. Wolfe advises for Grifols, Baxalta, Argenx, and UCB; receives speaker honoraria for Grifols and Baxalta; receives research support from CSL Behring; and serves as Associate Editor for Muscle and Nerve. Dr. Fullard reports no disclosures.
  • January 3 2017 Issue
    1) The Effects of Orthostatic Hypotension on Cognition in Parkinson's Disease 2) What's Trending: Carotid surgery trials3) Topic of the Month: Neuromuscular topicsThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Justin Centi about his paper on the effects of orthostatic hypotension on cognition in Parkinson disease. Dr. Andy Southerland is interviewing Dr. Seemant Chaturvedi for our “What's Trending” feature of the week about urgency for carotid surgery trials. In the next part of the podcast, Dr. Ted Burns interviews Dr. Michelle Mauermann about neuromuscular topics. Disclosures can be found at http://www.neurology.org.DISCLOSURES: Dr. Barrett has received research support from Axovant Sciences, Inc., the Virginia Center of Alzheimer's and Related Diseases, and the Department of Defense.Dr. Centi has been an employee of Commonwealth Psychology Associates LLC and Harvard Medical School/Partners Consortium in Neuropsychology; and has received research support from NIH-NINDS.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Chaturvedi has been a consultant for Merck; has served on the executive committee of ACT I study and CREST 2 study; serves on the editorial boards of Neurology, the Journal of Stroke & Cerebrovascular Disease, Stroke, and NEJM Journal Watch Neurology; has received research support from Boehringer-Ingelheim, NINDS, and the FDA; and has received compensation for expert witness testimony.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives publishing royalties for book Autonomic Neurology; and receives research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals.All other participants have no disclosures.
  • Delayed Recall - Movement Disorders (January 2017)
    The first interview is with Dr. Jeff Ratliff and Dr. Kailash Bhatia on the topic of dystonia. The second is with Dr. Alberto Espay and Dr. Roger Elble on tremor. These interviews were first released on November 1 and November 8, 2016. In the third week's interview, originally released on November 15, 2016, Dr. Alberto Espay interviews Don Gilbert on tics. In the fourth interview, from November 22, 2016, Dr. Ratliff speaks with Dr. Ruth Walker about chorea. The fifth and final interview, originally released on November 29, 2016, is an interview with Dr. Espay and Dr. Steven Frucht on the topic of myoclonus.
  • December 13 2016 Issue
    1) AAN guideline summary: Treatment of restless legs syndrome in adults 2) What's Trending: Interview with Dr. Steven Messé on why acute ischemic stroke patients are not receiving IV tPA3) Topic of the month: Neurology Today story about cases of acute flaccid myelitis spike: What the Center for Disease Control says you should look out forThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. John Winkelman about the AAN guideline summary on the treatment of restless legs syndrome in adults. Dr. Andy Southerland is interviewing Dr. Steven Messé for our “What's Trending” feature of the week about his paper on why are acute ischemic stroke patients not receiving IV tPA. In the next part of the podcast Dr. Ted Burns interviews Drs. Kevin Messacar and Ken Tyler about a Neurology Today story on the topic on cases of acute flaccid myelitis spike: What the Center for Disease Control says you should look out for.DISCLOSURES: Dr. Winkelman serves as Associate Editor for Sleep; serves as an editorial board member of Sleep Medicine and CNS Drugs; received honoraria from serving on the scientific advisory board of Merck Serono, Flex Pharma, UCB, Impax Pharmaceuticals, Pfizer Inc, Lacrima, Luitpold Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Xenoport, Zeo Inc., Sunovion, Insys, Takeda Pharmaceutical Company Limited, Jazz and Neurogen; receives royalties from the publication of the books: Foundations of Psychiatric Sleep Medicine and Nocturnal Leg Cramps; holds stock options in Flex Pharma; provided expert witness work for ArentFox and CantorColburn; received funding for travel from Novartis and Otsuka; currently performs neurophysiology studies as part of his practice;receives research support from Xenoport, GlaxoSmithKline, UCB, Sepracor, Pfizer Inc, Impax Pharmaceuticals, Purdue, Neurometrix and the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Messé received publishing royalties from UpToDate; received compensation from GlaxoSmithKline for consulting on protocol development for a trial of a neuroprotectant in high risk surgery; received research support from GlaxoSmithKline, Bayer Schering Pharma, WL Gore and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for PML Consortium; is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from the NIH. All other participants report no disclosures.
  • December 6 2016 Issue
    1) Systematic review and statistical analysis of the integrity of 33 randomized controlled trials2) What's Trending: Interview with Dr. Neil Garrett about his Nature Neuroscience article on dishonesty.3) Topic of the month: Neurology Today story about Zika virus and Guillain Barre syndrome detected in ColumbiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Mark Bolland about his paper on the systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Dr. Ted Burns is also interviewing Dr. Neil Garrett for our “What's Trending” feature of the week about his Nature Neuroscience paper on dishonesty. In the next part of the podcast Dr. Ted Burns interviews Dr. Carlos Pardo about a Neurology Today story on the topic of Zika virus and Guillain Barre syndrome detected in Columbia.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Bolland receives research support from the Health Research Council of New Zealand.Dr. Pardo receives research support from Bart McLean Fund for Neuroimmunology Research-Project Restore and the NIH.All other participants report no disclosures.
  • Delayed Recall - Neurogenetics (December 2016)
    Interviews on neurological topics related to genetics
  • November 29 2016 Issue
    1) Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis2) e-Pearl topic: Hemiplegic migraine3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Adam Numis interviews Dr. David Gloss about this AAN Practice Advisory paper on the utility of EEG theta and beta power ration in attention deficit hyperactivity disorder diagnosis. Dr. Ilena George is reading our e-Pearl of the week about hemiplegic migraine. In the next part of the podcast Dr. Alberto Espay interviews Dr. Steven Frucht on the topic of “how to approach” myoclonus.DISCLOSURES: Dr. Numis served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gloss serves on the Level of evidence team for Neurology®; is an Evidence-based medicine consultant for the American Academy of Neurology; receives royalties from the publication of the book Neurology for the Specialty Boards.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Frucht serves as Editor-in-Chief for the Journal of Clinical Movement Disorders; is a consultant for UCB; received speaker honoraria from Merz Pharmaceuticals, LLC and Impax; receives royalties from the publication of the book Movement Disorders Emergencies; and is employed by the American Academy of Neurology Movement Disorders Society.
  • November 22 2016 Issue
    1) Emerging temporal trends in tissue plasminogen activator use: Results from the BASIC project2) e-Pearl topic: Transthyretin familial amyloid polyneuropathy3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Lynda Lisabeth about her paper on temporal trends in tissue plasminogen activator administration for acute ischemic stroke. Dr. Ilena George is reading our e-Pearl of the week about transthyretin familial amyloid polyneuropathy. In the next part of the podcast Dr. Jeff Ratliff interviews Dr. Ruth Walker on the topic of chorea.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publication of the book Stroke and editing the book Neurology in Practice; and receives research support from the NIH.Dr. Lisabeth receives research support from the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Walker is a consultant for Neurocrine Biosciences, Inc.; assists with Audio-Digest Board Reviews; received funding for travel from Korean Movement Disorders Society and honoraria from Neurocrine Biosciences, Inc.
  • November 15 2016 Issue
    1) Efficacy and safety of deflazacort versus prednisone and placebo for Duchenne muscular dystrophy2) e-Pearl topic: Alien limb phenomenon3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Robert Griggs about his the efficacy and safety of deflazacort versus prednisone for boys with Duchenne muscular dystrophy. Dr. Ilena George is reading our e-Pearl of the week about alien limb phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Don Gilbert on the topic of tics.DISCLOSURES: Dr. Griggs serves as Correspondence Editor for Neurology®; serves as an editorial board member of NeuroTherapeutics and Current Treatment Opinions in Neurology; serves on the scientific advisory board for SAB for National Hospital Queen Square, Marathon Pharmaceuticals, PTC Therapeutics, Inc., DSMB, Taro Pharm and Sarepta Pharmaceuticals; is a consultant for Marathon, PTC Therapeutics, Sarepta, Taro Pharm and Idera Pharmaceuticals;receives royalties for data of previous studies from Taro Pharm and Marathon Pharmaceuticals; receives royalties from the publication of the books: Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition, Cecil Textbook of Medicine, multiple editions and Evaluation and Treatment of Myopathies; receives research support from Taro Pharma, Marathon Pharmaceuticals, Parent Project Muscular Dystrophy, Inc., Muscular Dystrophy Association, Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy and the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Gilbert serves on the scientific advisory boards of Investigations of Neuroplasticity Mechanisms in Autism Spectrum Disorders, the Berenson-Allen Center for Noninvasive Brain Stimulation, and Beth Israel Deaconess Medical Center; received honoraria from the Tourette Association of America, the Centers for Disease Control and Prevention, and the Hong Kong Society of Child Neurology and Developmental Pediatrics; received funding for travel for educational talks to physicians and affected patients and families;receives royalties from the publication of the book Movement Disorders in Childhood, 2nd edition; receives research support from Ecopipam Pharmaceuticals, Neurocrine Pharmaceuticals, EryDel Pharmaceuticals, and NIH; and has provided expert testimony for the Health Resources and Services Administration, Department of Health and Human Services regarding Division of Vaccine Injury Compensation Programs.
  • November 8 2016 Issue
    1) Progression of brain atrophy in PSP and CBS over six months and one year2) What's Trending: Interview with Mike Amery about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan interviews Dr. Adam Boxer about his paper about on progression of brain atrophy in progressive supranuclear palsy and corticobasal syndrome. Dr. Ted Burns is interviewing Mike Amery for our “What's Trending” feature of the week about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act. In the next part of the podcast Dr. Alberto Espay interviews Dr. Rodger Elble on the topic of “how to approach” tremor disorders.DISCLOSURES: Dr. Morgan is a consultant for Impax, Lundbeck Inc., National Parkinson Foundation, Teva Pharmaceutical Industries Ltd., and Veloxis; serves on the speakers' bureau of Impax and Teva Pharmaceutical Industries Ltd.; received compensation for review of medical records and expert witness testimony in multiple cases of litigation involving neurologic co; receives research support from National Parkinson Foundation, Parkinson's Outcome Project Grant and the NIH.Dr. Boxer serves on the scientific advisory board for Alector, Asceneuron and Delos; received funding for travel from the International Society for CNS Clinical Trials Methodology, the Movement Disorders Society, the Association for Frontotemporal Degeneration, Fidelity Biosciences Research Institute and the Tau Consortium; is a consultant for Abbvie, Ionis, Janssen and Merck Serono; holds stock options in Alector and Delos; receives research support from Avid, Biogen Idec, BMS, C2N, Cortice, Forum, Genentech, Inc., Janssen, Pfizer Inc, Eli Lilly and Company, Roche, TauRx, The Tau Research Consortium, the Bluefield Project, Corticobasal Degeneration Solutions, the Alzheimer's Association and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Amery is employed as Legislative Counsel for the American Academy of Neurology.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Elble receives research support from GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Phytopharm, Pfizer Inc, Ortho-McNeil, Spastic Paralysis Research Foundation of Kiwanis International, Illinois-Eastern Iowa District and the NIH.
  • Delayed Recall - Stroke (November 2016)
    Interviews from Neurology Today articles on the topic of stroke.
  • November 1 2016 Issue
    1) School aged cognition in children exposed to levetiracetam, topiramate or sodium valproate2) What's Trending: Interview with David Spencer about his book titled: “Navigating life with epilepsy” 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Rebecca Bromley about her paper about school aged cognition in children exposed to levetiracetam, topiramate or sodium valproate. Dr. Ted Burns is interviewing Dr. David Spencer for our “What's Trending” feature of the week about his recently published Neurology Now book titled: “Navigating life with epilepsy.” In the next part of the podcast Dr. Jeff Ratliff interviews Prof. Kailash Bhatia on the topic of “how to approach” dystonia.DISCLOSURES: Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort).Dr. Bromley provided expert testimony regarding fetal valproate syndrome in the UK; although this case did not go to court and received research support from Epilepsy Research UK.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Spencer serves as Patient Page Editor for Neurology®, including past 2 years EMedicine, Chief Editor, Journal of Behavior and Brain Science, Associate Editor Neurology Now, Professional Advisory Board, including past 2 years Epilepsy Currents: Contributing editor; received honorariafrom NeuroPace Inc.; receives research support from NeuroPace, Inc., Upsher-Smith Laboratories, Inc., and Acorda; and was a consultant in a legal case. Prof. Bhatia serves as Co-Editor in Chief for Movement disorders Clinical Practice, serves as an Associate Editor for Movement Disorders, serves as an editorial board member of Therapeutic Advances in Neurological Disorders; received funding for travel from GlaxoSmithKline, Orion Corporation, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceuticals Ltd, received honoraria from GlaxoSmithKline, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Ipsen Pharmaceuticals, Inc., MerzPharmaceuticals, LLC; receives royalties from the publication of Oxford Specialist Handbook of Parkinson's Disease and Other Movement Disorders, Marsdens book of Movement disorder, Lancet Neurology review article; receives research support from Wellcome Trust MRC strategic neurodegenerative disease initiative award, Parkinson's UK, Dystonia Coalition and The Bachmann-Strauss Foundation.
  • October 25 2016 Issue
    1) HIV associated motor neuron disease: HERV-K activation and response to anti-retroviral therapy 2) e-Pearl topic: Ataxia with vitamin E deficiency3) Topic of the month: Neurology Today story on functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional careThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Avindra Nath about his paper on human endogenous retrovirus-K in amyotrophic lateral sclerosis with HIV infection and response to treatment with anti-retroviral drugs. Dr. Sarah Wesley is reading our e-Pearl of the week about ataxia with vitamin E deficiency. In the next part of the podcast Dr. Andy Southerland interviews Prof. Heinrich Audebert about a Neurology Today story on the topic of functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Nath serves as Associate Editor for Journal of Neurovirology; has patents for Tat as an immunogen, Diosgenin for Treatment of Neurodegenerative Diseases; Role of Kv Channels in Neuroregeneration and Protection; Role of Lominoid compounds as neuroprotective agents; Tat ELISA; and receives research support from the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Prof. Audebert serves as Associate Editor for Frontiers of Teleneurology; is a consultant for Lundbeck Inc., Roche, Bayer Schering Pharma, Pfizer Inc; received speaker honoraria from Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Lundbeck Inc., Bayer Schering Pharma, UCB, Sanofi-aventis, Pfizer Inc, Bristol-Myers Squibb and EverNeuropharma; participated in an expert meeting launched by Lundbeck Inc. in order to estimate the target population for Desmoteplase; receives research support from the Technology Foundation Berlin and the Berlin Investment Bank with co-financing by the European Union, and Center for Stroke Research Berlin, funded by the German Federal Ministry of Education and Research.
  • October 18 2016 Issue
    1) Calcium supplementation and risk of dementia in women with cerebrovascular disease2) e-Pearl topic: MGMT promoter methylation in glioblastoma3) Topic of the month: Neurology Today story on a new brain map identifying previously unidentified brain areas and what it means for neurologyThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Silke Kern about her paper on whether calcium supplementation was associated with the development of dementia in women with cerebrovascular disease. Dr. Sarah Wesley is reading our e-Pearl of the week about MGMT promoter methylation in glioblastoma. In the next part of the podcast Dr. Ted Burns interviews Dr. Matthew Glasser about a Neurology Today story on the topic about a new brain map identifying previously unidentified brain areas and what it means for neurology.DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Kern serves as Associate Editor for Journal of Alzheimer`s disease.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.
  • October 11 2016 Issue
    1) Reducing costs while enhancing quality of care in MS2) What's Trending: Interview with Lyell Jones about the topic of the Axon Registry and how it interfaces with practice and reimbursement this is part 2 with part 1 appearing last month 3) Topic of the month: Neurology Today story on the AAN Guideline published in Neurology on the topic of recurrent stroke with patent foramen ovaleThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ilya Kister about his paper on the various approaches neurologists may contribute to cost containment while maintaining and enhancing the quality of MS care. Dr. Andy Southerland is interviewing Dr. Lyell Jones for our “What's Trending” feature of the week about the topic of the Axon Registry and how it interfaces with practice and reimbursement. This is part 2 with part 1 appearing last month. In the next part of the podcast Dr. Bryan Eckerle interviews Dr. Steven Messe about a Neurology Today story on the AAN Guideline published in Neurology on the topic of recurrent stroke with patent foramen ovale.DISCLOSURES: Dr. Keegan serves as an editorial board member of Multiple Sclerosis and Related Disorders; served as Chief Editor of eMedicine; receives royalties from the publication of the book: Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning; is a consultant for Novartis, Bristol-Meyers Squibb and Bionest; receives research support from Terumo BCT.Dr. Kister serves on the MS Franchise Data Generation advisory board for Biogen Idec and advisory board for Genentech, Inc.; received a one-time consulting fee from Biogen Idec; received research support from Biogen-Idec, Merck Serono, Novartis, Genzyme Corporation; Guthy-Jackson Charitable Foundation and National Multiple Sclerosis Society.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Messe received publishing royalties from UpToDate; received compensation from GlaxoSmithKline for consulting on protocol development for a trial of a neuroprotectant in high risk surgery; received research support from GlaxoSmithKline, Bayer Schering Pharma, WL Gore and the NIH.
  • October 4 2016
    1) Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up2) What's Trending: Interview with Ben Utecht about his recently published book titled: Counting the Days While My Mind Slips Away: A Love Letter to My Family3) Topic of the month: Neurology Today story about NEJM published paper on thymectomy for patients with myasthenia gravisThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Maarten Titulaer about his paper on the clinical features and long-term follow-up of anti-LGI1 encephalitis. Dr. Ted Burns is interviewing Mr. Ben Utecht for our “What's Trending” feature of the week about his recently published book titled: “Counting the Days While My Mind Slips Away: A Love Letter to My Family.” In the next part of the podcast Dr. Ted Burns interviews Dr. Gil Wolfe about a Neurology Today story on the topic of thymectomy for patients with myasthenia gravis.DISCLOSURES: Dr. Titulaer serves on the scientific advisory board for MedImmune; serves as an editorial board member for Neurology®: Neuroimmunology & Neuroinflammation; received funding for travel from Sun Pharma; receives research support from Netherlands Organization for Scientific Research, Dutch Epilepsy Foundations and ErasmusMC fellowship.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Mr. Ben Utecht receives honoraria from the American Academy of Neurology and the American Brain Foundation, Spokesperson Agreement.Dr. Wolfe serves as an Associate Editor of Muscle and Nerve; serves on the scientific advisory board for Grifols, Baxalta, Argen X and UCB; receives honoraria for serving on the speakers' bureau of Grifols and Baxalta; receives research support from CSL Behring.
  • Delayed Recall - Anoxic brain injury (October 2016)
    Interviews on evaluation of the anoxic brain injury patient.
  • September 27 2016 Issue
    1) Editorial Titled: The Terrorist inside My Husband's Brain2) e-Pearl topic: X-linked myopathy with excessive autophagy3) Topic of the month: Neurologic prognosis following cardiac arrestThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mrs. Susan Schneider Williams about her editorial on learning to deal with her husband's (Robin Williams) Lewy Body disease. Dr. Adam Numis is reading our e-Pearl of the week about X-linked myopathy with excessive autophagy. In the next part of the podcast Dr. Andy Schomer concludes his interview with Dr. Eelco Wijdicks about prognostic models and clinical findings of myoclonus.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Mrs. Schneider Williams serves on the board of directors for the American Brain Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks receives royalties from the publication of several books.
  • September 20 2016 Issue
    1) Influence of sodium consumption and associated knowledge on post-stroke hypertension in Uganda2) e-Pearl topic: Transient cerebral arteriopathy3) Topic of the month: Neurologic prognosis following cardiac arrestThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Larry Goldstein about his paper on the influence of sodium consumption and its associated knowledge on post-stroke patients with and without a history of hypertension in Uganda. Dr. Adam Numis is reading our e-Pearl of the week about transient cerebral arteriopathy. In the next part of the podcast Dr. Andy Schomer continues his interview with Dr. Eelco Wijdicks about the ancillary testing that is done in patients with cardiac arrest.DISCLOSURES: Dr. Goldstein serves as an editorial board member of Neurology®, Emergency Medicine, Cardiology Today and Stroke; serves as an Associate Editor for Cerebrovascular Diseases; serves on the scientific advisory board for Daichi Sanyo, Merz, Roche and Pfizer Inc; is a consultant for Artemida, Nestle and Stroke Hospitalization in Elderly with Medicare; receives honoraria from serving on the scientific advisory board of Pfizer Inc; receives royalties from the publication of the books: Screening for Asymptomatic Carotid Stenosis, Use and Utility of Stroke Scales and Grading Sysytems and Henry Stewart Talks, Secondary Stroke Prevention; receives research support from Stroke Hospitalization in Elderly with Medicare and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks receives royalties from the publication of several books.
  • September 13 2016 Issue
    1) Cortical superficial siderosis: Prevalence and biomarker profile in a memory clinic population2) What's Trending: Interview with Lyell Jones about Axon Registry and how it interfaces with practice and reimbursement (Part 1)3) Topic of the month: Neurologic prognosis following cardiac arrestThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Chris Tarolli interviews Dr. Sara Shams about her paper on the prevalence and biomarker profile of cortical superficial siderosis in a consecutive memory clinic population. Dr. Andy Southerland is interviewing Dr. Lyell Jones for our “What's Trending” feature of the week about the topic of the Axon Registry and how it interfaces with practice and reimbursement. This is part 1 with part 2 appearing next month. In the next part of the podcast Dr. Andy Schomer continues his interview with Dr. Eelco Wijdicks about the timing of the clinical examination of a patient following cardiac arrest.DISCLOSURES: Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Wijdicks receives royalties from the publication of several books.
  • September 6 2016 Issue
    1) Neurology® Clinical Practice: Incidence of meningeal enhancement on brain MRI secondary to lumbar puncture2) What's Trending: Interview with Robert Gross about his editorial on the trial article format being published this week3) Topic of the month: Neurologic prognosis following cardiac arrestThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jonathan Perk interviews Dr. Sarah Wesley about her Neurology® Clinical Practice paper on the unexplained meningeal enhancement after lumbar puncture. Dr. Ted Burns is interviewing Dr. Robert Gross for our “What's Trending” feature of the week about his editorial on the trial article format being published this week in Neurology. In the next part of the podcast Dr. Andy Schomer interviews Dr. Eelco Wijdicks about the treatment of cardiac arrest and hypothermia management.DISCLOSURES: Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Gross receives support for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH, since his appointment as Editor-in-Chief in 2009, he has ceased participation in industry-sponsored clinical trials and speakers' bureaus; receives an honorarium from AAN as Editor-in-Chief of Neurology®.Dr. Wijdicks receives royalties from the publication of several books.NO CME WILL BE OFFERED THIS WEEK.
  • Delayed Recall September 2016
    Zika virus interviews
  • August 30 2016 Issue
    1) Predictive value of ABCD2 and ABCD3-1 scores in TIA and minor stroke in the Stroke Unit Setting2) e-Pearl topic: Alternating hemiplegia of childhood3) Topic of the month: Neurology Today story about his book review on: “The Laws of Medicine: Field Notes from an Uncertain Science.”This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Anna Ranta interviews Dr. Michael Knoflach about his paper on the predictive value of ABCD2 and ABCD3-1 scores in transient ischemic attack and minor stroke in the Stroke Unit Setting. Dr. Steve O'Donnell is reading our e-Pearl of the week about alternating hemiplegia of childhood. Dr. Ted Burns interviews Jose Merino about a Neurology Today story about his book review on: “The Laws of Medicine: Field Notes from an Uncertain Science.”DISCLOSURES: Dr. Ranta receives research support from the New Zealand Health Research Council.Dr. O'Donnell serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Merino serves as US Clinical Research Editor for the BMJ; serves as Co-editor, blogging stroke (A Stroke journal blog); receives stroke outcomes adjudicator for the WHI study (NIH-funded); and DSMB of a PCORI-funded trial to evaluate depression in caregivers of patients with Alzheimer disease.
  • August 23 2016 Issue
    1) Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome2) e-Pearl topic: Moyamoya disease and syndrome3) Topic of the month: Neurology Today story on a published paper titled: Intensive Blood-Pressure Lowering in Patients with Acute Cerebral HemorrhageThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Drs. Francesc Graus and Josep Dalmau about their paper on the presentation and long-term outcome of anti-LGI1-associated cognitive impairment. Dr. Steve O'Donnell is reading our e-Pearl of the week about Moyamoya disease and syndrome. Dr. Javier Provencio interviews Dr. Adnan Qureshi about a Neurology Today story on his published paper titled: Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage.DISCLOSURES: Dr. Graus serves as an editorial board member of Lancet; receives license fee Payments from Euroimmun for the use of IgLON5 as a diagnostic test; holds a patent for the use of IgLON5 as a diagnostic test.Dr. Dalmau serves as Editor of Neurology®: Neuroimmunology & Neuroinfammation; serves as an Editorial board member of Neurology® and UpToDate; receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests; is a consult for Advance Medical, receives research support from Euroimmun and the NIH; receives revenue from Euroimmun for the following tests: NMDA receptor autoantibody test, GABA(B)R autoantibody test, GABA(A)R autoantibody test, DPPX autoantibody test and Iglon5 autoantibody test.Dr. O'Donnell serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Provencio serves as an editorial board member of Journal of Neuroimmunology, serves on the scientific advisory board for Minnetronix, INC. (travel related expenses) and Advanced Circulatory, Inc (travel related expenses); received honoraria from Bard, Inc.; receives royalties from the publication of the book “Family Guide to Surviving the ICU”; receives research support from Bard Inc., Cryothermics INC. and the NIH.
  • August 16 2016 Issue
    1) Neurology® Neuroimmunology & Neuroinflammation: Next-generation sequencing in neuropathological diagnosis of infections of the nervous system2) e-Pearl topic: GABAb receptor encephalitis3) Topic of the month: Neurology Today story about the global burden of strokeThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Carlo Pardo about his Neurology® Neuroimmunology & Neuroinflammation paper on next-generation sequencing in neuropathological diagnosis of infections of the nervous system. Dr. Steve O'Donnell is reading our e-Pearl of the week about GABAb receptor encephalitis. Dr. Andy Southerland interviews Dr. Vladimir Hachinski about a Neurology Today story on the topic of the global burden of stroke.DISCLOSURES: Dr. Pardo receive research support from the Bart McLean Fund for Neuroimmunology Research-Project Restore and the NIH.Dr. O'Donnell serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.NO CME WILL BE OFFERED THIS WEEK.
  • August 9 2016 Issue
    1) Impaired self-agency in functional movement disorders2) What's Trending: Interview with James Sejvar about possible links between Zika virus, microcephaly, and Guillain–Barre syndrome3) Topic of the month: Neurology Today story about where advances are revolutionizing stroke treatmentThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Carine Maurer about her paper on impaired self-agency in functional movement disorders Dr. Andy Southerland is interviewing Dr. James Sejvar for our “What's Trending” feature of the week on the topic of possible links between Zika virus, microcephaly, and Guillain–Barre syndrome. Dr. Andy Southerland interviews Dr. Ralph Sacco about a Neurology Today story on the topic of where advances are revolutionizing stroke treatment.DISCLOSURES: Dr. Maurer receives research support from the NINDS Intramural Program.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Sacco serves as an editorial board member of Stroke and Neuroepidemiology; serves on the scientific advisory board for DSMB for SOCRATES Trial through UCSF(indirect sponsor Astra Zeneca) and EUCLID trial through Duke Clinical Research Institute (indirect sponsor Astra Zeneca); receives research support from Boehringer Ingelheim, Evelyn McKnight Brain Institute, American Heart Association Burgher Foundation and the NIH.
  • August 2 2016 Issue
    1) The clinical spectrum of Caspr2-antibody associated disease2) What's Trending: Interview with Lenore Launer about how hostile attitudes and effortful coping in young adulthood can predict cognition in later life 3) Topic of the month: Neurology Today story about five mentally stimulating activities associated with a lower risk for mild cognitive impairmentThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeremy Lanford interviews Dr. Maarten Titulaer about his paper on the clinical spectrum of Caspr2-antibody associated disease. Dr. Ted Burns is interviewing Dr. Lenore Launer for our “What's Trending” feature of the week about her paper on how hostile attitudes and effortful coping in young adulthood can predict cognition in later life. Dr. Ted Burns interviews Drs. Janina Krell-Roesch and Gregg Day about a Neurology Today story on the topic of five mentally stimulating activities associated with a lower risk for mild cognitive impairment.DISCLOSURES: Dr. Titulaer serves on the scientific advisory board for MedImmune; serves as an editorial board member for Neurology®: Neuroimmunology & Neuroinflammation; received funding for travel from Sun Pharma; receives research support from Netherlands Organization for Scientific Research, Dutch Epilepsy Foundations and ErasmusMC fellowship.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Launer receives research support from the National Institute on Aging Intramural Research Program.Dr. Day received funding for travel from Pfizer, Canada for Future Leader in Dementia award; receives Research support from Avid Pharmaceuticals, American Brain Foundation, Clinical Research Training Fellowship, Eugene M Johnson Jr, Weston Brain Institute Postdoctoral Fellowship; and holds stock options in ANI Pharmaceuticals (2014-2015).
  • July 26 2016 issue
    1) International consensus guidance for management of myasthenia gravis2) e-Pearl topic: Progressive multifocal leukoencephalopathy3) Topic of the month: Neurology Year in Review Plenary Session at the AAN meeting on the topic of headacheThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Donald Sanders about the executive summary on the international consensus guidance for management of myasthenia gravis. Dr. Ilena George is reading our e-Pearl of the week about progressive multifocal leukoencephalopathy. Dr. Tesha Monteith interviews Dr. Richard Lipton about his Neurology Year in Review Plenary Session at the AAN meeting on the topic of headache.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Sanders receives royalties from the publication of the book: Single Fiber EMG; serves on the medical advisory board for Accordant Health Services; is a consultant for ArGen-X, Jacobus Pharmaceutical Co., Inc, Modus Outcomes, Momenta Pharmaceuticals, Inc. and UCB Celltech.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Lipton receives royalties for books published from Oxford University Press and Baxter Publishing; Receives honoraria for serving on the scientific advisory board for Alder, Allergan, Inc., American Headache Society, Autonomic Technologies, Avanir Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly and Company, eNeura Therapeutics, Informa, Merck Serono, Novartis, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Vedanta; is a consultant for Alder, Allergan, Inc., American Headache Society, Autonomic Technologies, Avanir Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly and Company, eNeura Therapeutics, Informa, Merck Serono, Novartis, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Vedanta; holds stock options in eNeura Pharma; receives research support from Bristol-Myers Squibb, Vedanta Research Migraine epidemiology and Progression. Boston Scientific Occipital Nerve Stimulation in Migraine, ElectroCore Vagal Nerve Stimulation for Migraine and Cluster, Novartis Sleep and Migraine, Allergan Botox in Migraine, Allergan Chronic Migraine Epidemiology and Outcome Study, S & L Marx Foundation Alzheimer's Research and the NIH.
  • July 19 2016 Issue
    1) Zika virus-associated Guillain-Barre Syndrome Variant in Haiti2 e-Pearl topic: Juvenile Huntington Disease3) Topic of the month: Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer diseaseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Stephen Donahue interviews Dr. Aaron Berkowitz about his paper on Zika virus-associated Guillain-Barre syndrome variant in Haiti. Dr. Ilena George is reading our e-Pearl of the week about juvenile Huntington disease. Dr. Alberto Espay interviews Dr. Alireza Atri about his Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer disease.DISCLOSURES: Dr. Berkowitz receives royalties from the publication of the book: Clinical Pathophysiology Made Ridiculously Simple and the book: The Improvising Mind; received funding for travel from Stevens Institute of Technology; received speaker honorarium from Audio Digest; and received honorarium for recorded CME lecture.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.
  • July 12 Issue
    1) Neurology® Clinical Practice: Alice in Wonderland syndrome: a systematic review2) What's Trending: Interview with Clinton Wright about his paper on leisure time physical activity and how it is associated with cognitive decline3) Topic of the month: Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndromeThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Lapides interviews Dr. Jan Dirk Blom about his Neurology: Clinical Practice paper on the Alice in Wonderland syndrome. Dr. Ted Burns is interviewing Dr. Clinton Wright for our “What's Trending” feature of the week about his paper on leisure time physical activity and how it is associated with cognitive decline. Dr. Alberto Espay interviews Dr. Jeremy Schmahmann about his Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndrome.DISCLOSURES: Dr. Blom receives royalties from the publication of the book Hallucinations, Research and Practice and the book A Dictionary of Hallucinations.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Wright receives royalties from UpToDate website for two chapters on vascular dementia; receives research support from American Stroke Association-Bugher Foundation Centers of Excellence project and the NIH.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as aneditorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Schmahmann serves as an editorial board member of The Cerebellum and its sister journal, Cerebellum and Ataxias; serves on the scientific advisory board for Ataxion, Inc. and Atlas Ventures; Receives royalties from the publications of the books: The Cerebellum and Cognition: International Review of Neurobiology, MRI Atlas of the Human Cerebellum, Pathways of the Brain, Cerebellar Disorders in Children: Clinics in Development Medicine, and Handbook of the Cerebellum and Cerebellar Disorders; is a consultant for Takeda Pharmaceutical Company Limited; holds stock option in Ataxion, Inc. and Atlas Ventures; receives research support from Birmingham Foundation, MINDlink Foundation, Sidney R. Baer Jr., Foundation, National Ataxia Foundation, Ataxia Telangiectasia Children's Project and the NIH.NO CME WILL BE OFFERED THIS WEEK.
  • Migraine updates and what we have learned - July 2016
    Migraine updates and discussion on the topics of migraine genetics, science behind lifestyle factors, science behind lifestyle factors and clinical trials - July 2016
  • Plenary Session Interviews - May 2016
    Plenary Session Interviews - May 2016
  • July 5 2016 Issue
    1) Low-cost, tablet-based option for prehospital neurologic assessment: the iTREAT Study2) What's Trending: Interview with Dafne Horovitz about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection3) Topic of the month: Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Andy Southerland about his paper on a low-cost, tablet-based option for prehospital neurologic assessment. Dr. Ted Burns is interviewing Dr. Dafne Horovitz for our “What's Trending” feature of the week about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection. Dr. Alberto Espay interviews Drs. Dave Knopman and Kaycee Sink about their Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementia.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publications of the books Stroke and Neurology in Practice [Edited book]; and receives research support from the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Horovitz serves as Associate Editor for Journal of Community Genetics; received speaker honoraria from Biomarin Pharmaceutical, Genzyme-Sanofi, Shire Pharmaceuticals, Inc. and Alexion Pharmaceuticals, Inc.; received funding for travel to medical meeting from Genzyme-Sanofi and Shire Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Knopman serves on the scientific advisory board for Consultant Bluefield project, Lundbeck Pharmaceuticals Inc., DIAN study DSMB; served as Associate Editor for Neurology® until October 2015; receives research support from the NIH, Mayo Alzheimer's Disease Research Center, Mayo Alzheimer Disease Patient Registry, ARIC Dementia Study and Chronic Kidney Disease and Cognitive functioning; received funding for travel to two lectures Alzheimer Conference, Seoul Korea and Behavioral Neurology Conference, Hyderabad, India.Dr. Sink served on the data safety monitoring board for two NIH funded clinical trials; initiated grants from the Alzheimer's Association and the Donald W. Reynolds Foundation as an investigator; received research support from the NIH.
  • June 14 Issue
    1) Quality improvement in neurology: Parkinson disease update quality measurement set2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: George C. Cotzias Lecture at the AAN Meeting on antibody mediated disorders of the synapseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Drs. Janis Miyasaki and Stewart Factor about the AAN paper on new quality measures developed to improve outcomes for patients with Parkinson disease. Dr. Ted Burns is interviewing Dr. Ansgar Furst for our “What's Trending” feature of the week about his editorial on incidental findings for what's to come in amyloid plaques in traumatic brain injury. Dr. Alberto Espay interviews Dr. Josep Dalmau about his George C. Cotzias Lecture at the AAN Meeting on the topic of antibody mediated disorders of the synapse.DISCLOSURES: Dr. Miyasaki received honoraria and funding for travel from Teva Pharmaceutical Industries Ltd.; received funding for travel from Merz Pharmaceuticals, LLC; received travel honoraria from The International Parkinson Disease and Movement Disorders Society; is a consultant for Merz Pharmaceuticals, LLC; receives royalties from the publication of the book “Psychogenic Movement Disorders;” receives research support from PCORI: 2015-2018 and Parkinson Alberta.Dr. Factor served as an editorial board member of Neurotherapeutics; serves on the data safety monitoring board for Lundbeck, Inc; is a consultant for UCB; is a consultant and video reviewer for clinical trials for Avanir, Neurocrine and Auspex/Teva Pharmaceutical Industries Ltd.; receives royalties from the publications of the books “Parkinson's disease diagnosis and clinical management” and “Drug induced movement disorders;” gave expert testimony in Kmart trial (2014-2016); receives research support from Ceregene, Cynapsus, Sangamo, Teva Pharmaceutical Industries Ltd., Ipsen Pharmaceuticals, Inc., USWorldMeds, Allergen, Inc., Medtronics, Inc., Auspex, Genzyme Corporation, Michael J. Fox Foundation and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Dalmau serves as Editor of Neurology®: Neuroimmunology & Neuroinfammation; serves as an Editorial board member of Neurology® and UpToDate; receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests; is a consult for Advance Medical, receives research support from Euroimmun and the NIH; receives revenue from Euroimmun for the following tests: NMDA receptor autoantibody test, GABA(B)R autoantibody test, GABA(A)R autoantibody test, DPPX autoantibody test and Iglon5 autoantibody test.
  • June 7 2016 Issue
    1) Neurology® Genetics: Clinical and genetic features of cervical dystonia in a large multi-center cohort 2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: Abstract presentation at the AAN meeting on the spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteriaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Mark LeDoux about his Neurology: Genetics paper on the clinical and genetic features of cervical dystonia. Dr. Ted Burns is interviewing Dr. Dave Sharp for our “What's Trending” feature of the week about his paper on amyloid pathology and axonal injury after brain trauma. Dr. Andy Southerland interviews Dr. Andy Solomon about his abstract presentation at the AAN meeting on the spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteria.DISCLOSURES: Dr. LeDoux serves on the scientific advisory boards of Spastic Paraplegia Foundation; serves as Chairman on the board of medical advisors of the National Spasmodic Torticollis Association; serves as an editorial board member of Parkinsonism and Related Disorders, Tremor and other hyperkinetic movement disorders, PLOS ONE and Neurology®; is a consultant for Azilect Advisory Board, Mayo Clinic, Teva Pharmaceutical Industries Ltd., Lundbeck Inc.; serves on the speakers' bureau of Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; receives funding for travel from Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; receives royalties from the publication of the books “Animal models of movement disorders” and “Movement disorders: Genetics and models;” receives research support from Benign Essential Blepharospasm Research FDN, CHDI, Enroll HD, Omeros, Phase 2, Auspex, US WorldMeds, Mysticol, Protocol, Accorda and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Sharp receives research support from UK Medical Research Council, European Union, Wellcome Trust, Rosetrees Trust, Action Medical Research, Public engagement grant from The Physiological Society, The Royal Society Summer Science Exhibition and the NIH (UK).Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Solomon received research support from the Portland Veterans Affairs Medical Center Fellowship in Multiple Sclerosis and Neuroimmunology and Partners Multiple Sclerosis Fellowship Award.NO CME WILL BE OFFERED THIS WEEK.
  • May 31 2016 Issue
    1) APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline 2) e-Pearl topic: Ocular neuromyotonia3) Topic of the month: Neurology Today story about Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 2)This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Prof. Martha Morris about her paper on APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. Dr. Adam Numis is reading our e-Pearl of the week about ocular neuromyotonia. Dr. Ted Burns interviews Dr. Gary Franklin about a Neurology Today story on the topic of the new Center for Disease Control guidelines on prescribing opioids (Part 2).DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Prof. Morris is a consultant for Neurotrack; serves on the scientific advisory board for the University of Chicago; received funding for travel from the University of California; receives research support from the Abbott Fund and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Franklin serves as an editorial board member of Neuroepidemiology; serves on the Levels of Evidence Team for Neurology®; is a consultant for the California State Compensation Insurance Fund; receives research support from the Centers for Disease Control and Prevention.
  • May 24 2016 Issue
    1) Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies2) e-Pearl topic: Neurologic manifestations of hereditary hemorrhagic telangiectasia3) Topic of the month: Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 1)This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Flaherty interviews Dr. Loch Macdonald about his paper on review and meta-analysis of 25 studies about the natural history of cavernous malformation. Dr. Adam Numis is reading our e-Pearl of the week about neurologic manifestations of hereditary hemorrhagic telangiectasia. Dr. Ted Burns interviews Dr. Gary Franklin about a Neurology Today story on the topic of the new Center for Disease Control guidelines on prescribing opioids (Part 1).DISCLOSURES: Dr. Flaherty serves on the scientific advisory board for DSMB member, I-DEF Trial (NINDS sponsored ICH treatment trial); has a patent pending, non-invasive CNS monitor; owns company stock as co-founder of SENSE Diagnostics, LLC (our product is currently investigational and not on the market); serves on the speakers' bureau of CSL Behring and Janssen; receives research support from American Heart Association, Pfizer Inc, Bristol-Myers Squibb, NIH and as Principal Investigator of a phase II, NINDS funded trial testing recombinant activated factor VII for treatment of intracerebral hemorrhage where study drug is supplied by Novo Nordisk.Dr. Macdonald serves as an editorial board member of Stroke, Journal of Neurosurgery, Neurosurgery, Journal of cerebral blood flow and metabolism, Neurocritical care, World Neurosurgery, Surgical Neurology International, Translational stroke research and Cerebrovascular diseases; treats unruptured aneurysm patients (1% effort); holds stock options in Edge Therapeutics, Inc; has a patent for treatment of delayed cerebral ischemia and subdural hemorrhage, intracranial drug delivery systems; receives research support from Canadian Institutes of Health Research, Brain Aneurysm Foundation, Heart and Stroke Foundation of Canada and Physicians Services Incorporated Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Franklin serves as an editorial board member of Neuroepidemiology; serves on the Levels of Evidence Team for Neurology®; is a consultant for the California State Compensation Insurance Fund; receives research support from the Centers for Disease Control and Prevention.
  • May 17 2016 Issue
    1) Variability in Physician Prognosis and Recommendations after Intracerebral Hemorrhage2) e-Pearl topic: Eye and facial findings in psychogenic non-epileptic seizures 3) Topic of the month: Neurology Today story about lead crisis in Flint exposing continuing risk to children nationwideThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Javier Provencio interviews Dr. Darin Zahuranec about his paper on variability in physician prognosis and recommendations after intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about eye and facial findings in psychogenic non-epileptic seizures. Dr. Ted Burns interviews Dr. Chris Holstege about a Neurology Today story on the topic of lead crisis in Flint exposes continuing risk to children nationwide: What neurologists should know and what they can do about it.DISCLOSURES: Dr. Provencio serves on the scientific advisory boards for Minnetronix, INC., Advanced Circulatory, Inc; serves on the data safety monitoring board for the ASTROH trial; Received honoraria and funding for travel from Bard, Inc.; serves as an editorial board member of Journal of Neuroimmunology; receives royalties from the publication of the book Family guide toSurviving the ICU; served on the board of directors of the Neurocritical Care Society; serves as President for the Ohio Chapter of the Society of Critical Care Medicine; receives research support From Bard Inc., Systemic Normothermia in ICH (SNICH), Crothermics INC. and the NIH.Dr. Zahuranec receives research support from Medtronic, Inc. and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.
  • May 10 2016 Issue
    1) Neurology® Clinical Practice: Clinical Exome Sequencing in Neurologic Disease 2) What's Trending: Interview with Natalia del Campo about her paper on relationship of regional brain beta-amyloid to gait speed3) Topic of the month: Neurology Today story about pioglitazone found to be associated with a lower risk of secondary stroke in Non-diabetic patients with insulin resistanceThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Brent Fogel about his Neurology: Clinical Practice paper on clinical exome sequencing in neurologic disease. Dr. Ted Burns is interviewing Dr. Natalia del Campo for our “What's Trending” feature of the week about her paper on relationship of regional brain beta-amyloid to gait speed. Dr. Andy Southerland interviews Dr. Walter Kernan about a Neurology Today story on the topic of pioglitazone found to be associated with a lower risk of secondary stroke in Non-diabetic patients with insulin resistance.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Fogel received speaker honoraria from the American Academy of Neurology and American Physician Institute for Advanced Professional Studies; received funding for travel from American Physician Institute for Advanced Professional Studies and National Ataxia Foundation; receives research support from American Physician Institute for Advance Professional Studies, National Ataxia Foundation and the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Kernan academic institution receives research support from Takeda Pharmaceutical Company Limited and the NIH.NO CME WILL BE OFFERED THIS WEEK.
  • May 3 2016 Issue
    1) Neurology® Neuroimmunology & Neuroinflammation: VZV in biopsy-positive and -negative giant cell arteritis: analysis of 100+ temporal arteries2) What's Trending: Interview with Kimberley R. Barker about “altmetrics”3) Topic of the month: Neurology Today story about epidemiologists tracking possible links between Zika virus, microcephaly, and Guillain–Barre syndromeThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Don Gilden about his Neurology: Neuroimmunology & Neuroinflammation paper on varicella zoster virus in over 100 temporal arteries that showed clinical features of giant cell arteritis. Dr. Andy Southerland is interviewing Kimberley R. Barker for our “What's Trending” feature of the week about “altmetrics.” Dr. Ted Burns interviews Dr. James Sejvar about a Neurology Today story on the topic of epidemiologists tracking possible links between Zika virus, microcephaly, and Guillain–Barre syndrome.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Gilden serves as Senior Associate Editor for Journal of NeuroVirology, serves as an editorial Board member of In Vivo, Journal of Virology, Scientific American Medicine, Virus Genes, Neurology®, and the Journal of the Nuerological Sciences; receives research support from the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium ofr improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.NO CME WILL BE OFFERED THIS WEEK.
  • April 26 2016 Issue
    1) The association between hospitalization and care after transient ischemic attack or minor stroke2) e-Pearl topic: Neuroretinitis3) Topic of the month: Migraine awareness seriesThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Moira Kapral about her paper on the association between hospitalization and care after transient ischemic attack or minor stroke. Dr. Sarah Wesley is reading our e-Pearl of the week about neuroretinitis. Dr. Tesha Monteith interviews Dr. Stephen Silberstein about the topic of migraine clinical trials: A drug therapy and neuromodulation update. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke viamobile telemedicine;” and gave legal expert review.Dr. Kapral serves as Guest Editor for Cardiovascular Quality and Outcomes; serves as an editorial board member of Circulation; receives research support from the Heart and Stroke Foundation of Canada.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Silberstein serves as an editorial board member of Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management and Neurology®; serves on the scientific advisory board for Alder, Allergan, Inc., Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Inc., Mitsubishi Tanabe Pharma Corporation, Neuralieve, NINDS, Pfizer Inc, Supernus and Teva Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Inc., Neuralieve, Pfizer, Inc, Supernus and Teva Pharmaceutical Industries Ltd.; receives research support from American Headache Society®, International Headache Society and the NIH.
  • April 19 2016 Issue
    1) Standardized EEG interpretation accurately predicts prognosis after cardiac arrest2) e-Pearl topic: Panayiotopoulos syndrome3) Topic of the month: Migraine awareness seriesThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Fugate interviews Dr. Tobias Cronberg about his paper on standardized EEG interpretation and how it predicts prognosis after cardiac arrest. Dr. Sarah Wesley is reading our e-Pearl of the week about Panayiotopoulos syndrome. Dr. Tesha Monteith interviews Dr. Messoud Ashina about the topic of neuroimaging biomarkers and human models for new drug targets: Lessons from PACAP38. DISCLOSURES: Dr. Cronberg receives research support from the Regional Research Support, Region Skane, The Swedish Heart and Lung Association, The Skane University Hospital Foundations, The Gyllenstierna-Krapperup Foundation, The Swedish Society of Medicine, The Koch Foundation and The Segerfalk Foundation.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Ashina serves as an associate editor of Cephalgia Member of advisory board: The Journal of Headache and Pain; is a consultant or scientific adviser for the ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received an honoraria for lecturing from Allergan, Inc.; receivesresearch support from the Research Foundation of the Capital Region of Denmark, the Danish Council for Independent Research-Medical Sciences, the Novo Nordisk Foundation, IMK Almene Foundation, and the Cool Sorption Foundation.
  • April 12 2016 Issue
    1) Dichlorphenamide in periodic paralysis 2) What's Trending: Editorial on the Zika Virus and what the neurologist wants to know3) Topic of the month: Migraine awareness seriesThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Valeria Sansone about her paper on dichlorphenamide in periodic paralysis. Dr. Ted Burns is interviewing Dr. Gretchen Birbeck for our “What's Trending” feature of the week about her editorial on the Zika Virus and what the neurologist wants to know. Dr. Tesha Monteith interviews Dr. Peter Goadsby about the topic of science behind lifestyle factors: Our basic instincts and the migraine brain. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Birbeck serves as Section Editor and Curator for Without Borders mini-site Neurology®; receives research support from the NIH and Dana Foundation Neuroimaging Grant.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Goadsby serves as an editorial board member for Journal Watch Neurology; receives royalties from the publication of Mechanism and Management of Headache. (7th ed.); was a consultant for Alder Bio, Allergan, Inc., Amgen, ATI, Boehringer Ingelheim, BMS, Boston Scientific, Colucid, Coherex, DrReddy, Eli Lilly and Company, Gammacore, GlaxoSmithKline, Impax, J&J Linde Gases, Lundbeck Inc., MAP Pharmaceuticals, Medtronic, Inc., MSD, Neuralieve, Nevrocorp, Pfizer Inc, Zogenix; receives research support from Amgen and Allergan, Inc.; has worked with legal firms handling patent matters.
  • April 5 2016 Issue
    1) Mid-life exercise blood pressure, heart rate and fitness relate to brain volume two decades later2) What's Trending: Antibiotic-associated encephalopathy 3) Topic of the month: Migraine awareness seriesThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Nicole Spartano about her paper on the mid-life exercise blood pressure, heart rate and fitness and how it relates to brain volume two decades later. Dr. Ted Burns is interviewing Dr. Shamik Bhattacharyya for our “What's Trending” feature of the week about his paper on antibiotic-associated encephalopathy. Dr. Tesha Monteith interviews Dr. Aarno Palotie about the topic of migraine genetics: What have we learned. DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Spartano receives research support from the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Palotie serves as a member of the Pfizer Genetics Scientific Advisory Panel; receives research support from Finnish Academy, European Union NIH, NINDS, Juselius Foundation and Finnish Foundation for Cardiovascular Research.
  • March 29 2016 Issue
    1) Neurology® Clinical Practice article titled: How do you treat anti-NMDA receptor encephalitis?2) e-Pearl topic: Primary lateral sclerosis3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Luca Bartolini about his Neurology: Clinical Practice paper on how you treat anti-NMDA receptor encephalitis. Dr. Steve O'Donnell is reading our e-Pearl of the week about primary lateral sclerosis. In the next part of the podcast Dr. Nick Brenton interviews Dr. Leigh Charvet about the topic of cognitive, emotional and behavioral outcomes in pediatric multiple sclerosis. DISCLOSURES: Dr. Bartolini serves as Section Editor for Neurology Clinical Practice.Dr. O'Donnell serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Charvet has received research support from Novartis.NO CME WILL BE OFFERED THIS WEEK.
  • March 22 2016 Issue
    1) Statin pretreatment is associated with better outcomes in large-artery atherosclerotic stroke2) e-Pearl topic: Fatal familial insomnia3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Georgios Tsivgoulis about his paper on how statin pretreatment is associated with better outcome in large-artery atherosclerotic stroke. Dr. Steve O'Donnell is reading our e-Pearl of the week about fatal familial insomnia. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Emmanuelle Waubant about the topic of vitamin D in pediatric multiple sclerosis. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Tsivgoulis serves as Associate Editor for Neurosonology; serves as an editorial board member of Journal of Neuroimaging; and receives research support from the European Regional Development Fund.Dr. O'Donnell serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada.Dr. Waubant serves on the scientific advisory board for Novartis; serves as an editorial board member of Annals of Clinical and Translational Neurology; is an ad hoc consultant for Roche and MedDay; received funding for travel for one educational physician lecture from Genentech, Inc.; receives royalties from the publication of the book Demyelinating disorders of the central nervous system in childhood; receives research support for trials of ocrelizumab in PPMS (Roche), and fingolimod in pediatric MS (Novartis); receives research support from the National Multiple Sclerosis Society, the Race to Erase MS and NIH.
  • March 15 2016 Issue
    1) Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes2) What's Trending: Editorial on if stress could cause a stroke3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kathryn Nevel interviews Dr. Andrew McKeon about his paper on clinical features and treatment outcomes of metabotropic glutamate receptor type 1 autoimmunity. Dr. Ted Burns is interviewing Dr. Jennifer Majersik for our “What's Trending” feature of the week about her editorial on if stress could cause a stroke. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Ann Yeh about the topic of exercise in pediatric multiple sclerosis. DISCLOSURES: Dr. McKeon receives research support from Medimmune, Inc.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Majersik serves as an editorial board member of Neurology; and receives research support from the NIH.Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada.Dr. Yeh perform multiple sclerosis relapse adjudication for ACI services on a fee-for-service basis; serves as an editorial board member of Neurology; receives research support from the Canadian Institutes of Health Research, Patient-Centered Outcomes Research Institute, MS Monitoring system pilot funding, National MS Society, MS Society, Dairy Farmers of Ontario, SickKids Innovation Fund, MS Research Foundation (Canada), and Rare Diseases Foundation.
  • March 8 2016 Issue
    1) Transient ischemic attack service provision: A review of available service models2) What's Trending: Mediterranean diet and brain structure in a multiethnic elderly cohort3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Anna Ranta about her paper on transient ischemic attacks as predictors of high risk for subsequent strokes. Dr. Ted Burns is interviewing Dr. Yian Gu for our “What's Trending” feature of the week about his paper on the Mediterranean diet and brain structure in a multiethnic elderly cohort. In the next part of the podcast Dr. Nick Brenton interviews Dr. Daniela Pohl about the topic of disease-modifying therapy management in pediatric multiple sclerosis. DISCLOSURES: Dr. Ranta receives research support from the New Zealand Health Research Council.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Pohl received funding for travel from Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, ENS, Merck Serono, Consortium of Multiple Sclerosis Center, LACTRIMS and National Multiple Sclerosis Society; received speaker honoraria from Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, Merck Serono and Consortium of Multiple Sclerosis Center; serves on the scientific advisory board for Biogen Idec and Merck Serono.
  • Delayed Recall - March 2016
    Tele-neurology and tele-stroke - from September 2015 LOTWs
  • March 1 2016 Issue
    1) Neurology® Neuroimmunology & Neuroinflammation: Therapy with natalizumab is associated with high JCV sero-conversion and rising JCV index values 2) What's Trending: Interviews with Sandi Moriarity and Andy Lucas about their positions and responsibilities with the Neurology podcasts3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Nicholas Schwab about his Neurology: Neuroimmunology & Neuroinflammation paper on therapy with natalizumab and how it is associated with high JCV sero-conversion and rising JCV index values. Dr. Ted Burns is interviewing Sandi Moriarity and Andy Lucas for our “What's Trending” feature of the week about their positions and responsibilities with the Neurology podcast. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Brenda Banwell about the topic of diagnosis of pediatric multiple sclerosis and acute disseminated encephalomyelitis.DISCLOSURES: Dr. Schwab received funding for travel expenses from Biogen Idec; received speaking honoraria from Novartis; has a patent for Usage of L-selectin as predictive marker for progressive multifocal leukoencephalopathy; and receives research support from the Deutsche Forschungsgemeinschaft German Research Foundation and University Münster, IMF.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Sandi Moriarity is Senior Production Editor, Neurology.Andy Lucas is Audio-Visual Administrator, American Academy of Neurology.Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada.Dr. Banwell serves as an editorial board member of Neurology and Multiple Sclerosis and Related Disorders; serves on the scientific advisory board for Biogen Idec, Sanofi-aventis, Eli Lilly and Company, Novartis; served as a consultant to Biogen Idec, Eli Lilly and Company, Sanofi-aventis; spoken at an event supported by the Consortium of MS Centers; receives research support from the Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Research Foundation, and the National Multiple Sclerosis Society.NO CME WILL BE OFFERED THIS WEEK.
  • February 23 2016 Issue
    1) Neurology® Genetics: Late diagnosis of cerebral folate deficiency: Fewer seizures with folinic acid in adult siblings 2) e-Pearl topic: Stroke-like migraine attacks after radiation therapy (SMART) Syndrome3) Topic of the month: Neurology Today story about unraveling the genetics of Alzheimer disease and attending the ‘Oscars of Science' This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Dave Dyment about his Neurology: Genetics paper on late diagnosis of cerebral folate deficiency. Dr. Ilena George is reading our e-Pearl of the week about stroke-like migraine attacks after radiation therapy (SMART) syndrome. Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of unraveling the genetics of Alzheimer disease and attending the ‘Oscars of Science.' DISCLOSURES: Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. George serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Hardy serves on the scientific advisory boards for Eisai Inc. and Eli Lilly and Company; is a Consultant for Eisai Inc.NO CME WILL BE OFFERED THIS WEEK.
  • Feburary 16 2016 Issue
    1) Neurology® Neuroimmunology & Neuroinflammation: Vasculitis neuropathy following exposure to minocycline 2) e-Pearl topic: Primary progressive aphasia3) Topic of the month: Neurology Today story about a wearable EEG device This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Chafic Karam about his Neurology: Neuroimmunology & Neuroinflammation paper on vasculitis neuropathy following exposure to minocycline. Dr. Ilena George is reading our e-Pearl of the week about primary progressive aphasia. Dr. Ted Burns interviews Dr. Jacqueline French about a Neurology Today story on the topic of a wearable EEG device. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Karam serves as Deputy Editor for Neurology Write Click; served on the editorial team for the Neurology® Resident and Fellow Section; received speaker honoraria from Nufactor, Inc.; received consulting honoraria from Lundbeck Inc.Dr. George serves on the editorial team for the Neurology Resident and Fellow Section.Dr. French is a consultant for Acorda Therapeutics, Anavex, Brabant Pharma, Bio-Pharm Solutions, Eisai Inc., GlaxoSmithKline, GW Pharma, Impax, Johnson and Johnson, Marinus Pharmaceuticals, Inc., Neusentis, Novartis, Pfizer Inc, Sage, Sunovion Pharmaceuticals Inc., SK Life Sciences, Supernus, Takeda, UCB Pharma, Upsher-Smith Laboratories, Inc., Ultragenyx, Vertex, Zogenix, and Zynerba, all consulting was on behalf of the Epilepsy Study Consortium, and fees are paid to the consortium and New York University receives salary support from the consortium; serves as Associate Editor for Epilepsia; serves as an Editorial board member for Lancet Neurology, Neurology Today and Epilepsy Currents; research support from Acorda Therapeutics, Alexza, LCGH, Eisai Inc., Lundbeck Inc, Pfizer Inc, SK Life Sciences, UCB Pharma, Upsher-Smith Laboratories, Vertex, NIH, and the Epilepsy Foundation.NO CME WILL BE OFFERED THIS WEEK.
  • February 9 2016 Issue
    1) Mid-life milk consumption and substantia nigra neuron density at death2) What's Trending: Interview with Dr. Ray Dorsey about new Neurology site, which will be called Innovations in Care Delivery3) Topic of the month: Neurology Today story about should there be a moratorium on human germline editingThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Robert Abbott about his paper on mid-life milk consumption and substantia nigra neuro density at death. Dr. Robert Gross is interviewing Dr. Ray Dorsey for our “What's Trending” feature of the week about being the section editor and curator of our new Neurology site, which will be called Innovations in Care Delivery. In the next part of the podcast Dr. Ted Burns interviews Dr. Thomas Bird about a Neurology Today story on the topic of should there be a moratorium on human germline editing. DISCLOSURES: Dr. Abbott serves as an editorial board member of Keio Journal of Medicine Journal of Epidemiology, and receives non-profit research support from Pacific Health Research and Education Institute.Dr. Gross is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH; since his appointment as Editor-in-Chief in 2009, he has ceased participation in industry-sponsored clinical trials and speakers' bureaus and receives an honorarium from AAN as Editor-in-Chief of Neurology.Dr. Dorsey serves on the scientific advisory board of Shire Pharmaceuticals, Huntington's Disease Society of America and NINDS; serves as Editor for HD Insights; serves as an editorial board member of the Journal of Huntington's Disease; serves as Section Editor and Curator for Innovations in Care Delivery mini-site Neurology; received travel funding and honoraria from the American Academy of Neurology; has a patent application related to telemedicine; includes telemedicine in his clinical practice as a movement disorder neurologist (20% effort); has received compensation for expert testimony; is a consultant for 23andME, Amgen, Avid radiopharmaceuticals, Clintrex, Lundbeck Inc, MC10, Inc., Shire Pharmaceuticals, MedAvante, Transpanency Life Sciences and NINDS; receives research support from AMC Health, Avid Radiopharmaceuticals, Biogen Idec, Great Lakes Neurotechnologies, Lundbeck Inc, Medtronic, Inc., Prana Biotechnology, Agency for Health Care Research and Quality; NINDS, National Science Foundation, Patient-Centered Outcomes Research Institute; Davis Phinney Foundation, Michael J. Fox Foundation, Sage Bionetworks.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Bird serves as an editorial board member of GeneReviews.org; has a patent for Genetic testing technology for CMT1C and SCA14 and receives research support from the Department of Veterans' Affairs, Merit Research Grant.
  • February 2 2016 Issue
    1) Orthostatic tremor: Clinical, electrophysiologic and treatment findings in 184 patients2) What's Trending: Interview with Dr. Gretchen Birbeck about Global Neurology site, which will be called Without Borders3) Topic of the month: Neurology Today story about the SPRINT trial and lowering of blood pressure and strokeThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Anhar Hassan about her paper on the clinical, electrophysiologic and treatment findings in 184 patients with orthostatic tremor. Dr. Robert Gross is interviewing Dr. Gretchen Birbeck for our “What's Trending” feature of the week about being the section editor and curator of our Global Neurology site, which will be called Without Borders. Dr. Ted Burns interviews Dr. James Grotta about a Neurology Today story on the topic of the SPRINT trial and lowering of blood pressure and stroke. DISCLOSURES: Dr. Gross is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH; since his appointment as Editor-in-Chief in 2009, he has ceased participation in industry-sponsored clinical trials and speakers' bureaus and receives an honorarium from AAN as Editor-in-Chief of Neurology.Dr. Birbeck serves as Section Editor and Curator for Without Borders mini-site Neurology; receives research support from the NIH and Dana Foundation Neuroimaging Grant.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Grotta serves as an editorial board member for International Journal of Stroke, serves as Consulting editor for Stroke; serves on the steering committee for a clinical trial, Lundbeck Inc.; is a consultant for Specialists on Call, Frazer ambulance and Haemonetics Corporation; has a patent for a composition and method for treatment of cerebral ischemia; receives royalties from the publication of the books Acute Stroke Care and Stroke: Pathology, Diagnosis, and Management; receives research support from Genentech, Inc., Haemonetics Corporation, Coviden, Halle Family/Discount Tire Fund, Alexander Foundation and Mobile Stroke Unit Fund (various donors).
  • January 26 2016 Issue
    1) Overdiagnosis of idiopathic intracranial hypertension2) e-Pearl topic: Neurologic manifestations of Hemolytic Uremic syndrome3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Valerie Biousse about her paper on overdiagnosis of idiopathic intracranial hypertension. Dr. Adam Numis is reading our e-Pearl of the week about neurologic manifestations of Hemolytic Uremic syndrome. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. James F. Meschia about the topic of what's on the horizon in endovascular stroke therapy. DISCLOSURES: Dr. Biousse serves as an editorial board member of American Journal of Ophthalmology and Journal of Neuro-ophthalmology; is a consultant for GenSight; receives royalties from the publication of the books Walsh and Hoyt's Clinical Neuro-Ophthalmology, Neuro-Ophthalmology Illustrated and from Up-to-Date; and receives research support for Research to Prevent Blindness.Dr. Numis serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Meschia serves as an editorial board member of Mayo Clinic Proceedings, Stroke and the European Journal of Neurology; receives research support from the NINDS for efforts devoted to the SiGN study.
  • January 19 2016 Issue
    1) Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF2) e-Pearl topic: Treatment of pediatric onset neuromyelitis optica3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Vincent Thijs about his paper on predictors for atrial fibrillation detection after cryptogenic stroke. Dr. Adam Numis is reading our e-Pearl of the week about treatment of pediatric onset neuromyelitis optica. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. Lee H. Schwamm about the topic of implications for stroke systems of care in endovascular stroke therapy. DISCLOSURES: Dr. Thijs serves as an Associate Editor for Acta Neurologica Belgica; serves as an editorial board member of Stroke and European Journal of Emergency Medicine; serves on the scientific advisory board for Sygnis Ax200 steering committee, Boehringer Ingelheim Belgium advisory board, Boehringer Ingelheim international advisory board, Medtronic steering committee of the REACT-AF trial; is a consultant for Boehringer Ingelheim, Pfizer Inc, Bayer Schering Pharma, AstraZeneca. Medtronic, Inc.; serves on the speakers bureau of Pfizer Inc, Boehringer Ingelheim and Medtronic, Inc.; received funding for travel or speaker honoraria from Medtronic, Inc.; Boehringer Ingelheim, Pfizer Inc, and Bayer Schering Pharma; receives research support from SYGNIS AG, Medtronic, Inc., Pfizer Inc, AstraZeneca, Boehringer Ingelheim and VIB Flanders Research Fund (FWO).Dr. Numis serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Schwamm serves on the scientific advisory board for CoAxia, Lundbeck Inc. DIAS 4 steering Committee, LifeImage and Medtronic, Inc.; serves as an editorial board member for Neurocritical Care, Stroke and Frontiers in TeleNeurology; receives royalties from the publication of the book Acute Ischemic Stroke: Imaging and Intervention, 2nd Edition; is a consultant for Lundbeck Inc. DIAS 4 steering Committee, LifeImage, Medtronic, Inc., and Massachusetts Department of Public Health; has a patent for Imaging system for obtaining quantitative perfusion indices. US Patent 6,542,769. 2003 Apr 1, The General Hospital Corporation assignee, Inventors: Schwamm LH and Sorensen AG; is the principal investigator of an investigator-initiated study of extended-window intravenous thrombolysis funded by the National Institutes of Neurological Disorders and Stroke (clinicaltrials.gov/show/NCT01282242) for which Genentech provides alteplase free of charge to Massachusetts General Hospital as well as supplemental per-patient payments to participating sites; is the chair of the AHA/ASA GWTG stroke clinical work group.
  • January 12 2016 Issue
    1) Neurology® Clinical Practice: Anti-GAD syndrome with concomitant cerebellar ataxia, stiff-person syndrome, and limbic encephalitis2) What's Trending: Current exciting projects at the AAN3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Sara Schaefer about her Neurology: Clinical Practice paper on anti-GAD syndrome with concomitant cerebellar ataxia, stiff-person syndrome, and limbic encephalitis. Dr. Ted Burns is interviewing Cathy Rydell for our “What's Trending” feature of the week about current exciting projects happening at the AAN. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. Max Wintermark about the topic of imaging modalities used as selection criteria in endovascular stroke therapy. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Catherine M. Rydell is Executive Director & Chief Executive Officer, American Academy of Neurology.Dr. Wintermark serves as an editorial board member of American Journal of Neuroradiology and American Journal of Roentgenology; serves on the scientific advisory board for the GE-NFL board.NO CME WILL BE OFFERED THIS WEEK.
  • Physician Burnout; a primer for neurologists
    Physician Burnout; a primer for neurologists
  • January 5 2016 Issue
    1) Pregnancy outcomes in aquaporin-4 positive neuromyelitis optica2) What's Trending: Safety and tolerability of resveratrol for Alzheimer disease3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Maria Isabel S. Leite about her paper on pregnancy outcomes in aquaporin-4 positive neuromyelitis optica. Dr. Ted Burns is interviewing Dr. R. Scott Turner for our “What's Trending” feature of the week about his paper on a randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. Pooja Khatri about the topic of broad overview of the new clinical trials in endovascular stroke therapy. DISCLOSURES: Dr. Leite serves as an editorial board member for Neuromuscular Disorders; has received travel grant and speaking honoraria from Biogen Idec and travel grant from Novartis; is supported by NHS National Specialized Commissioning Group for Neuromyelitis Optica, UK and by NIHR Oxford Biomedical Research Centre.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Turner serves on the data safety and monitoring board for the National Institute on Aging; serves as an editorial board Member for Frontiers in Neuroscience and Neuropsychology and Cognition; receives research support from the National Institute on Aging.Dr. Khatri provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc, Genentech, Inc. and the NIH.
  • December 15 2015 Issue
    1) Neurology® Neuroimmunology & Neuroinflammation Journal: Basal ganglia T1-hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Dr. Eoin Flanagan about his Neurology: Neuroimmunology & Neuroinflammation paper on basal ganglia T1-hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Dr. Adam Numis is reading our e-Pearl of the week about genetic testing in facioscapulohumeral dystrophy. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of immunotherapy for autoimmune cerebellar ataxia. The participants had nothing to disclose except Drs. Numis, Burns and Ringel.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Ringel serves as editor of Neurology Today.NO CME WILL BE OFFERED THIS WEEK.
  • December 8 2015 Issue
    1) Response to shunting and predictors of response in idiopathic normal pressure hydrocephalus and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. John Halperin about the AAN guideline on response to shunting and predictors of response in idiopathic normal pressure hydrocephalus. Dr. Ted Burns is interviewing Dr. Qadeer Arshad for our “What's Trending” feature of the week about his paper on electrocortical therapy for motion sickness. In the next part of the podcast Dr. Ted Burns interviews Dr. Lorenz Studer about a Neurology Today story on the topic of stem cell therapy in Parkinson disease.The participants had nothing to disclose except Drs. Mateen, Halperin, Burns and Studer. Dr. Mateen received research support from the Canadian Institute of Health Research.Dr. Halperin serves as an editorial board member of The Neurologist, ACP PIER, Current Neurology & Neuroscience Reports; serves on the evidence-based medicine group for Neurology®; receives speakers' honoraria from the American Academy of Neurology, Flemish Neurological Society, University of Maryland, Winthrop University Hospital and Inova Health System; receives royalties from the publication of the book Lyme disease-An evidence-based approach and from Up-to-Date; gave expert testimony in medical malpractice cases defending physicians related to Lyme disease; received research support from Centers for Disease Control & Prevention, Lyme disease vs. MS.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Studer serves on the scientific advisory board for Allen Brain Institute and Neurona Irc.; received travel of compensation Allen Brain Institute and Neurona Irc.; is a consultant for Allen BrainInstitute and Neurona Irc.; is a consultant for Allen Brain Institute and Neurona Irc.; has a patent for dopaminergic neuron.
  • December 1 2015 Issue
    1) Endovascular versus medical management of acute ischemic stroke and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Brad Worrall about his paper on endovascular versus medical management of acute ischemic stroke. Dr. Ted Burns is interviewing Dr. Daniel Kaufer for our “What's Trending” feature of the week about the AAN Behavioral Neurology Section Workgroup paper on improving clinical cognitive testing. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of defective nuclear transport and endogenous retrovirus in ALS. The participants had nothing to disclose except Drs. Barrett, Worrall, Burns, Kaufer and Ringel.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.Dr. Worrall serves as Associate Editor for Neurology®; receives royalties as Chapter Author for Merritt's Neurology editions 10, 11, and 12; and receives research support from the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Kaufer is a consultant for Janssen Research and Development; receives research support from TauRx Therapeutics Ltd, Navidea Biopharmaceuticals, Inc., Guardian Angel Thrift Fund, National Football League Players Association and the NIH.Dr. Ringel serves as editor of Neurology Today.
  • November 24 2015 Issue
    1) Stroke risk stratification in acute dizziness presentations and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Kevin Kerber about his paper on stroke risk stratification in acute dizziness presentations. Dr. Sarah Wesley is reading our e-Pearl of the week about focal cortical dysplasia. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Jacqueline Palace about the topic of aquaporin-4 molecular mimicry/pathogenesis/research developments. The participants had nothing to disclose except Drs. Southerland, Kerber, Wesley, Clardy and Palace.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Kerber received funding for travel from Elsevier Inc. and the American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; is a consultant for the American Academy of Neurology, University of California San Francisco (including work on a project funded by AstraZeneca), and Best Doctors, Inc.; receives research support from the NIH; received speaker honoraria from American Academy of Neurology and University of California San Francisco and loan repayment award from the NIH; reviewed legal records of Phil Pearsons, MD, JD and National Medical Consultants.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Palace serves as on the scientific advisory board for Merck Serono, Bayer Schering Pharma, Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis Pharmaceuticals UK Ltd., Sanofi-aventis, Alexion; received support for attending ECTRIMS Merck Serono Novartis and Biogen Idec Talks at scientific meetings (majority have CME) Bayer Schering Pharma, Biogen Idec, Merck Serono, Medimmune; is a consultant for Ono Pharmaceuticals Ltd., Chugai Pharma Ltd., CI Consulting, Biogen Idec, GlaxoSmithKline, Alexion; serves on the speakers' bureau of Teva The CMSC, U. S.; receives research support from Bayer Schering Pharma, Merck Serono, Novartis Teva Pharmaceutical Industries Ltd., MS Society UK, Guthy Jackson Foundation and Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service; receives revenue from a patent from ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.
  • November 17 2015 Issue
    1) Autoimmune post-herpes simplex encephalitis in adults and teenagers and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Josep Dalmau about his paper on autoimmune post-herpes simplex encephalitis in adults and teenagers. Dr. Sarah Wesley is reading our e-Pearl of the week about immunotherapy-responsive seizures. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Dean Wingerchuk about the topic of new guidelines for neuromyelitis optica. The participants had nothing to disclose except Drs. Dalmau, Wesley, Clardy and Wingerchuk.Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Wingerchuk serves as an editorial advisory board member for Current Medical Research and Opinion and Drugs in Context; serves as an editorial board member for Journal of Clinical Apheresis; serves as Co-Editor-in-Chief of The Neurologist; served on the adjudication committee for therapeutic trial for MedImmune; is a consultant for Alexion and MedImmune; receives research support from Alexion, TerumoBCT and Guthy-Jackson Charitable Foundation.
  • November 10 2015 Issue
    1) Spectrum of cognition short of dementia and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. David Knopman about his paper on the spectrum of cognition short of dementia. Dr. Ted Burns is interviewing Dr. Terrence Cascino for our “What's Trending” feature of the week about what AAN is doing to combat the trend of physician burnout. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Sean Pittock about the topic of neuromyelitis optica assay development, treatments and mimics, including MOG antibodies. The participants had nothing to disclose except Drs. Jeff Burns, Knopman, Burns, Cascino, Clardy and Pittock.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Knopman served as Deputy Editor for Neurology®; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Cooperative Study; serves as a consultant to the Bluefield Project to Cure Frontotemporal Dementia; and receives research support from the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Cascino serves as President for the American Academy of Neurology.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Pittock receives research support from Alexion, Guthy Jackson Charitable Foundation and the NIH.
  • November 3 2015 Issue
    1) Neurology® Neuroimmunology & Neuroinflammation: Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Isabel Illa about her Neurology: Neuroimmunology & Neuroinflammation paper on rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Dr. Ted Burns is interviewing Dr. Murray Grossman for our “What's Trending” feature of the week about his paper on the classification of primary progressive aphasia and its variants. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Jeff Bennett about the topic of latest developments in neuromyelitis optica using his antibody library. The participants had nothing to disclose except Drs. Illa, Burns, Grossman, Clardy and Bennett.Dr. Illa received a travel grant from Genzyme; serves as an editorial board member of Neurologia; holds a patent for Dysferlin detection in monocytes; has consulted for Grifols; received research support from Fondo de Investigaciones Sanitarias and ISCIII, Ministry of Health (Spain), Fundacion Gemio.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Grossman serves on the scientific advisory board for Forum; serves as an editorial board member of Neurology®, Journal of Neurolinguistics, Journal of Alzheimer's Disease; serves on the editorial advisory board for Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration; receives research support from Wyncote Foundation, ALS Association and the NIH; received travel funding for a site visit from Max-Planck Society.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Bennett serves on the scientific advisory board for Apsara Therapeutics; serves as an editorial board member of Journal of Neuro-ophthalmology, Multiple Sclerosis Journal and Neurology® Neuroimmunology and Neuroimflammation; has patents for compositions and methods for the treatment of neuromyelitis optica and novel blocking monoclonal therapy for neuromyelitis optica; is a consultant for EMD-Serono, Questcor Pharmaceuticals, Alnaylam Pharmaceuticals, Medimmune, Abbvie, Novartis, Chugai Pharmaceuticals Co., Ltd., Genzyme Corporation, Genentech, Inc.; receives license fee payments from Aquaporumab; has rights for future royalty payments from Aquaporumab; holds stock options in Apsara Therapeutics; receives research support from Questcor Pharmaceuticals, Novartis, NIH and Guthy-Jackson Foundation.NO CME WILL BE OFFERED THIS WEEK.
  • October 27 2015 Issue
    1) Infection, vaccination and childhood arterial ischemic stroke and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark McAllister interviews Dr. Heather Fullerton about her paper on infection, vaccination and childhood arterial ischemic stroke. Dr. Adam Numis is reading our e-Pearl of the week about Lafora body disease. In the next part of the podcast Dr. Ted Burns interviews Dr. Jim Bernat about his Neurology Today book review about “The Digital Doctor.” The participants had nothing to disclose except Drs. Fullerton, Numis, Burns and Bernat.Dr. Fullerton serves as an editorial board member of Stroke; serves on a DSMB for the NIH for clinical trials related to sickle cell disease and stroke; and receives research support from American Heart Association Established Investigator Award.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Bernat serves as an editorial board member of Neurocritical Care, Neurology Today, The Physician's Index for Ethics and Medicine and Multiple Sclerosis and Related Diseases; receives royalties from the publication of the books Ethical and Legal Issues in Neurology, Ethical Issues in Neurology, 3rd ed. and Palliative Care in Neurology.
  • October 20 2015 Issue
    1) Neurology® Genetics: Phenotypic and molecular analyses of primary lateral sclerosis and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Hitoshi Mitsumoto about his Neurology: Genetics paper on the phenotypic and molecular analyses of primary lateral sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about cerebral amyloid angiopathy-related inflammation. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of systemic exertion intolerance disease. The participants had nothing to disclose except Drs. Dimberg, Mitsumoto, Numis, Burns and Ringel.Dr. Dimberg serves as an editorial board member of Nerve and Muscle Junction Podcast.Dr. Mitsumoto is a consultant for Biogen Idec; receives research support from Avanir Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Biogen Idec and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Ringel serves as editor of Neurology Today.NO CME WILL BE OFFERED THIS WEEK.
  • October 13 2015 Issue
    1) Longitudinal study of normal cognition in Parkinson disease and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interviews Dr. Daniel Weintraub about his paper on studying normal cognition in Parkinson disease. Dr. Ted Burns is interviewing Mike Avery for our “What's Trending” feature of the week about things happening in the Beltway of interest to neurologists. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of uptick in cases of narcolepsy. The participants had nothing to disclose except Drs. Barrett, Weintraub, Burns and Ringel.Dr. Barrett received research support from the Virginia Center of Alzheimer´s and Related Diseases Research Award Fund.Dr. Weintraub serves as an editorial board member of Movement Disorders Journal and Journal of Parkinson's Disease; serves on the scientific advisory boards for Pfizer, Inc, Teva Pharmaceuticals Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Lundbeck Inc. UCB, Bristol-Myers Squibb, Novartis, Clintrex, LLC, Theravance Biopharma, Medivation, Inc. Non-profit-CHDI, ADCS; receives licensing fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease; receives research support from Novartis, Michael J. Fox Foundation and the NIH; gave expert testimony for defense in 2012-2014 in two lawsuits related to impulse control disorders in Parkinson disease.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Ringel serves as editor of Neurology Today.
  • October 6 2015 Issue
    1) Evaluation of outcome measures for neurogenic claudication and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. John Markman about his paper on a patient-centered approach for evaluation of outcome measures for neurogenic claudication. Dr. Ted Burns is interviewing Dr. Robert Gross for our “What's Trending” feature of the week about Neurology's spoke journals. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of acute flaccid myelitis. The participants had nothing to disclose except Drs. Burns, Markman and Ringel.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Markman serves on the scientific advisory board for Allergan, Inc., Pfizer Inc, Purdue Pharma L. P., Chromocell Corporation, Plasma Surgical, Nektar, Depomed, Inc., Regeneron Pharmaceuticals; serves as an editorial board member of Merck Serono; is a consultant for Xian Janssen Pharmaceutical Ltd. and Nektar; receives research support from Depomed, Inc., Pfizer Inc and as a special government employee of the Food and Drug Administration.Dr. Gross is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH, since his appointment as Editor-in-Chief in 2009, he has ceased participation in industry-sponsored clinical trials and speakers' bureaus, receives an honorarium from AAN as Editor-in-Chief of Neurology.Dr. Ringel serves as editor of Neurology Today.
  • September 29 2015 Issue
    1) Hemorrhagic stroke following use of the synthetic marijuana "spice" and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. David Rose about his paper on hemorrhagic stroke following use of the synthetic marijuana "spice." Dr. Sarah Wesley is reading our e-Pearl of the week about Hirayama disease. In the next part of the podcast Dr. Andy Southerland interviews Dr. Jennifer Majersik about the topic of tele-neurology quality measures. The participants had nothing to disclose except Drs. Rose, Wesley, Southerland and Majersik.Dr. Rose serves as an editorial board member of Neurohospitalist Journal and serves on the Speakers' bureau of Boehringer Ingelheim.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Majersik receives research support from the NIH.
  • September 22 2015 Issue
    1) Acute headache diagnosis in pregnant women and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Teshamae Monteith interviews Dr. Matthew Robbins about his paper on acute headache diagnosis in pregnant women. Dr. Sarah Wesley is reading our e-Pearl of the week about primary lateral sclerosis. In the next part of the podcast Dr. Andy Southerland interviews Dr. Jack Tsao about the topic of reimbursement, credentialing, and policy updates. The participants had nothing to disclose except Drs. Monteith, Robbins, Wesley, Southerland and Tsao.Dr. Monteith serves as an editorial advisory board member for Neurology Now; and receives research support from the NIH.Dr. Robbins serves as an editorial board member of Headache and The Einstein Journal of Biology and Medicine; received honoraria for educational content and presentation American Headache Society and Prova Education and receives royalties from the publication of the book Headache (Neurology in Practice series).Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Tsao receives royalties from the publication of the book Traumatic Brain Injury: A Clinician's Guide to Diagnosis, Management, and Rehabilitation and receives research support from the US Army Medical Research and Materiel Command and the Wounded, Ill & Injured Directorate, US Navy Bureau of Medicine and Surgery.
  • September 15 2015 Issue
    1) Neurology® Clinical Practice: Medical Marijuana: Between a plant and a hard place and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Wong interviews Dr. David Gloss about his Neurology Clinical Practice paper on medical marijuana: Between a plant and a hard place. Dr. Sarah Wesley is reading our e-Pearl of the week about arterial retinal ischemic disease. In the next part of the podcast Dr. Andy Southerland interviews Dr. Bert Vargas about the topic of teleconcussion. The participants had nothing to disclose except Drs. Gloss, Wesley, Southerland and Vargas.Dr. Gloss serves as an evidence-based medicine consultant for the American Academy of Neurology; serves as an LOE associate editor for Neurology® and receives royalties from the publicationof the book Neurology for the Specialty Boards.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Vargas serves on the scientific advisory boards Allergan, Inc and Zogenix, Inc.; receives honoraria for travel from the American Headache Society.NO CME WILL BE OFFERED THIS WEEK.
  • September 8 2015 Issue
    1) Pathogenic effects of antibodies on gut and brain neurons in anti-DPPX encephalitis and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Johannes Piepgras about his paper on pathogenic effects of antibodies on gut and brain neurons in anti-DPPX encephalitis. Dr. Ted Burns is interviewing Morgan Sorenson for our "What's Trending" feature of the week about twitter handles. In the next part of the podcast Dr. Andy Southerland interviews Dr. Kevin Barrett about the topic of teleneurology (non-stroke applications). The participants had nothing to disclose except Drs. Burns, Sorenson, Southerland and Barrett.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Morgan Sorenson is Managing Editor, Neurology® Neuroimmunology & Neuroinflammation.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.
  • Delayed Recall - Oliver Sacks Tribute
    Interviews with Oliver Sacks. Lesson of the Week interviews from January 2011.
  • September 1 2015 Issue
    1) Neurology® Neuroimmunology & Neuroinflammation: Aquaporin-4 autoimmunity and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Vanda Lennon about her Neurology: Neuroimmunology & Neuroinflammation paper on aquaporin-4 autoimmunity. Dr. Ted Burns is interviewing Kathy Pieper for our "What's Trending" feature of the week about you tube videos. In the next part of the podcast Dr. Andy Southerland interviews Dr. Kevin Barrett about the topic of updates in telestroke. The participants had nothing to disclose except Drs. Lennon, Burns, Pieper, Southerland and Barrett.Dr. Lennon receives research support from the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Kathy Pieper is Managing Editor, Neurology®.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.NO CME WILL BE OFFERED THIS WEEK.
  • August 25 2015 Issue
    1) Migraine and risk of stroke in older adults and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Teshamae Monteith about her paper on migraine and risk of stroke in older adults. Dr. Adam Numis is reading our e-Pearl of the week about neurosyphilis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of antemortem signatures of neurodegenerative proteinopathies. The participants had nothing to disclose except Drs. Southerland, Monteith, Numis, Espay and Josephs.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Monteith serves as an editorial advisory board member for Neurology Now; and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.
  • August 18 2015 Issue
    1) Opioids for chronic non-cancer pain and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen Nadeau and Gary Franklin about their papers on opioids for chronic non-cancer pain and the policy behind prescribing them. Dr. Adam Numis is reading our e-Pearl of the week about vaccinations and seizures. In the next part of the podcast Dr. Alberto Espay interviews Dr. Virginia Lee about her Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of transmission of alpha-Synuclein in Parkinson disease: Pathogenesis and implications for therapy. The participants had nothing to disclose except Drs. Burns, Nadeau, Franklin, Numis, Espay and Lee.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Nadeau served on the DSMB for the National Institute of Neurological Disorders and Stroke and National Institute of Child Health and Human Development funded Interdisciplinary Comprehensive Arm Rehab Evaluation, DSMB ; served as an Associate Editor of the Journal of the International Neuropsychological Society; received honoraria and funding for travel for an International Neuropsychological Society meeting; received funding for travel for an American Neuropsychiatric Association meeting; receives royalties from the publication of the book The Neural Architecture of Grammar ; and receives research support from a VA Rehabilitation R&D Grant and University of Florida McKnight Brain Institute Brain and Spinal Cord Injury Research Trust Fund Grant.Dr. Franklin serves as an editorial board member of Neurology® Levels of Evidence Team and Neuroepidemiology; is a consultant for the California State Compensation Insurance Fund and receives research support from the Centers for Disease Control and Prevention (CDC).Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Lee serves as an editorial board member of Laboratory Investigation, Neurorehabilitation and Neural Repair, NeuroSignals, Neuron, Experimental Neurology, Science Magazine; receives research support from Ware Benaroya and the NIH; receives revenue for the following patent: "Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants" Penn G1120, Patent # 5,792,900.
  • August 11 2015 Issue
    1) CIDP diagnostic pit-falls and perception of treatment benefits and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Mauermann interviews Dr. Jeffrey Allen about his paper on chronic inflammatory demyelinating polyneuropathy diagnostic pit-falls and perception of treatment benefits. Dr. Adam Numis is reading our e-Pearl of the week about exam findings in hemifacial spasms. In the next part of the podcast Dr. Alberto Espay interviews Dr. Howard Weiner about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of immune mechanisms in neurologic diseases. The participants had nothing to disclose except Drs. Mauermann, Allen, Numis, Espay and Weiner.Dr. Mauermann receives research support from ISIS Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc. and the NIH.Dr. Allen is a consultant for AxelaCare and CSL Behring.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Weiner is a consultant for Biogen Idec, Novartis, Merck Serono, Sanofi-aventis, Teva Pharmaceutical Industries Ltd. and Therapix Biosciences Ltd.; served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis; receives research support from EMD, Merck Serono, National Multiple Sclerosis Society, and the NIH.
  • N2 August 2015 Issue
    Josep O. Dalmau, Editor of Neurology: Neuroimmunology & Neuroinfammation introduces the podcast inverview. Dr. Laura Benjamin interviews Dr. Don Gilden about his paper Widespread arterial infection by varicella zoster virus explains refractory giant cell arteritis.J. Damlau is the editor of Neurology: Neuroimmunology & Neuroinflammation, is on the editorial board for Neurology UpToDate, holds patents for and receives royalties from Ma2 autoantibody test, NMDA receptor autoantibody test, GABA(B) receptor autoantibody test, GABA(A) receptor autoantibody test, DPPX autoantibody test, IgLON5 autoantibody test, received research support from Euroimmun, NIH, Fondo de Investigaciones Sanitarias de la Seguridad Social (Spanish Government); L. Benjamin reports no disclosures; D. Gilden is a senior Associate editor for Journal of NeuroVirology, is on the editorial board for In Vivio, Journal of Virology, Scientific American Medicine, Virus Genes, Neurology, Journal of the Neurological Sciences, received research support from NIH;
  • August 4 2015 Issue
    1) Aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erik Ensrud interviews Dr. Grete Andersen about her paper on aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy. Dr. Adam Numis is reading our e-Pearl of the week about non-invasive imaging of arterial dissection with MRI. In the next part of the podcast Dr. Alberto Espay interviews Dr. Stefan Pulst about his George C. Cotzias Lecture at the AAN Meeting about the topic of degenerative ataxias: From genes to therapies. The participants had nothing to disclose except Drs. Ensrud, Numis, Espay and Pulst.Dr. Ensrud serves on the data safety monitoring board for phase II trial of methotrexate in myastenia gravis; is a consultant for Skulpt/Convergence Medical Devices and FDA; received honoraria and funding for travel from Osler Institute; received funding for travel from American Association of Physical Medicine and Rehabilitation; and received honoraria from American Association of Neuromuscular and Electrodiagnostic Medicine.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Pulst serves as Editor-in-Chief of Current Genomics; serves as Editor of Neurology® Genetics; serves as an editorial board member of Journal of Cerebellum, NeuroMolecular Medicine, Continuum, Experimental Neurology, Neurogenetics, and Nature Clinical Practice Neurology; is author on patents re: Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Schwannomin-binding-proteins; and Compositions and methods for spinocerebellar ataxia; receives royalties from the publications of the books The Ataxias, Genetics in Neurology, Genetics of Movement Disorders, Neurogenetics, and Molecular Genetic Testing in Neurology, 2nd–5th ed.; serves on the speakers' bureau for Athena Diagnostics; receives research support from the NIH and the National Ataxia Foundation; receives license fee payments from Cedars-Sinai Medical Center; and has provided expert testimony in a medico-legal case.
  • Delayed Recall - Inflammatory Myopathy (August 2015)
    Inflammatory myopathy. Lesson of the Week interviews from May 2015.
  • July 28 2015 Issue
    1) Evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Rabi Tawil about his paper on the evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy. Dr. Sarah Wesley is reading our e-Pearl of the week about vertical nystagmus. In the next part of the podcast Dr. Alberto Espay interviews Dr. Helen Mayberg about her Robert Wartenberg Lecture at the AAN Meeting on the topic of what deep brain stimulation has taught us about the neurology of depression. The participants had nothing to disclose except Drs. Burns, Tawil, Wesley and Espay.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Tawil serves as an editorial board member of Journal of Neuromuscular Diseases; serves on the safety monitoring board of Novartis; receives royalties from the publication of the books Neuromuscular Disorders (Rabi N. Tawil & Shannon Venance, Editors) and Neurology in Practice Series; receives research support from the NIH and Spinal Muscular Atrophy Foundation.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.
  • July 21 2015 Issue
    1) Paraneoplastic neurologic disorders in small cell lung carcinoma and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Paul Gozzard about his paper on paraneoplastic neurologic disorders in small cell lung carcinoma. Dr. Sarah Wesley is reading our e-Pearl of the week about Balint Syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Lloyd Kasper about his Hot Topic Lecture at the AAN Meeting on the topic of digesting the gut microbiome: role in CNS demyelinating disease. The participants had nothing to disclose except Drs. Dimberg, Wesley and Espay.Dr. Dimberg serves as an editorial board member of Nerve and Muscle Junction Podcast.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.
  • July 14 2015 Issue
    1) Early EEG contributing to multimodal outcome prediction of postanoxic coma and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Schomer interviews Dr. Jeannette Hofmeijer about her paper on early EEG contributing to multimodal outcome prediction of postanoxic coma. Dr. Sarah Wesley is reading our e-Pearl of the week about Susac syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Daniel Lowenstein about his H. Houston Merritt Lecture at the AAN Meeting on the topic of advances in the treatments for epilepsy. The participants had nothing to disclose except Drs. Wesley, Espay and Lowenstein.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Lowenstein receives research support from the NIH.
  • July 7 2015 Issue
    1) Switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ludwig Kappos about his paper on switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis. Dr. Sarah Wesley is reading our e-Pearl of the week about dopamine-responsive dystonia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Timothy Pedley about his Presidential Lecture at the AAN Meeting about the topics of neurologists' burnout, cost and quality of healthcare, value of neurology to congress and payers along with maintenance of certification. The participants had nothing to disclose except Drs. Keegan, Kappos, Wesley, Espay and Pedley.Dr. Keegan serves as Chief Editor of eMedicine; serves as an editorial board member of Multiple Sclerosis and Related Disorders; is a consultant for Novartis, Bristol-Meyers Squibb, Bionest Partners and receives research support from Terumo BCT and Caridian BCT.Dr. Kappos serves as an editorial board member of Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders and Journal of Neurology; receives research support from Actelion Pharmaceuticals Ltd, Addex, Bayer Schering Pharma, Biogen Idec, Biotica, CSL Behring, Genzyme Corporation, Eli Lilly and Company, Merck Serono, Mitsubishi, Novartis, Ono Pharma, Pfizer Inc, Receptos, Roche, Sanofi-aventis, Santhera, Siemens, Teva Pharmaceutical Industries Ltd., UCB, Xenoport, Swiss National Research Foundation and the European Union and The Swiss MS Society; honoraria and other payments for all these activities have been exclusively used for funding of research of his department.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Pedley serves as an editorial board member of Journal of Clinical Neurophysiology and Nature Reviews Neurology and as Editor-in-Chief (Neurology) for UpToDate; serves as President for the American Academy of Neurology; receives royalties form the publication of the books Current Practice of Clinical Electroencephalography, Epilepsy: A comprehensive Textbook and Merritt's Neurology.
  • Delayed Recall - Autoimmune & Paraneoplastic Encephalitis (July 2015)
    Stroke in Systemic Disease. Lesson of the Week interviews from March 2015.
  • June 16 2015 Issue
    1) Screening with MRI for accurate and rapid stroke treatment and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Amie Hsia about her paper on screening with MRI for accurate and rapid stroke treatment. Dr. James Addington is reading our e-Pearl of the week about intracranial hypotension. In the next part of the podcast Dr. Lara Marcuse interviews Mia about the topic of Anti-N-methyl-D-aspartate. The participants had nothing to disclose except Dr. Loddenkemper and Addington.Dr. Barrett serves as an Associate Editor for Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.
  • June 9 2015 Issue
    1) Time from convulsive status epilepticus onset to anticonvulsant administration in children and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Tobias Loddenkemper about his paper on time from convulsive status epilepticus onset to anticonvulsant administration in children. Dr. James Addington is reading our e-Pearl of the week about cannabis in epilepsy. In the next part of the podcast Dr. Lara Marcuse interviews Stephen Haslett about the topic of herpes simplex virus encephalitis. The participants had nothing to disclose except Dr. Loddenkemper and Addington.Dr. Loddenkemper performs video EEG long term monitoring, EEGs and other electrophysiological studies at Boston Children's Hospital (20% effort); evaluates pediatric neurology patients; serves on the Laboratory Accreditation Board for Long Term (Epilepsy and Intensive Care Unit) Monitoring, on the Council of the American Clinical Neurophysiology Society, on the American Board of Clinical Neurophysiology; serves as an Associate Editor for Seizure serves as Contributing Editor for Epilepsy Currents; serves as an Associate Editor for Wyllie's Treatment of Epilepsy 6th edition; is part of pending patent applications to detect seizures and to diagnose epilepsy; receives research support from the American Epilepsy Society, the Epilepsy Foundation of America, the Epilepsy Therapy Project, PCORI, the Pediatric Epilepsy Research Foundation, Cure, Danny-Did Foundation, HHV-6 Foundation, Lundbeck Inc., Eisai Inc., and Upsher-Smith Laboratories, Inc.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.
  • June 2 2015 Issue
    1) Tele-stroke and tele-neurology and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nina Solenski interviews Dr. Sunil Mutgi about his paper on tele-stroke and tele-neurology. Dr. James Addington is reading our e-Pearl of the week about cerebral vasospasm in subarachnoid hemorrhage. In the next part of the podcast Dr. Lara Marcuse interviews Kenneth Kearins and his wife Patricia Kennedy about the topic of autoimmune encephalitis with antibodies to LGI-1. The participants had nothing to disclose except Dr. Addington.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.
  • Delayed Recall - Genetic Testing (June 2015)
    Implementation of Genetic Testing. Lesson of the Week interviews from April 2015.
  • May 26 2015 Issue
    1) Rising cost of multiple sclerosis drugs in the U. S. and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Jones interviews Dr. Daniel Hartung about his paper on the rising cost of multiple sclerosis drugs in the U. S. Dr. Adam Numis is reading our e-Pearl of the week about Walker-Warburg syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of treatment overview of immunotherapy for the immune-mediated myopathies. The participants had nothing to disclose except Drs. Jones, Hartung, Numis, Burns and Mammen.Dr. Jones has received personal compensation for attending consultant meetings for Biogen Idec, Novartis and Genzyme Corporation.Dr. Hartung serves on the data safety monitoring board for Kaiser Permanente Center for Health Research; is a consultant for Alkermes Inc.; receives research support from Alkermes Inc. and the Center for Disease Control and National Institute on Drug Abuse. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.
  • May 19 2015 Issue
    1) Looking ahead by looking back at practicing neurology and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Steven Ringel about his paper on looking ahead by looking back at practicing neurology. Dr. Adam Numis is reading our e-Pearl of the week about neurologic complications of heroin inhalation. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of inclusion body myositis. The participants had nothing to disclose except Drs. Ringel, Numis, Burns and Mammen.Dr. Ringel serves as Editor of Neurology Today.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.
  • May 12 2015 Issue
    1) Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Don Gilden about his paper on the prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Dr. Adam Numis is reading our e-Pearl of the week about unresponsive CIDP: Is it POEMS? In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of dermatomyositis. The participants had nothing to disclose except Drs. Gilden, Numis, Burns and Mammen.Dr. Gilden serves as an Senior Associate Editor for Journal of NeuroVirology; serves as an editorial board member of In Vivo, Journal of Virology, Scientific American Medicine, Virus Genes, Neurology and Journal of the Neurological Sciences; and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.
  • May 5 2015 Issue
    1) Dystonia: Five new things and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Brian Berman about his paper on five new things about dystonia. Dr. Adam Numis is reading our e-Pearl of the week about hereditary hemorrhagic telangectasia. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of immune-mediated necrotizing myopathy. The participants had nothing to disclose except Drs. Berman, Numis, Burns and Mammen.Dr. Berman serves on the Medical Advisory Boards for the Benign Essential Blepharospasm Research Foundation and the National Spasmodic Torticollis Association; has received funding for travel to conferences from Parkinson Study Group, American Neurological Association, Movement Disorder Society, Dystonia Medical Research Foundation, Benign Essential Blepharospasm Research Foundation; serves on the editorial board of Journal of Neurology and Neurophysiology; receives research support from the NIH, Dystonia Coalition, Dystonia Medical Research Foundation, Colorado Translational Research Imaging Center, University of Colorado Center for Neuroscience, The Dana Foundation, and the Benign Essential Blepharospasm Research Foundation. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.
  • Delayed Recall - Autoimmune & Paraneoplastic Encephalitis (May 2015)
    Autoimmune & Paraneoplastic Encephalitis. Lesson of the Week interviews from February 2015.
  • April 28 2015 Issue
    1) Medicare payments to the Neurology workforce in 2012 and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews with Drs. Lesli Skolarus and Kevin Kerber about their paper on Medicare payments to the Neurology workforce in 2012. Dr. Sarah Wesley is reading our e-Pearl of the week about dural arteriovenous fistulas. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel MacArthur about other issues related to genetic testing. The participants had nothing to disclose except Drs. Southerland, Kerber, Skolarus, Wesley and Burns.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Kerber received honoraria from Elsevier Inc., Michigan Academy of Family Physicians and American Academy of Neurology; is a consultant for University of California San Francisco, Best Doctors, Inc. and American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; participated in legal proceedings by reviewing legal records of Phil Pearsons, MD, JD; and receives research support from NIH.Dr. Skolarus received funding for travel to AUPN meeting; receives institutional support from the University of Michigan for stroke-related research projects; and receives research support from the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.
  • April 21 2015 Issue
    1) How C90orf72 promotor hypermethylation is neuroprotective and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Corey McMillan about his paper on how C90orf72 promotor hypermethylation is neuroprotective. Dr. Sarah Wesley is reading our e-Pearl of the week about paraneoplastic cerebellar degeneration. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel MacArthur about the variants of unknown significance. The participants had nothing to disclose except Drs. Burns, McMillan and Wesley.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. McMillan received payment for being plenary speaker at the 2015 International Conference on Frontotemporal Degeneration; and receives research support from the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.
  • April 14 2015 Issue
    1) Being diagnosed with multiple sclerosis and how she has focused on living with the disease and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Ms. Janice Dean about being diagnosed with multiple sclerosis and how she has focused on living with the disease. Dr. Sarah Wesley is reading our e-Pearl of the week about spinobulbar muscular atrophy. In the next part of the podcast Dr. Ted Burns interviews Drs. Radhika Dhamija and Christopher Klein about the reporting of sequence variants and also how the interpretability of the data is rapidly changing and what the implications of this change may be. The participants had nothing to disclose except Drs. Burns, Wesley and Klein.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Klein serves as an editorial board member of Journal of Peripheral Nerve Society; and receives research support from NIH.
  • April 7 2015 Issue
    1) Update of quality measures in epilepsy and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Suski interviews Dr. Nathan Fountain about his paper on the update of quality measures in epilepsy. Dr. Sarah Wesley is reading our e-Pearl of the week about hemicrania continua. In the next part of the podcast Dr. Ted Burns interviews Drs. Radhika Dhamija and Christopher Klein about the topic of next generation sequencing. The participants had nothing to disclose except Drs. Fountain, Wesley, Burns and Klein.Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Klein serves as an editorial board member of Journal of Peripheral Nerve Society; and receives research support from NIH.
  • Delayed Recall - Myelopathy Due to Systemic Disease (April 2015)
    Myelopathy Due to Systemic Disease. Lesson of the Week interviews from January 2015.
  • March 31 2015 Issue
    1) When a serum test overrides the clinical assessment and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Josep Dalmau about his paper on when a serum test overrides the clinical assessment. Dr. James Addington is reading our e-Pearl of the week about lissencephaly. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Mitch Elkind about the topic of stroke in the setting of systemic infection. The participants had nothing to disclose except Drs. Dalmau, Addington, Johansen and Elkind.Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Elkind serves as Section editor for the Neurology® Resident and Fellow Section; serves on the scientific advisory board for Biogen IDEC, Boehringer Ingelheim, BMS-Pfizer Partnership, Janssen Pharmaceutical; is a consultant for Daiichi Sankyo, BMS-Pfizer Partnership and Biotelemetry; participated in legal proceedings for Organon/Merck Serono, NuvaRing and stroke litigation; receives research support from American Heart Association National Board of Directors, American Heart Association Founders Affiliate Board of Directors, American Heart Association NY City Board of Directors and the NIH.
  • March 24 2015 Issue
    1) Clinical and serological characterization of the antibodies to GABAA receptor a1 and y2 subunits and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Angela Vincent about her paper on the clinical and serological characterization of the antibodies to GABAA receptor a1 and y2 subunits. Dr. James Addington is reading our e-Pearl of the week about navigating painful neuropathies. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Steve Zeiler about the topic of stroke in the setting of CNS vasculitis. The participants had nothing to disclose except Drs. Vincent, Addington, Johansen and Zeiler.Dr. Vincent serves on the advisory editorial board Journal of Neurology; holds patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG; was a consultant with Athena Diagnostics; occasional small honoraria, travel and speaker honoraria from Baxter International Inc. and Biogen Idec; receives royalties from Athena Diagnostics (MuSK assays), from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010); and receives research support from the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Zeiler receives research support from Johns Hopkins Neurology and NIH; has provided expert legal testimony in 2013 and 2014.
  • March 17 2015 Issue
    1) Age of first exposure to football and the effect of later-life cognitive impairment on former NFL players and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Robert Stern about his paper on the age of first exposure to football and the effect of later-life cognitive impairment on former NFL players. Dr. James Addington is reading our e-Pearl of the week about REM behavior disorder. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Kevin Barrett about the topic of stroke in the setting of Endocrine disorders. The participants had nothing to disclose except Drs. Goodkin, Stern, Addington, Johansen and Barrett.Dr. Goodkin serves on the scientific advisory board for Tuberous Sclerosis Alliance and CURE Infantile Spasms; serves as an editorial board member of Neurology, Surgical Neurology International and Epilepsia; receive a royalty from UpToDate for co-authorship of an entry entitled The "choking game" and other strangulation activities in children and adolescents; will be receiving royalties for editing Epilepsy as part of the Neurology in Practice series and receives research support from the NIH.Dr. Stern serves as an Associate Editor of Journal of Neuropsychiatry and Clinical Neurosciences; serves as an editorial board member of Archives of Clinical Neuropsychology; serves as a Review Editor of Frontiers in Neurotrauma and Frontiers in Sports Neurology; serves as Series Editor of Alzheimer's Research and Therapy; serves on the Mackey-White Traumatic Brain Injury Committee of the National Football League Players Association; serves on the medical advisory board of Sports Legacy Institute, the National Graves' Disease Foundation and Amarantus Biosciences (paid advisor); serves on the Medical and Scientific Advisory Committee of the MA/NH Chapter of the Alzheimer's Association; is a consultant for Janssen Research & Development and Athena Diagnostics; receives publishing royalties from Psychological Assessment Resources, Inc. for the Visual Analog Mood Scales, the Boston Qualitative Scoring System for the Rey-Osterreith Complex Figure, and the Neuropsychological Assessment Battery; receives research support from Eisai Inc., Eli Lilly and Company, Amarantus Biosciences, Aethlon Medical, Avid Radiopharmaceuticals, the Department of Defense and the NIH; received honorariums from, Braintree Neurorehabilitation Conference, National Academy of Neuropsychology, Harvard Medical School, The German Center for Research and Innovation and Ludwig-Maximilians-Universitat Munchen, Medical University of South Carolina, Spaulding Rehabilitation Hospital and 8th Annual National Summit on Sports Concussion.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.
  • March 10 2015 Issue
    1) PARK 10 locus being a major locus for sporadic, neuropathologically-confirmed Parkinson disease and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Jeffrey Vance about his paper on the PARK 10 locus being a major locus for sporadic, neuropathologically-confirmed Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about a mnemonic for the clinical manifestations of CADASIL. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Kevin Barrett about the topic of stroke in the setting of Renal disease. The participants had nothing to disclose except Drs. Vance, Addington, Johansen and Barrett.Dr. Vance serves as an editorial board member of American Journal of Neurodegenerative Diseases; speaker honoraria from Movement Disorders Society, Society of Neuroscience, Hussman Foundation, travel reimbursement for NIH for meeting on Parkinson Disease and NIH for study section; has patents for method of detecting Charcot-Marie-Tooth disease type 2A, TRPC6 involved in glomerulonephritis and methods for identifying an individual at increased risk of developing coronary artery disease; receives research support from NIH; receives royalties for invention from Duke University.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.
  • March 3 2015 Issue
    1) Utilization of antiepileptic drugs in pregnant women in Florida Medicaid and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Xuerong Wen about her paper on the utilization of antiepileptic drugs in pregnant women in Florida Medicaid. Dr. James Addington is reading our e-Pearl of the week about primary orthostatic tremor. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Victor Urrutia about the topic of hemoglobinopathies and stroke. The participants had nothing to disclose except Drs. Fountain, Addington, Johansen and Urrutia.Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Urrutia serves as a Guest Editor for Frontiers; was asked to consult for New York University to conduct a stroke center certification mock survey; receives research support from Genentech, Inc. and the NIH.
  • Delayed Recall - Therapeutics in Epilepsy (March 2015)
    Therapeutics in Epilepsy. Lesson of the Week interviews from April 2014.
  • February 24 2015 Issue
    1) Aspirin and intracerebral hemorrhage: Where are we now and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Reza Behrouz about his paper on where we are regarding aspirin use in relation to intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about POLG mutations in neurologic disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about some of his recent discoveries regarding pathogenic mechanism in autoimmune encephalitis, as well as current challenges facing autoimmune neurology. The participants had nothing to disclose except Drs. Southerland, Behrouz, Numis and Dalmau.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Behrouz serves as a Contributing Editor to Practical Neurology and as an Associate Editor for BioMed Central Neurology; and has participated in medico-legal cases.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.
  • February 17 2015 Issue
    1) Olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Werner Poewe about his paper on olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD. Dr. Adam Numis is reading our e-Pearl of the week about Fragile X tremor ataxia syndrome. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about other recently described antibodies associated with autoimmune encephalitis. The participants had nothing to disclose except Drs. Poewe, Numis and Dalmau.Dr. Poewe has received consultancy and lecture fees from Abbott, AstraZeneca, Teva Pharmaceutical Industries Ltd, Novartis, GlaxoSmithKline, Boehringer Ingelheim, UCB, Orion Pharma Ltd., and Merck Serono in relation to clinical drug development programs for Parkinson disease; has received research support from the Michael J. Fox Foundation; receives royalties from the publications of the books: Therapeutics of Parkinson's disease and other movement disorders, Non-motor symptoms of Parkinson's disease and Parkinson-syndrome und andere Bewegungsstorungen.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.
  • February 10 2015 Issue
    1) Non-cognitive symptoms of early Alzheimer disease and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Catherine Roe about her paper on non-cognitive symptoms of early Alzheimer disease. Dr. Adam Numis is reading our e-Pearl of the week about cannabidiol in the treatment of epilepsy. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of NMDA receptor encephalitis. The participants had nothing to disclose except Drs. Burns, Roe, Numis and Dalmau.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Roe receives salary support from the NIH, the Longer Life Foundation, the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, The Farrell Family Research Fund, and F. Simmons and O. Mohan; receives research support from the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, the Longer Life Foundation, The Farrell Family Research Fund, and F. Simmons and O. Mohan.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.
  • February 3 2015 Issue
    1) Optimal achieved blood pressure in acute intracerebral hemorrhage and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Craig Anderson about his paper on the optimal achieved blood pressure in acute intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about neuropathy in Fabry disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of autoimmune and paraneoplastic encephalitis and how recent discoveries have changed our understanding of these disorders. The participants had nothing to disclose except Drs. Anderson, Numis and Dalmau.Dr. Anderson serves as an editorial board member of Stroke, Cerebrovascular Diseases, and Medical Journal of Australia; receives honoraria from serving on the scientific advisory board for Pfizer Inc and The Medicines Company; receives funding for travel from Takeda China and Covidien; and receives research support from the National Health and Medical Research Council (NHMRC) of Australia.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.
  • Delayed Recall - Movement Disorder Emergencies (February 2015)
    Movement Disorder Emergencies. Lesson of the Week interviews from November 2014.
  • January 27 2015 Issue
    1) Causes, management and predictors of outcome in acute encephalitis and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Alejandro Rabinstein about his paper on the causes, management and predictors of outcome in acute encephalitis. Dr. Sarah Wesley is reading our e-Pearl of the week about Charcot-Marie-Tooth. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: chemo, mets, AMN, organ/failure/dysfxn and extramed hemato. The participants had nothing to disclose except Drs. Canning, Wesley, Burns and Lewis.Dr. Rabinstein serves as an Associate Editor of Neurocritical Care, serves as an editorial board member of Neurology®, served on the safety monitoring board for the PREVAIL trial; receives royalties from the publication of the books Practical Neuroimaging in Stroke and What To Do? Neurocritical Care and receives research support from DJO Global.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.
  • January 20 2015 Issue
    1) Exercise for falls prevention in Parkinson disease and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michele Fullard interviews Dr. Colleen Canning about her paper on exercise for falls prevention in Parkinson disease. Dr. Sarah Wesley is reading our e-Pearl of the week about subacute sclerosing panencephalitis. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: drugs, toxins, vitamin and minerals. The participants had nothing to disclose except Drs. Canning, Wesley, Burns and Lewis.Dr. Canning received funding for travel expenses and honorarium from the Movement Disorders Society, Singapore General Hospital, Australian and New Zealand Falls Prevention Society; receives research support from the Australian Government National Health and Medical Research Council, Parkinson's NSW and Harry Secomb Foundation.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.
  • January 13 2015 Issue
    1) Reduced trigeminovascular cyclicity in patients with menstrually-related migraine and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Antoinette Maassen van den Brink about her paper on reduced trigeminovascular cyclicity in patients with menstrually-related migraine. Dr. Sarah Wesley is reading our e-Pearl of the week about tauopathies. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: infections. The participants had nothing to disclose except Drs. Southerland, Maassen van den Brink, Wesley, Burns and Lewis.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Maassen van den Brink received support for congress visits from Menarini Group; receives research support from Netherlands Organization for Scientific Research, Dutch Brain Foundation, Netherlands Heart Foundation, MAP Pharmaceuticals, Inc. and Allergan, Inc.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.
  • Delayed Recall - Neuro-Infectious Diseases, Part II (January 2015)
    Neuro-infectious diseases part II. Lesson of the Week interviews from October 2014.
  • January 6 2015 Issue
    1) Optimal combination of secondary prevention drug treatment and stroke outcomes and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Bruce Ovbiagele about his paper on the optimal combination of secondary prevention drug treatment and stroke outcomes. Dr. Sarah Wesley is reading our e-Pearl of the week about persistent cryptococcal meningitis. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: autoimmune disorders. The participants had nothing to disclose except Drs. Southerland, Ovbiagele, Wesley, Burns and Lewis.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Ovbiagele serves as an Assistant Editor of Stroke; serves as an Associate Editor of the Journal of Neurological Sciences; serves on the editorial board of the Journal of Stroke and Cerebrovascular Diseases and receives research support from the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.
  • December 9 2014 Issue
    1) Physician burnout: A neurologic crisis and 2) Topic of the month: Living legend interviews: A career as a neurologist. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bruce Sigsbee about his paper on physician burnout. Dr. James Addington is reading our e-Pearl of the week about colloid cysts. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Josep Dalmau about his career as a neurologist. The participants had nothing to disclose except Drs. Burns, Sigsbee, Addington and Dalmau.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Sigsbee is a consultant for a non-profit, the American Academy of Neurology, on healthcare policy and advocacy.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.
  • December 2 2014 Issue
    1) Results of two-year B-vitamin treatment on cognitive performance and 2) Topic of the month: Living legend interviews: A career as a neurologist. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Ms. Nikita van der Zwaluw & Dr. Rosalie A. M. Dhonukshe-Rutten about their paper on the results of a two-year B-vitamin treatment for cognitive performance. Dr. James Addington is reading our e-Pearl of the week about Rasmussen encephalitis. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Philip Low about his career as a neurologist. The participants had nothing to disclose except Drs. Burns, Addington and Low.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Low serves as Clinical Editor for Autonomic Neuroscience; is a consultant for WR Medical Electronics, Inc. and receives research support from the NIH and FDA.
  • Delayed Recall - Concussion (December 2014)
    Topics on concussion. Interview with Ben Utecht and the Lesson of the Week interviews from September 2014.
  • November 25 2014 Issue
    1) Her experiences and observations dealing with stroke recovery and rehabilitation and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Ms. Esmeralda Santiago about her experiences and observations dealing with stroke recovery and rehabilitation. Dr. Adam Numis is reading our e-Pearl of the week about variants of sporadic Creutzfeld-Jakob disease. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: tic status. The participants had nothing to disclose except Drs. Southerland, Addington and Frucht.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.
  • November 18 2014 Issue
    1) Dietary treatment in adults with refractory epilepsy and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Pavel Klein about his paper on dietary treatment in adults with refractory epilepsy. Dr. Adam Numis is reading our e-Pearl of the week about intraventricular neurocysticercosis. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: dystonic storm. The participants had nothing to disclose except Drs. Klein, Numis and Frucht.Dr. Klein serves on the scientific advisory board for Eisai Inc., Sunovion Pharmaceuticals, Inc., Acorda Therapeutics.; serves on the speakers' boards of UCB, Eisai Inc., Sunovion Pharmaceuticals, Inc.; receives research support from UCB, SK Life Science, Inc., Marinus Pharmaceuticals, Inc. and Lundbeck Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.
  • November 11 2014 Issue
    1) DPPX potassium channel antibody and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Oliver Tobin about his paper on the DPPX potassium channel antibody. Dr. Adam Numis is reading our e-Pearl of the week about cortical vein thrombosis. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: neuroleptic malignant syndrome. The participants had nothing to disclose except Drs. Burns, Numis and Frucht.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.
  • November 4 2014 Issue
    1) Imaging prodromal Parkinson disease and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alberto Espay interviews Dr. Danna Jennings about her paper on imaging prodromal Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about distal hereditary neuropathies. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: serotonin syndrome. The participants had nothing to disclose except Drs. Espay, Jennings, Numis and Frucht.Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Jennings received speaker honoraria from Novartis; serves on the speaker board of UCB; receives research funding from Michael J. Fox Foundation, FORUM Pharmaceuticals, Concert Pharmaceuticals, Inc.; Omeros, Amgen, Abbvie, Merck Serono, Eli Lilly and Company, Avid Radiopharmaceuticals, Inc.; Navidea Biopharmaceuticals, Inc.; Eisai Inc., TauRx Therapeutics Ltd and Biogen Idec.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.
  • Delayed Recall - November 2014
    Oral Anticoagulants in Stroke. Lesson of the week interviews from February 2014.
  • October 28 2014 Issue
    Cerebral amyloid angiopathy-related inflammation and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Prachi Mehndiratta interviews Dr. Aaron Berkowitz about his paper on cerebral amyloid angiopathy-related inflammation. Dr. Adam Numis is reading our e-Pearl of the week about nasociliary reflex. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurocysticercosis, its common manifestations, investigations and treatment. The participants had nothing to disclose except Drs. Numis and Roos.Dr. Berkowitz received speaker honoraria from Stevens Institute of Technology and receives royalties from the publications of the books Clinical Pathophysiology Made Ridiculously Simple, MedMaster and The Improvising Mind, Oxford.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.
  • October 21 2014 Issue
    1) Blood pressure management in stroke and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Ritvij Bowry about his paper on blood pressure management in stroke. Dr. Adam Numis is reading our e-Pearl of the week about Ondine's curse. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about Creutzfeldt–Jakob disease, its clinical symptoms, signs, natural course and treatment. The participants had nothing to disclose except Drs. Numis and Roos.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.
  • October 14 2014 Issue
    1) Why brain death is considered death and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Drs. Chris Burkle and Eelco Wijdicks about their paper on why brain death is considered death. Dr. Adam Numis is reading our e-Pearl of the week about equine encephalitides. In the next part of the podcast Dr. Chenjie Xia interviews Dr. David Clifford about progressive multifocal leukoencephalopathy and neurologic care of patients with HIV/AIDS. The participants had nothing to disclose except Drs. Wijdicks, Numis and Clifford.Dr. Wijdicks served as Editor-in-Chief of Neurocritical Care and receives royalties from the publication of several books published by Oxford University Press.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clifford has served/serves on scientific advisory boards for Amgen, Biogen Idec/Quintiles, BMS, Genentech, Inc., Genzyme Corporation, Pfizer Inc, Millennium Pharmaceuticals, Inc. and Sanofi-aventis; received a speaker honorarium from Sun Pharmaceuticals; serves/has served as a consultant for Millennium Pharmaceuticals, Inc., Genzyme Corporation, Biogen Idec, IAS-USA, CMSC/ACTRIMS, ECTRIMS, Drinker, Biddle, Reath, Cytheris and Novartis; receives research support from Lilly, Roche, Alzheimer Association and the NIH (NIMH, NINR); and has provided consultation in medico-legal cases.
  • October 7 2014 Issue
    1) Clinical and ethical judgment and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Dan Larriviere interviews Dr. Ciro Ramos-Estebanez about his paper on clinical and ethical judgment. Dr. Adam Numis is reading our e-Pearl of the week about Brun's nystagmus. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Justin McArthur about the salient and clinically relevant features of HIV and its neurologic complications. The participants had nothing to disclose except Drs. Larriviere, Numis and McArthur.Dr. Larriviere serves as an Associate Editor of Continuum Audio; serves on the editorial advisory board of Neurology Today and receives speaker honoraria from American Association for the Advancement of Science.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. McArthur serves on the scientific advisory board of Relevare Pharmaceuticals LTD.; holds stock options in Relevare Pharmaceuticals LTD.; holds a patent for a device for thermal stimulation of small neural fibers with the World Intellectual Property Organization, International Publication Number WO 03/040672 A2, medical device for treatment of ulnar neuropathy. UlnarGuard ™ (JHU Ref: 4545) and immunophilin ligand treatment of antiretroviral toxic neuropathy (Provisional application number 60/466,650).
  • Delayed Recall - October 2014
    Mitochondrial disorders. Lesson of the week interviews from March 2014
  • September 30 2014 Issue
    1) The takeaway Frenzel goggles: a Fresnel-based device and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Reza Seyedsadjadi interviews Dr. Michael Strupp about his paper on the takeaway Frenzel goggles: a Fresnel-based device. Dr. James Addington is reading our e-Pearl of the week about steroid-responsive encephalopathy. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the impact of concussion and traumatic brain injury in society. The participants had nothing to disclose except Drs. Strupp, Addington and Jaffee.Dr. Strupp serves as Joint-Chief Editor of the Journal of Neurology, Editor-in-Chief of Frontiers in Neuro-otology Section Editor of F1000; serves on the scientific advisory board for Abbott and Pierre-Fabre; receives royalties from the publication of the book Vertigo and dizziness - common complaints; received speaker honoraria from Abbott, GlaxoSmithKline, Merck Serono, Henning Arzneimittel GmbH & Co. KG, Pierre Fabre Laboratories, UCB and Eisai Inc. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.
  • September 23 2014 Issue
    1) Editorial on his career-ending traumatic brain injury and his concerns about the consequence of such injuries for his future and for others affected and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mr. Ben Utecht about his editorial on his career-ending traumatic brain injury and his concerns about the consequence of such injuries for his future and for others affected. Dr. James Addington is reading our e-Pearl of the week about POTS syndrome. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the management of patients with chronic issues related to post concussive symptoms. The participants had nothing to disclose except Drs. Burns, Addington, Jaffee and Mr. Utecht.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Mr. Utecht serves as a spokesperson for the AAN/ABF.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.
  • September 16 2014 Issue
    1) Course of psychiatric symptoms and global cognition in early Parkinson disease and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Barrett interviews Dr. Dan Weintraub about his paper on the course of psychiatric symptoms and global cognition in early Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about KCNQ2 in early onset epileptic encephalopathy. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the management of concussion after the diagnosis has been made and the recommendation for graduated return to play or normal activities. The participants had nothing to disclose except Drs. Barrett, Weintraub, Addington and Jaffee.Dr. Barrett receives research support from the Virginia Center of Alzheimer's and Related Diseases Research Award Fund.Dr. Weintraub serves as an editorial board member of Movement Disorders Journal and Journal of Parkinson's disease; serves on the scientific advisory boards of Pfizer Inc, Teva Pharmaceuticals Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Lundbeck Inc., UCB, Bristol-Myers Squibb, Novartis, Clintrex, Theravance, Medication Non-profit-CHDI, ADCS; receives license fee payments from the University of Pennsylvania for licensing of questionnaire for impulsive-compulsive disorders in Parkinson disease and QUIP and QUIP-RS; gave expert testimony for defense in two lawsuits related to impulse control disorders in Parkinson disease; receives research support from Michael J. Fox Foundation, Department of Veterans Affairs, Novartis and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.
  • September 9 2014 Issue
    1) Mirror therapy in unilateral neglect after stroke and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Jeyaraj Pandian about his paper on mirror therapy in unilateral neglect after stroke. Dr. James Addington is reading our e-Pearl of the week about basilar-type migraine. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the acute diagnosis and management of concussion. The participants had nothing to disclose except Drs. Southerland, Pandian, Addington and Jaffee.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Pandian serves as Editor-in-Chief of CHRISMED J Health and Research; serves on the scientific advisory board of International J Stroke and serves as an Associate Editor for the Neurology India Journal.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.
  • September 2 2014 Issue
    1) Current practices in feeding tube placement for US acute ischemic stroke inpatients and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Drs. Ben George and Adam Kelly about their paper on current practices in feeding tube placement for US acute ischemic stroke inpatients. Dr. James Addington is reading our e-Pearl of the week about childhood stroke: think metabolic. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the definition of concussion and how the grading has evolved over recent years. The participants had nothing to disclose except Drs. Barrett, George, Kelly, Addington and Jaffee.Dr. Barrett serves as an editorial board member of Neurology; serves as an Associate Editor of Neurohospitalist and receives research support from the NIH.Dr. George receives research support from the American Heart Association/American Stroke Association and the Parkinson's disease Foundation.Dr. Kelly serves as an editorial board member of Continuum; serves as Guest Editor for Cerebrovascular Disease issue, April 2014 and received research support from the Donald W. Reynolds Foundation.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.
  • Delayed Recall - September 2014
    Area of functional symptoms & conversion disorders. Lesson of the Week interviews from November 2013.
  • August 26 2014 Issue
    1) Growth hormone treatment for childhood short stature and risk of stroke in early adulthood and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Cyrus Boelman interviews Dr. Emmanuel Touze about his paper on growth hormone treatment for childhood short stature and risk of stroke in early childhood. Dr. Adam Numis is reading our e-Pearl of the week about LG-1 antibodies in limbic encephalitis. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Don Levy about approaches of Integrative Medicine practitioners to patient care. The participants had nothing to disclose except Dr. Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.
  • August 19 2014 Issue
    1) A clinical pathologic study of depressive symptoms and cognitive decline in old age and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Robert S. Wilson about his paper on depressive symptoms and cognitive decline in old age. Dr. Adam Numis is reading our e-Pearl of the week about ictal syncope. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Tieraona Low Dog about complementary alternative medicine therapies using supplements for treatment of headaches. The participants had nothing to disclose except Drs. Burns, Wilson and Numis. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Wilson serves as a Consulting Editor of Aging, Neuropsychology and Cognition, Psychology and Aging, and Neuropsychology; is a consultant for Pain Therapeutics, Inc.; and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.
  • August 12 2014 Issue
    1) Untreated brain arteriovenous malformations: Patient level meta-analysis of hemorrhage predictors and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeremy Lanford interviews Dr. Helen Kim about her paper on untreated brain arteriovenous malformations. Dr. Adam Numis is reading our e-Pearl of the week about spinal epidural abscesses. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Remy Coeytaux about complementary alternative medicine to chronic pain and integrative medicine approaches. The participants had nothing to disclose except Drs. Coeytaux and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Coeytaux is a consultant for Samueli Institute and receives research support from the NIH.
  • August 5 2014 Issue
    1) Palliative care and neurology: Time for a paradigm shift and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Bragg interviews Dr. Benzi Kluger about his paper on palliative care and neurology: Time for a paradigm shift. Dr. Adam Numis is reading our e-Pearl of the week about intravascular B-cell lymphoma. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Pushpa Narayanaswami about complementary alternative medicine therapies for patients with multiple sclerosis. The participants had nothing to disclose except Drs. Kluger, Numis, and Narayanaswami.Dr. Kluger serves as an editorial board member of Frontiers in Movement Disorders; received speaker honoraria from Teva Pharmaceutical Industrials Ltd., Parkinson's Association of the Rockies and National Parkinson's Foundation; receives research support from the US Army Research Laboratory and US Army Research Office, Veterans Affairs Medical Center CRICC Program, Michael J. Fox Foundation, University of Colorado Hospital Clinical Effectiveness and Patient Safety Program and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Narayanaswami serves as an editorial board member of Neurology® Level of Evidence Review Team; is a consultant for Blue Cross Blue Shield of Massachusetts, Pharmacy and Therapeutics Committee, Advanced Medical and Boston Clinical Research Institute; performs EMG in her clinical practice (35% effort); receives research support from Merz Pharmaceuticals, Inc., Solstice Pharma and AHRQ; received research support from the NIH.
  • Delayed Recall - August 2014
    Viral meningoencephalitides, lyme disease, & bacterial meningoencephalitides. Lesson of the week interviews from June 2014.
  • July 29 2014 Issue
    1) Evaluation and construction of diagnostic criteria for inclusion body myositis and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steven A. Greenberg about his paper on evaluation and construction of diagnostic criteria for inclusion body myositis. Dr. James Addington is reading our e-Pearl of the week about Rapid-Onset Dystonia Parkinsonism. In the next part of the podcast Dr. Alberto Espay continues his interview with Dr. Jon Stone including questions about his Contemporary Clinical Issues Lecture about functional (psychogenic) disorders in neurology from the audience at Interview Central and his responses. The participants had nothing to disclose except Drs. Burns, Greenberg, Addington, Espay and Stone.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Greenberg is a consultant for MedImmune, aTyr Pharma; receives publishing royalties from the publication of the book EMG Pearls; receives license fee payments from Composition and Methods for Diagnosing and Assessing Inflammatory Myopathies, MedImmune; receives revenue for patents for composition and methods for diagnosing and assessing inflammatory myopathies, detecting inclusion body myositis; receives research support from MedImmune, Novartis and the NIH; serves on the scientific advisory board for MedImmune; received funding for travel from Biogen Idec and Genzyme Corporation.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Stone received speaker honoraria from the Movement Disorders Society, British Medical Association, American Academy of Neurology Royal College of Psychiatrists, UCB Pharma, Novartis, Tribunals Judiciary (UK); receives research support from the National Research Strategy Career Fellow with NHS Scotland Research; receives publishing royalties from UptoDate 2014; runs a free self-help website for patients with functional disorders http://www.neurosymptoms.org; carries out regular expert witness work in relation to personal injury and medical negligence.
  • July 22 2014 Issue
    1) Traumatic brain injury and risk of dementia in older veterans and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Deborah Barnes about her paper on traumatic brain injury and risk of dementia in older veterans. Dr. James Addington is reading our e-Pearl of the week about chronic traumatic encephalopathy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jon Stone about his Contemporary Clinical Issues Lecture at the AAN Meeting about functional (psychogenic) disorders in neurology. The participants had nothing to disclose except Drs. Mateen, Barnes, Addington, Espay and Stone.Dr. Mateen received funding support from the Canadian Institute of Health Research.Dr. Barnes receives research support from UCB, Department of Defense, Department of Veterans Affairs, NARSAD (Brain & Behavior Research Foundation), S.D. Bechtel Jr. Foundation, philanthrophic support via Osher Center for Integrative Medicine, University of California, San Francisco, patient centered outcomes research institute and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Stone received speaker honoraria from the Movement Disorders Society, British Medical Association, American Academy of Neurology Royal College of Psychiatrists, UCB Pharma, Novartis, Tribunals Judiciary (UK); receives research support from the National Research Strategy Career Fellow with NHS Scotland Research; receives publishing royalties from UptoDate 2014; runs a free self-help website for patients with functional disorders http://www.neurosymptoms.org; carries out regular expert witness work in relation to personal injury and medical negligence.
  • July 15 2014 Issue
    1) Defining the clinical course of multiple sclerosis: The 2013 revisions and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Fred Lublin about his paper on defining the clinical course of multiple sclerosis: The 2013 revisions. Dr. James Addington is reading our e-Pearl of the week about familial fatal insomnia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Eidelberg about his Hot Topics Lecture at the AAN Meeting about functional connectivity and functional imaging in movement disorders. The participants had nothing to disclose except Drs. Keegan, Lublin, Addington, Espay and Eidelberg.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Lublin serves as co-Chief Editor of Multiple Sclerosis and Related Disorders; serves on the scientific advisory boards and as a consultant for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals Ltd, Sanofi-aventis, Acorda Therapeutics Inc, Questcor Pharmaceuticals, Roche, Genentech, Inc., Celgene, Johnson & Johnson, Revalesio Corporation, Coronado Bioscience, Genzyme Corporation, MedImmune, Bristol-Myers Squibb, XenoPort, Inc., Receptos Inc, Forward Pharma, to- BBB technologies; receives research support from Biogen Idec, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc, Novartis, Genzyme Corporation, Sanofi-aventis, Celgene, National Multiple Sclerosis Society and the NIH; holds financial interests/stock options in Cognition Pharmaceuticals. Inc. and may discuss unapproved agents that are in the MS developmental pipeline with any recommendations on their use.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Eidelberg serves as an Associate Editor of Journal of Neuroscience; serves as an editorial board member of Journal of Nuclear Medicine, Current Opinion in Neurology, Annals of Neurology and NeuroImage; serves on the scientific advisory board for the Michael J. Fox Foundation, ; co-inventor of United States Patent No. 5, 632,276 and No. 5,873,823 without financial gain; receives research support from the Michael J. Fox Foundation and the NIH.
  • July 8 2014 Issue
    1) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Russell Dale about his paper on utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Dr. James Addington is reading our e-Pearl of the week about pseudo-internuclear ophthalmoplegia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Holtzman about his Robert Wartenberg Lecture at the AAN Meeting about Alzheimer's disease in 2014: Mapping a road forward. The participants had nothing to disclose except Drs. Dale, Addington, Espay and Holtzman.Dr. Dale serves on the scientific advisory board for Queensland Children's Medical Institute; serves as an editorial advisory board member of Multiple Sclerosis and Related Disorders Journal; received honoraria for lecturing from Biogen Idec; receives research support from the National Health and Medical Research Council. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Holtzman serves as an Associate Editor of Annuals of Neurology; serves as an editorial board member of Neurobiology of Disease, Experimental Neurology, Molecular Neurodegeneration, Science Translational Medicine and Journal of Experimental Medicine; co-founder of C2N Diagnostic LLC; is a consultant for AstraZeneca, Genentech, Inc., Bristol-Myers Squibb and Forum Pharmaceuticals; receives research support AstraZeneca, Eli Lilly and Company, Biogen Idec, C2N Diagnostic LLC, Cure Alzheimer's Disease, Tau Consortium, Ellison Medical Foundation and the NIH.
  • Delayed Recall - July 2014 - Critical Care Neurology
    Topics in critical care neurology. Lessons of the week from May 2014
  • July 1 2014 Issue
    1) Long-term safety and effectiveness of natalizumab for re-dosing and treatment of multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ruth Ann Marrie interviews Dr. Paul O'Connor about his paper on long-term safety and effectiveness of natalizumab for re-dosing and treatment of multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about inclusion body myositis. In the next part of the podcast Dr. Alberto Espay interviews Dr. James Bernat about his Presidential Lecture at the AAN Meeting about challenges to ethics and professionalism facing the contemporary neurologist. The participants had nothing to disclose except Drs. Marrie, O'Connor, Addington, Espay and Bernat.Dr. Marrie serves on the editorial board for Neurology® and Multiple Sclerosis Journal; receives research support from Sanofi-aventis, Canadian Institutes of Health Research, Public Health Agency of Canada, Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, Multiple Sclerosis Scientific Foundation and Consortium of Multiple Sclerosis Centers.Dr. O'Connor served on the editorial advisory board of the MS Journal; serves on the scientific advisory board for Novartis, Sanofi-aventis, Bravo Pharmaceuticals, Genentech, Inc., Roche and Actelion Pharmaceuticals Ltd; is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Sanofi-aventis and Novartis; received funding for travel to advisory board meeting in Toronto; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec and as National Scientific and Clinical Advisor to the MS Society of Canada. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Bernat serves as an unpaid editorial board member of Neurocritical Care, Neurology Today, and Multiple Sclerosis and Related Diseases; a paid editorial board member of The Physician's Index for Ethics and Medicine; and receives royalties from the publication of the books Ethical Issues in Neurology, 3rd ed, Palliative Care in Neurology, and Ethical and Legal Issues in Neurology.
  • June 17 2014 Issue
    1) Factors associated with recovery from acute optic neuritis in multiple sclerosis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Tanuja Chitnis about her paper on factors associated with recovery from acute optic neuritis in multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about tanycytic ependymal tumors. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Bacterial meningoencephalitides. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Chitnis is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis, Sanofi-aventis; receives research support from Merck Serono and Novartis in the form of Independent Investigator Awards, National Multiple Sclerosis Society. the Peabody Foundation and the Guthy-Jackson Charitable Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.
  • June 10 2014 Issue
    1) Abnormal thalamic function in patients with vestibular migraine and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Jen interviews Dr. Gioacchino Tedeschi about his paper on abnormal thalamic function in patients with vestibular migraine. Dr. Adam Numis is reading our e-Pearl of the week about Gerstmann-Straussler-Scheinker syndrome. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Lyme disease. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos.Dr. Jen serves as a Section Editor for Experimental Brain Research; serves as an Associate Editor for Frontiers in Neuro-otology; receives research support from the FDA.Dr. Tedeschi receives speaker honoraria from Novartis, Schwarz Pharma AG, UCB, Lundbeck Inc., GlaxoSmithKline and AbbVie.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.
  • June 3 2014 Issue
    1) Anti-agrin autoantibodies in myasthenia gravis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Arthur Melms about his paper on anti-agrin autoantibodies in myasthenia gravis. Dr. Adam Numis is reading our e-Pearl of the week about myopathy masquerading as myasthenia. In the next part of the podcast Dr. Chenjie Xia interviews Drs. Maria Nagel and Don Gilden about neurology and infectious diseases: Viral meningoencephalitides. The participants had nothing to disclose except Drs. Burns, Melms, Numis, Nagel and Gilden.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Melms performs clinical procedures as Professor of Neurology and Neurorehabilitation at the University of Erlangen, Germany (20%) and is clinical director of a privately owned neurological rehabilitation hospital (80%); clinical research is supported by the Ernst Freiberger Foundation, Berlin, Germany; received speaker honoraria from GlaxoSmithKline; received research support from German Research Agency, Collaborative Research Center 685, Immunotherapy, and the Gemeinützige Hertie Foundation, Frankfurt/Main, Germany.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Nagel receives research support from the NIH.Dr. Gilden serves as Senior Associate Editor of Journal of NeuroVirology; serves as an editorial board member of In Vivo, Journal of Virology; Scientific American Medicine, Virus Genes, Neurology Journal, receives research support from the NIH.
  • Delayed Recall - June 2014 - Movement Disorders II
    Parkinson's & parkinsonism disorders. Lesson of the Week interviews from January 2014.
  • May 27 2014 Issue
    1) Effects of cannabis on cognition in patients with multiple sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Anthony Feinstein about his paper on the effects of cannabis on cognition in patients with multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about spinal dural arteriovenous fistula. In the next part of the podcast Dr. Mike Brogan interviews Dr. Claude Hemphill about the management of intracranial hypertension. The participants had nothing to disclose except Drs. Feinstein, Addington and Hemphill.Dr. Feinstein serves as an editorial board member of Multiple Sclerosis and African Journal of Psychiatry; receives royalties from the publication of the book The Clinical Neuropsychiatry of Multiple Sclerosis; performs neuropsychiatric evaluation, cognitive testing, brain imaging in neuropsychiatry clinical practice; receives research support from Biogen Idec, Canadian Institute of Health Research, Multiple Sclerosis Society of Canada and University of Toronto; received honoraria for lectures from Merck Serono, Novartis and Teva Pharmaceutical Industries Ltd.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Hemphill serves as an editorial board member of Neurocritical Care; holds stock options for serving on the scientific advisory board for Ornim Medical; receives research support from Cerebrotech Medical; funding as PI for hub site for Neurological Emergencies Treatment Trials Network; received a one-time speaking honorarium from Besins Critical Care, LLC and honoraria from Edge Therapeutics, Inc. for consulting; gave expert witness review and testimony on various cases related to stroke and neurocritical care.
  • May 20 2014 Issue
    1) Cerebrospinal fluid AB42 predicting early onset Parkinson disease and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interviews Dr. Henrik Zetterberg about his paper on cerebrospinal fluid A?42 predicting early onset Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about Kennedy disease. In the next part of the podcast Dr. Mike Brogan interviews Dr. Laurie Gutmann about critical illness in polyneuropathy and myopathy. The participants had nothing to disclose except Drs. Zetterberg, Addington and Gutmann.Dr. Zetterberg serves as Senior Editor of the Journal of Alzheimer's disease; serves as Associate Editor of Alzheimer and Dementia; receives research support from the Swedish Research Council and Swedish State Support for Clinical Research. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gutmann receives royalties from Up-to-Date Online from the publication of Hypokalemic and Hyperkalemic Periodic Paralysis; receives research support from Alexion Pharmaceuticals, Inc. and the NIH.
  • May 13 2014 Issue
    1) Venous thromboembolism in amyotrophic lateral sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Lorne Zinman about his paper on venous thromboembolism in amyotrophic lateral sclerosis. Dr. James Addington is reading our e-Pearl of the week about SCN4A mutations. In the next part of the podcast Dr. Mike Brogan interviews Dr. Thomas Bleck about the management of status epilepticus in critical care. The participants had nothing to disclose except Drs. Burns, Zinman, Addington and Bleck.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Zinman serves on the scientific advisory board for the Data and Safety Monitoring Board NIH sponsored Tamoxiphen/Creatine ALS Study (non-profit entity); receives research support from the Garfield Weston Foundation, Public Health Agency of Canada, Canadian Institute of Health Research, ALS Society of Canada and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bleck serves on the data safety and monitoring boards of the NIH sponsored RAMPART and ProTECT trials.